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Abstract 
 
Vaccinia virus Lister strain, a large, structurally complex double stranded DNA pox 
virus, is being developed by a number of organisations around the world as an oncolytic 
and immunotherapeutic agent for the treatment of a broad range of cancers. Should 
these therapies prove to be efficacious in the clinic, large quantities of vaccinia virus 
will need to be produced at very high levels of purity as dosing requirements are 
expected to be as high as approximately 1x10
9
 pfu/dose. 
In this thesis, the development of two convective interaction media (CIM) monolith 
capture steps for vaccinia virus with considerable purification factors is described; one 
uses cation exchange while the other uses hydrophobic interaction chromatography. The 
purification process development involved an extensive material characterisation study 
resulting in enhanced product understanding, a rapid resin screening study aimed at 
quickly identifying suitable resin chemistries, followed by process optimisation studies 
on the best performing monoliths.  
After being challenged with crude infectious vaccinia harvest, CIM OH monoliths are 
shown to be able to recover up to 90% of the infectious virus loaded whilst removing up 
to 99% of the contaminating DNA (without nuclease treatment) and 100% of 
quantifiable protein. Binding capacities were shown to be in the order of 1x10
9
 pfu/mL. 
The high levels of both batch to batch and assay variability as well as the tendency of 
vaccinia virus to aggregate in the feed material, typical of viral processes especially 
when developed alongside un-optimised upstream conditions, are clearly demonstrated 
and the implications are explored. The results show that it can be challenging to draw 
robust conclusions on process performance. To minimise the effects of analytical 
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variability, a number of orthogonal analytical methods have been used to quantify and 
characterise viral particles. These include TCID50, nanoparticle tracking analysis 
(NTA), tunable resistive pulse sensing (TRPS), transmission electron microscopy 
(TEM), scanning electron microscopy (SEM), and real-time PCR (qPCR).  In order to 
put this into an industrial context, a comparative cost of goods analysis of monoliths and 
ultracentrifugation technologies for the purification of large viral particles is provided. 
This shows that both chromatography using monoliths and continuous flow 
ultracentrifugation can be economically viable, although both have limitations. The 
potential economic benefits of using a monolith-based process over an 
ultracentrifugation-based process are increased productivity, the ability to generate 
purer material and ease of scale-up.  
CIM monoliths are unique stationary phases that offer efficient separation and high 
productivity owing to fast cycle times and high binding capacities. Both cation 
exchange (CIM SO3) and hydrophobic interaction (CIM OH) monoliths are effectual at 
removing the majority of contaminants in a single purification step that can easily be 
scaled up to 8 L bed volumes. CIM monoliths have the potential to be an attractive 
option for future manufacturing processes for oncolytic viral therapies. They are shown 
in this thesis to achieve a higher percentage recovery and better removal of DNA, 
protein and aggregate than any other technology described in the literature to date.  
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Impact Statement  
 
The gene and immunotherapy field has picked up a lot in the last few years after some 
initial setbacks in the clinic. A number of in vivo and ex vivo viral constructs have 
recently entered clinical trials (Heo et al. 2013). 
Vaccinia virus has shown promising efficacy in both animal models and late stage 
cancer patients for both solid tumours and models for metastasis (Garber 2006;Kirn and 
Thorne 2009;Tysome et al. 2009;Tysome et al. 2011). While challenges associated with 
oncolytic viral therapies do exist (Ferguson et al. 2012), there is a chance that vaccinia 
virus will need to be produced for direct injection into patients at a commercial scale. 
The scale of this production will of course depend on the efficacy of the trial, the 
indication, and the dose required.  Clinical trials currently suggest that the total 
treatment dose requirement will need to be relatively high in order to achieve efficacy. 
It has been suggested that multiple treatments may be required each consisting of 1x10
9
 
pfu per patient (Heo, Reid, Ruo, Breitbach, Rose, Bloomston, Cho, Lim, Chung, Kim, 
Burke, Lencioni, Hickman, Moon, Lee, Kim, Daneshmand, Dubois, Longpre, Ngo, 
Rooney, Bell, Rhee, Patt, Hwang, & Kirn 2013). This will not only increase the costs of 
production but may also result in the requirement for purer material as increasing the 
amount of viral particles per dose will also increase the amount of impurities per dose, 
which even at lower doses is already recognised as an issue (Wolff and Reichl 2011). It 
is clear that without effective, engineering led, process development and optimisation, 
production costs can become crippling, especially as vaccinia processes to date tend to 
be low yielding with cell productivity less than 100 pfu/cell (Liu et al. 2016).  
The impact of this work inside academia will likely be twofold. Firstly, it will advance 
the levels of process knowledge and understanding of how vaccinia virus Lister strain 
interacts with charged and hydrophobic monolithic stationary phases. It will also enable 
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laboratories currently working with vaccinia virus Lister strain to produce material of a 
higher quality, in terms of purity, than previously possible in a single step. This will be 
especially relevant for groups currently relying on sucrose gradient ultracentrifugation 
or similar techniques. The wider medical community will indirectly benefit from this as 
the material supplied for pre-clinical and proof of concept studies will be more 
representative of that produced in late stage clinical and commercial processes. 
From an industrial perspective, the impact of this work, at least in the short term, will be 
the addition of another purification tool in the vaccinia virus purification development 
toolbox. The reason why this is important is that vaccinia is a challenging virus to 
purify due to its large size and complexity, and therefore the number of purification 
options available is limited. The default unit operation used to purify vaccinia and other 
viruses is still ultracentrifugation. This work will add to the growing debate on whether 
this technology is still of value. It adds insight into the associated cost of goods for both 
technologies, suggests potential mechanisms involved in the separation of vaccinia 
using CIM monoliths, and presents encouraging results indicating the production of 
highly pure vaccinia virus material using chromatography. 
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  Chapter 1
Aims and Objectives of Study 
 
The overall aim of this EngD project is to evaluate, understand, and work to reduce the 
current challenges faced by process scientists and engineers developing vaccinia virus 
constructs for vaccines and oncolytic therapies. 
One such challenge is the scalability and productivity of presently used purification unit 
operations, arguably the most common being ultracentrifugation. It has been suggested 
that chromatography using monoliths could present an attractive alternative to 
ultracentrifugation namely owing to their high binding capacity, flow independent 
binding and resolution, and scalability stated by the manufacturers of commercially 
available monoliths. 
The virus being used in this study is Barts Cancer Institute’s back bone attenuated 
vaccinia viral construct containing a RFP reporter gene (VVL15TK
-
RFP). The virus is 
currently being developed as an oncolytic virus against a range of cancers. 
To start with, an extensive vaccinia virus stability study will be performed to determine 
whether there are certain conditions, such as variations in buffer salts, NaCl 
concentration or pH that might affect the stability (measured by infectivity) of the virus 
at room temperature over time.  
Once this is ascertained, a process will be developed by screening different monolith 
chemistries for ability to bind and then elute the virus. As soon as a particular chemistry 
is found to reversibly bind the virus, a process of optimisation using both gradient 
elution and intelligent design of experiments (DoE) to develop stepwise elution 
schedules will be used. These strategies will help to determine windows of operation for 
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both binding, washing and eluting the column in order to maximise yield and purity of 
the final product.  
The binding capacity of vaccinia virus onto CIM monoliths should be high. Previous 
work at BIA Separations used pure tomato mosaic viral preps (ToMV) with a known 
mass concentration to estimate the theoretical dynamic binding capacity of ToMV on 
CIM monoliths. The total particle concentration bound to the resin was estimated using 
the mass of a single viral particle (Matjaž Peterka et al. 2010). This was performed by 
running a DBC on a 0.34 mL monolith disk with a high concentration of pure virus 
material. 
The theoretical binding capacity of vaccinia virus onto 6 µm channel monoliths has 
been estimated to be ~1.15x10
13 
particles/mL of monolith. This is assuming the 
following (Mao et al. 2017).  
 Surface area per gram of dry monolith (BET adsorption)= 2 m2 (6 µm 
channel monoliths) 
 Density is assumed to be 0.43 g/mL 
 Vaccinia is 300x250 nm (total cross sectional area =  7.5x10-14 m2  
 The entire monolith surface area is available for adsorption and has been 
functionalised with either -OH or -SO3 groups. 
 Particles adsorb in ordered monolayers across the whole surface  of the 
monolith 
 
Analytical methods currently used for evaluating the total number of infectious virus 
particles has been described extensively in the literature as being an area requiring 
increased scrutiny and validation during process development  (Darling et al. 1998). 
Current gold standards such as TCID50 are time consuming, involve tedious preparation, 
and have been reported to give highly variable results (Stoffel et al. 2005).  For this 
reason a combination of orthogonal analytical measurements including TCID50, 
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nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (TRPS), 
transmission electron microscopy (TEM), scanning electron microscopy (SEM), and 
real-time PCR (qPCR) will be used to characterise and quantify vaccinia virus particles.  
Bicinchoninic acid (BCA) assay will be used to quantify total protein and PicoGreen 
will be used to quantify double stranded DNA (dsDNA). Both total protein and DNA 
levels are identified as critical quality attributes (CQAs).  
The final results chapter will consist of a process economics analysis that compares a 
defined monolith-based chromatography process and an ultracentrifugation process 
from an overall cost of goods perspective. The aim of this analysis is to further our 
understanding of where the major costs and process risks from each process option are 
likely to come from. Initial assumptions will need to be made but these will be tested in 
a sensitivity analysis and then discussed in detail. Once complete, the model will be 
able to be used for two potential purposes. The first one would be to assist in identifying 
drivers for process development in a chromatographic purification process scenario. The 
second purpose of this model would be to act as a decision tool to support later 
discussions with Barts Cancer Institute, who are developing vaccinia virus as an 
oncolytic therapy for a range of cancers, in order to manufacture some of their 
constructs for clinical development. An example of a question that this model aims to 
answer is   “How well would a monolith process need to perform to ensure a cost 
benefit over an ultracentrifugation process?” 
A section on process validation will be included that aims to show how the CQAs for 
vaccinia virus produced in a commercial setting for an oncolytic indication might be 
defined. The challenges associated with their characterisation from the point of view of 
safety and efficacy will be described and best practices discussed. The validation 
challenges involved in the production of monoliths will also be presented as it is 
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thought that these will be important considerations when validating a monolith 
chromatography step.  
A number of challenges needed to be overcome over the course of this project. After 
conducting an internal risk assessment at UCL, Vaccinia virus was classified as 
requiring category 2 contwotainment. The department of Biochemical Engineering is 
organised into a number of labs and pilot facilities which are designed to be shared 
amongst all researchers and in some cases undergraduate and MSc students for the 
purposes of teaching. For this reason it was concluded that vaccinia virus would need to 
be handled in a specialist CAT II vaccine laboratory with dedicated equipment so as to 
reduce any risks of cross contamination. This was built and commissioned over the 
course of this project between 2012 and 2015, but it meant that a significant amount of 
work needed to be undertaken elsewhere. Some of the work was performed at BIA 
Separations in Slovenia. BIA Separations has access to chromatography equipment, 
however, didn’t have the ability to perform non-plate based assays so analytical 
measurements such as Western blots, qPCR, and NTA could not be performed. Barts 
Cancer Institute did allow access to western blot facilities, however it was decided that 
this additional assay didn’t add much clarity on how the system was performing as it is 
only semi-quantitative as well as fairly time consuming. 
 
Virus analytics are generally accepted as being time consuming, and imprecise meaning 
that a bottleneck in terms of throughput as well as the ability to make conclusive 
decisions presented itself.  
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Time was spent establishing and partially optimising TCID50, PicoGreen and BCA, as 
well as NTA, qPCR, TEM, and SEM as they became available towards the end of the 
project when labs at UCL became available. 
 
Red florescence was used to confirm infectious titre (as a second read out during 
TCID50 analysis).This also acted to increase the selectivity of the TCID50 assay 
confirming the presence of vaccinia virus. 
 
The aim of this project was to understand and work to reduce the challenges in vaccinia 
virus purification. A monoliths capture step was evaluated and shown to be a reasonable 
process option for manufacture at 100L scale. 
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  Chapter 2
 
Introduction 
 
2.1 Vaccinia Virus 
2.1.1 Taxonomy, Classification, and Properties of Vaccinia Virus 
 
The exact origin of vaccinia virus is not known. There are, however, a number of 
theories. One is that vaccinia virus was a form of orthopoxvirus that previously infected 
animals but is no longer endemic. Another suggestion is that it may have originated 
from horsepox virus as at least one strain of vaccinia virus (Ankara) was isolated from a 
horse (Antonio Alcami et al., 2010). Vaccinia is also said to be closely related to 
cowpox (Bourquain et al. 2013). 
Vaccinia virus is a member of the Poxviridae family of viruses and is a large, complex, 
double stranded DNA-based poxvirus. The virus is described as “brick-shaped” with 
dimensions of approximately 300 x 250 nm (Michen and Graule 2010). 
The Poxviridae family of viruses is split into two additional subclasses that infect 
vertebrates and insects; these are named Chordopoxvirinae and Entomopoxvirinate 
respectively. Vaccinia virus, which belongs to the subfamily Chordopoxvirinae, belongs 
to the genus Orthopoxvirus (Wittek 1994).  
The mass of a typical vaccinia virus particle has been found experimentally by using 
microscale silicon cantilever resonators and atomic force microscopy to be of ~7.9 (+/-) 
4.6 femtograms (fg)  and ~12.4 (+/-) 1.3 fg (Johnson et al. 2006). This data was 
obtained from cantilevers of 6 µm x 4 µm and 21 µm x 9 µm respectively.  
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The isoelectric point (pI) of vaccinia virus Lister strain, which is likely to be an 
important consideration when developing adsorption-based processes, was found 
experimentally to range from 3.0, when using micro-electrophoesis with pure material, 
to 5.1, when using isoelectric focusing techniques with more crude material (Michen & 
Graule 2010). The pI of a protein is the pH in which the total net charge of the molecule 
is equal. This is documented as being determined by the superposition of the protonated 
and unprotonated functional groups. In the case of vaccinia, complexity is increased 
exponentially as there are multiple different proteins on the viral surface, each one with 
a different isoelectric point. As vaccinia virus is over an order of magnitude lager than a 
typical protein such as a monoclonal antibody (mAb) (~12nm), the location of charge 
densities on the viral surface will also have an effect on the adsorption characteristics of 
the virus, meaning that even if the overall net charge is negative at physiological pH a 
virus may still be able to adsorb to a cation exchange (CIEX) matrix. 
 
2.1.2 Vaccinia Virus Life Cycle 
 
The life cycle of vaccinia virus is complex, the mechanisms of which are of particular 
importance both clinically and from a process development perspective when 
developing oncolytic vectors.  
Unusually for DNA-based virus, vaccinia replicates in the cytoplasm of a host cell, and 
once mature, is referred to as Intracellular Mature Virus (IMV). At this stage the virion 
is thought to be surrounded by a lipoprotein membrane (Townsley et al. 2005). As the 
IMV moves away from the viral factory, transported on microtubules, it is wrapped with 
a double membrane derived from the trans-Golgi apparatus and is given the name 
Intracellular Enveloped Virus (IEV). The IEV is then moved to the cell surface by 
35 
 
fusing with the cell membrane, becoming referred to as Cell Associated Enveloped 
Virus (CEV). This induces the formation of actin tails that act to propel the virus away 
from the cell surface. At this point the virus is known as Extracellular Enveloped Virus 
(EEV) (Smith et al. 2002). 
The therapeutic benefits of the different viral forms are not well known. All viral forms 
are known to be infectious, but there is some speculation that vaccinia virions with a 
producer cell derived envelope (IEV,CEV, or EEV) might stimulate more of an innate 
immune response than IMV which in turn is thought to limit the number of infectious 
viral particles able to migrate to tumorigenic tissues (Ferguson, Lemoine, & Wang 
2012). 
 
2.1.3 Use of Vaccinia as a Smallpox Vaccine (1967-1980) 
2.1.3.1 Background and History of Smallpox Vaccination  
 
Edward Jenner is regarded worldwide as the initial promoter of vaccination after 
publishing his work entitled “An inquiry into the causes and effects of the variolae 
vaccinae” in 1798. 
This work describes the use of cowpox, horsepox and attenuated smallpox to vaccinate 
against endemic smallpox, which at the end of the 18
th
 century was recognised as a 
major public health threat (Baxby 1999). 
 The worldwide eradication of smallpox, which was declared by the World Health 
Organisation (WHO) in May 1980 (Fenner et al. 1988), is arguably the most famous use 
of vaccinia virus in the 20
th
 century.  It was a program launched in 1967 and run over 13 
years, that aimed to eradicate smallpox from 31 countries around the world.  According 
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to (Fenner, Henderson, Arita, Jezek, & Ladnyi 1988) it is estimated that ~300 million 
people were vaccinated each year.   
 
2.1.3.2 Obstacles in the Development and Supply Chain of vaccinia virus 
as a smallpox vaccine 
 
Due to the immense scale of the project, vaccinating such a large group of people from 
all over the word using an infectious virus, the WHO had to deal with a number of 
significant engineering challenges. The first was how to produce enough virus to meet 
the world’s demand. The next challenge revolved around how to effectively distribute 
the vaccines to hot and hard to access places across the globe without it loosing 
infectivity.  
In answer to the first obstacle, three main strategies of vaccine production were 
established. Virus was produced within endemic countries, donations were made 
directly to the WHO, subsequent to a resolution of the Twelfth World Health Assembly 
in 1959 (Fenner, Henderson, Arita, Jezek, & Ladnyi 1988), and virus was supplied 
directly to developing countries from bilateral aid organisations. 
The second obstacle was tackled by the use of freeze-drying, a technique rediscovered 
by Shackell in 1909 (Meryman 1976). It was used in place of a liquid formulation for 
the New York City Board of Health (NYCBOH) strain of vaccinia virus, which was 
developed in part by Wyeth® as Dryvax® (J.Michael Lane 2003). The advantages of 
the freeze-dried virus preparations were that they had an increased shelf-life and could 
be distributed easily without losing infectivity (J.Michael Lane 2003). 
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2.1.3.3 Production of the Smallpox Vaccine (Vaccinia Virus) 
 
During the eradication program vaccinia virus was generated from lymph collected 
from the skin of live animals, often calves and sheep, that had been infected with 
vaccinia (Monath et al. 2004). Purification was then performed by using sucrose 
gradient ultracentrifugation, which would typically give a  percentage viral recovery of 
between 33% and 63% (Joklik 1962). While quality control measures were on the 
agenda of the WHO, they were not as developed as they are today. The manufacture of 
vaccinia virus in the form of Dryvax® by Wyeth® caused a number of undesirable side 
effects due to the presence of adventitious agents and other impurities (Monath, 
Caldwell, Mundt, Fusco, Johnson, Buller, Liu, Gardner, Downing, Blum, Kemp, 
Nichols, & Weltzin 2004). Adverse reactions included major cutaneous reactions such 
as vaccinial skin infection, particularly in patients with eczema, as well as acute 
myopericarditis (inflammation of the pericardium and heart) and encephalitis 
(inflammation of the brain). This was often seen in immunocompromised patients and 
patients with cardiac diseases. For this reason there has been a strong drive since this 
campaign to improve the safety of viruses and other therapeutic agents by developing 
well characterised and validated processes. Work has also focused on modifying 
existing strains to reduce virulence and pathogenicity (Tartaglia et al. 1992).  
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2.1.4 Use of vaccinia as an oncolytic and immunotherapy vector  
2.1.4.1 Background to Oncolytic and immunotherapeutic viral therapies  
 
An oncolytic virus is a virus that is known to infect, replicate in and lyse tumour cells 
preferentially to normal cells. Oncolytic viruses are also thought to be able to stimulate 
anti-tumour specific immune responses against certain antigens produced by cancer 
cells.  
The immunogenicity of cancer cells (their ability to stimulate an adaptive immune 
response) varies between cancer types and also among individuals. It is thought likely 
by Pierre G. Coulie (Blankenstein et al. 2012) that all tumours cells present antigens 
that can be recognised and targeted by T-cells. However certain cancers, one example 
being melanomas, produce antigens that trigger a more elicit immune response than 
antigens specific to other cancer types. This allows for the development of more 
effective immunotherapies.  
It has been postulated in the past that differences in immunogenicity of cancer cells has 
to do with their expression of self and non-self-antigens. Self-antigens are antigens that 
are normally produced by healthy cells in the body while non-self-antigens are antigens 
specifically produced by tumour cells. More recently, however, this theory has been 
challenged, and (Pradeu and Carosella 2006) describe an alternative. This is that it is not 
the difference in an antigen’s origin that impacts its immunogenicity, but in fact 
differences in the molecular structure of the antigen’s epitope. They put forward the 
view that epitope structures that are significantly different to those that the immune cells 
regularly interact with are more likely to elicit an immune response. This is potentially 
significant as a non-self-antigen may be able to fool the immune system by mimicking 
epitope structures of self-antigens. 
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A number of monoclonal antibodies acting as vaccines and immunomodulation agents 
against cancer have already been approved by the FDA, but it is widely accepted that 
combinatorial immunotherapies and more effective delivery platforms need to be found 
if the treatment of cancer by immunotherapy is going to be successful.  
 
2.1.4.2 Recent Advances in Oncolytic Therapeutics  
 
A number of viruses have been considered for their potential oncolytic applications. It 
has become relatively well known that viruses such as vaccinia (Hung et al. 2006), 
reovirus and Newcastle disease virus (McCart et al. 2001), as well as human papilloma 
virus (HPV) and Epstein-Barr virus (EBV) (Blankenstein, Coulie, Gilboa, & Jaffee 
2012) can infect and replicate in tumour cells preferentially to normal cells. In addition, 
herpes simplex virus type 1 and adenovirus can be engineered to be less pathogenic to 
healthy human cells and more tumour specific, suggesting that they could be developed 
into successful oncolytic agents (Ferguson, Lemoine, & Wang 2012), although 
oncolytic adenovirus has a number of limitations, most notably being poor spread 
through tumour cells (Shayakhmetov et al. 2002).  
The first oncolytic therapy, Oncorine, was licenced in China for the treatment of head 
and neck cancer in November 2005, and produced by Shanghai Sunway Biotech. This 
virus is a genetically modified recombinant human adenovirus 5 (AdV) (Garber 2006).  
While this has been identified as a fantastic and encouraging result for the field, Ken 
Garber outlines that further work is needed in order to convince the rest of the 
developed world to invest in the same strategies in his review article “China Approves 
World’s First Oncolytic Virus Therapy For Cancer Treatment” (Garber 2006). It 
appears that the Chinese regulators based their approval on objective response rate 
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rather than overall patient survival. This was made difficult owing to the fact that a 
number of patients lived in rural places and were never revisited by doctors once initial 
responses were recorded. This is recognised as a “weakness in the clinical trial” by the 
company’s president and plans to report survival rates in subsequent trails, as well as an 
intention to follow up with a number of patients from the AdV trail has been stated by 
Shanghai Sunway Biotech (Garber 2006).  
More recently T-Vec or Imlygic
®
 licenced by Amgen, Inc. became the first oncolytic 
viral therapy licenced in the US. T-Vec was derived from human herpes simplex virus 
type 1 and was licenced on 27
th
 October 2015 by the US food and drugs administration 
(FDA) as an oncolytic virus for use in melanoma patients with injectable but non-
resectable lesions in the skin and lymph nodes (Pol et al. 2016). 
 
2.1.4.3 Obstacles to the Systemic Delivery of Oncolytic Viral Therapies   
 
The delivery of oncolytic viruses by intravenous injection has a number of potential 
advantages.  A viral therapy that can be injected intravenously has the potential of being 
able to reach distant metastasis as well as primary tumours. Intratumoural injection of 
oncolytic virus has shown some success in targeting solid tumours; however, it is well 
understood that death from cancer is often due to metastatic disease or recurrence, 
especially in distant hard to reach tumours, for example in the brain or pancreas 
(Ferguson, Lemoine, & Wang 2012). 
One of the major challenges is that host defences limit the ability of viruses to infect 
tumour cells, particularly when injected intravenously. These include the activation of 
complement, neutralising antibodies and antiviral cytokines. There has also been 
reported uptake of virus by tissues and macrophages, all which limit the ability of the 
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virus to remain in the bloodstream and target distant metastasis (Ferguson, Lemoine, & 
Wang 2012;Wong et al. 2010). The limited ability of certain viruses to trigger a tumour-
specific immune response can also be a limiting factor (Pol, Kroemer, & Galluzzi 
2016). The limitations of systematic delivery of oncolytic viruses can be observed in 
Figure 2.1.  
 
Figure 2.1: Illustration to show hurdles encountered by the systemic delivery of oncolytic 
viruses (Adapted from (Ferguson, Lemoine, & Wang 2012)). This shows that the action of 
blood vessels, neutralising antibodies, and uptake by organs can reduce the amount of 
virus available for uptake by tumour cells.  
 
2.1.4.4 Clinical Applications of Vaccinia Virus 
 
There are a number of reasons why vaccinia virus has been identified as a good 
candidate for oncolytic therapy (Kirn & Thorne 2009). One reason is that there is a lot 
of both laboratory and clinical data available on vaccinia virus biology and host 
response profiles to infection, following the use of multiple vaccinia virus strains during 
the smallpox eradication program. Commonly used strains for therapeutic use include 
the New York City Board of Health (NYCBOH), Lister, Copenhagen, Western Reserve, 
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Tian Tan, Modified Vaccinia Ankara (MVA), and NYVAC (derived from the 
Copenhagen strain) (Kirn & Thorne 2009). It should be noted that these vary in their 
oncolytic potential.  
Another reason is that vaccinia has been shown to be very tumour selective, this is due 
in part to the fact that tumour cells produce less interferons (IFN) than normal cells in 
response to vaccinia virus infection (Luker et al. 2005). Vaccinia virus has also been 
shown to have a high host range and tissue tropism, allowing for broad spectrum tumour 
specificity (Tysome, Briat, Alusi, Cao, Gao, Yu, Wang, Yang, Dong, Wang, Deng, 
Francis, Timiryasova, Fodor, Lemoine, & Wang 2009).  
Throughout the past decade, genetic engineering has been used to increase viral safety 
profiles and enhance clinical efficacy. One example of a genetic modification used in 
pre-clinical trials using the Western Reserve strain of vaccinia virus is the deletions in 
both the thymidine kinase (TK) and vaccinia growth factor (VGF) genes. This was 
found to activate the transcription factor E2F and the Epidermal growth factor receptor 
pathway (EGFR pathway), which in turn triggers the oncolytic effect (Kirn & Thorne 
2009).  
The virus was also engineered to express granulocyte-macrophage colony-stimulating 
factor (GM-CSF) which was shown to stimulate viral attack of foreign tumour cells. 
This reduced the potency of vaccinia virus in normal cells while increasing it in tumour 
cells (Thorne et al. 2007).  
A different approach using the Lister stain of vaccinia virus for the treatment of 
pancreatic cancer is the insertion of a combined endostatin-angiostatin fusion gene 
(Scappaticci et al. 2001) which, when inserted in combination, has been shown to act 
synergistically to inhibit angiogenesis (Tysome, Briat, Alusi, Cao, Gao, Yu, Wang, 
Yang, Dong, Wang, Deng, Francis, Timiryasova, Fodor, Lemoine, & Wang 2009). This 
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approach has also been demonstrated in head and neck squamous cell carcinoma 
(HNSCC) models in vitro as well as in vivo (Tysome, Wang, Alusi, Briat, 
Gangeswaran, Wang, Bhakta, Fodor, Lemoine, & Wang 2011). 
The potential therapeutic benefit of oncolytic viral vectors is undoubtedly very high. It 
is clear that a significant amount of work is still required in order to find viral strains 
with the right genetic modifications to deliver optimal therapeutic outcomes, but these 
medicines will also need to be affordable. This will require the development of 
commercially scalable and cost-effective processes early on in clinical development. 
 
2.2 Options and Considerations When Developing Viral Bioprocesses 
2.2.1 Introduction 
 
In the early 20
th
 century, from around 1900 until 1966, the smallpox vaccine (vaccinia 
virus) was produced from the lymph of calves and sheep. In the 1920’s the concept of 
bacterially sterile cell culture preparations was starting to become better understood and 
legislated. The large number of vaccinia doses required for the eradication of smallpox, 
however, meant that the majority of vaccines were not able to be produced in sterile 
culture, even though the technology was available (Fenner, Henderson, Arita, Jezek, & 
Ladnyi 1988). The result was that viral preparations were often contaminated with 
bacteria and toxins that could not be completely removed by technologies such as 
ultracentrifugation. This increased the incidence of adventitious side effects.  
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2.2.2 Cell Culture and Primary Recovery 
 
The majority of modern viral therapies including vaccines are now produced in either 
chicken eggs, or cell culture, with common cell lines being human, monkey, avian and 
insect cells. With the advancement of modern adherent cell culture technologies, egg-
based manufacturing is usually not the preferred option. This is due to costs associated 
with scaling out, as well as environmental and animal welfare concerns. There are also 
risks to manufacturing resulting from avian flu and other diseases. Having said this, for 
the manufacturing of influenza vaccine, egg-based production is used for the majority of 
vaccines manufactured globally (Soema et al. 2015).  
Many viral cell lines are adherent, and will only grow as monolayers on solid surfaces. 
Technologies currently used for culture of adherent cells with their pros and cons are 
listed in Table 2.1 
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Table 2.1 List of currently available technologies for expanding adherent cell lines with pros, cons as well as an example of commercially available systems 
(table not exhaustive) 
Technology Pros Cons Example 
T-Flasks 
Roller - 
Bottles 
Cell stacks  
- Good productivity 
- Easy to handle in small volumes 
- Flexible 
- Can recover cells easily 
- Do not require cell line development 
- Limited scale up capacity 
- Not well controlled or automated 
- Hard to run in fed batch mode 
Corning
®
 Cell 
Culture Flasks 
Packed Bed Bioreactors - Scales up to ≥ 500 m2  
- Can be run in fed batch or perfusion mode 
- Fully intergraded controls 
- Does not require cell line development 
- Poorly characterised small scale 
systems 
- Inherent variability in packed bed 
characteristics 
- Cannot recover cells easily 
iCellis 500 (Pall Inc) 
Hollow Fibre Bioreactor - High surface area to volume ratio (100-200 
cm
2
/mL 
- Can be run at low sheer for longer process 
times 
- HF designed now well characterised in 
terms of porosity and uniformity 
- Well characterised small scale units 
- Can be run in Fed batch or perfusion  
- Fully intergraded controls 
- Max surface area limited to 2.5 m2 
(lower than the iCellis) 
- Difficult to harvest cells (although 
easier than iCellis)  
- May require cell line development  
FiberCell cartridges 
(FibreCell System 
Inc) 
Micro carriers  - Easily scalable  
- Large surface area achievable  
- Fully integrated controls 
- Can run in fed-batch and perfusion reactors 
- May require cell line development  
- Hard to recover cells  
- Possible productivity limitations 
Cytodex  
GE Healthcare 
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For therapeutic areas such as some cancers, or genetic disorders affecting muscular 
tissues (an example being Duchenne Muscular Dystrophy), the amount of therapeutic 
virus needed to be produced is considerable. Some examples of technologies designed 
to scale up adhering cells are shown in Table 2.1; however, challenges to large scale 
production are a massive driver to adapt commonly used cell lines such as CV-1, Vero, 
or HEK293 cells to grow in suspension. The reasons for this are that adherent cell 
culture technologies will always be limited by scale, therefore affecting overall process 
productivity. It can also be very difficult with many technologies to recover the cells 
which, especially for purposes of in-line monitoring, makes robust process control and 
characterisation difficult. The major disadvantage of adapting an adherent cell line to 
grow in culture, however, is that it requires extensive cell line development which in 
turn requires time, resources and significant expertise. 
Infectious viral particles in culture have been shown to be concentrated both inside the 
cell, therefore requiring cell lysis, and in the supernatant. Specific examples are vaccinia 
virus (Smith, Vanderplasschen, & Law 2002), which has a number of viral forms that 
are concentrated inside the cell, and murine leukaemia virus (MLV) (Aboud et al. 
1982). As a rule of thumb, it is often seen that non-enveloped virus such as AAV are 
concentrated inside the cell, whereas enveloped viruses such as Lentivirus are 
concentrated in the supernatant (Segura et al. 2011). If the virus is concentrated in the 
supernatant, the main challenge becomes removing the cells whilst maintaining high 
yields of infectious virus. It can also be a challenge to remove host cell proteins, DNA, 
lipids, and other process-related impurities. 
If the virus is located intracellularly, then cellular disruption is required in order to 
release the virus. Perhaps the most common laboratory scale method for cell disruption 
is multiple freeze thaw cycles of pelleted cells post centrifugation. At large scale, 
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however, this becomes impractical and expensive. Scalable methods include hypotonic 
shock, chemical lysis, ultra-sonication and mechanical disruption. Mechanical 
disruption by homogenisation is arguably the method of choice due to its ease of 
scalability and reproducibility (Monath, Caldwell, Mundt, Fusco, Johnson, Buller, Liu, 
Gardner, Downing, Blum, Kemp, Nichols, & Weltzin 2004). Changes in pressure and 
high shear forces can be produced and controlled to break open cells without damaging 
the viral particles, although this will likely depend on the viral size liability. An 
example of the use of homogenisation can be found in (Joklik 1962). Alternatives are 
agitation with glass beads as described in (Zwartouw et al. 1962). 
In terms of cell removal, common methods include centrifugation and microfiltration. 
Flocculation, precipitation and aqueous two phase extraction, some of which will be 
described in more detail later in this chapter, have been attempted but are not common 
practice. Centrifugation is a common primary recovery unit operation in protein 
manufacturing due in part to its ease of scalability (Maybury et al. 2000). As many 
oncolytic and gene therapy products are currently produced at relatively small scale, 
microfiltration unit operations are discussed more in relation to viral primary recovery 
processes. Companies such as EMD Millipore and 3M have commercialised a range of 
depth filters which they have suggested can be used generically for viral bioprocesses. 
Application notes are available showing the use of depth filters as a primary recovery 
step for cell culture-based influenza vaccine processes (EMD Millipore 2014). 
Membrane filters of differing pore sizes can be run in both dead end and tangential flow 
filtration (TFF) mode. An example of membrane dead end filtration can be found when 
manufacturing cGMP lentiviral vectors (Ausubel et al. 2012). Examples of TFF 
filtration applications in viral primary recovery and as a viral concentration step can be 
found in Section 2.2.3.2. 
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2.2.3 Purification 
2.2.3.1 Ultracentrifugation 
 
The gold standard unit operation for the purification of viral particles is 
ultracentrifugation, used throughout the 20
th
 century for the purification of multiple pox 
viruses (Zwartouw, Westwood, & Appleyard 1962). Ultracentrifugation can be broken 
down into two different modes (Segura, Kamen, & Garnier 2011). The first is 
equilibrium density ultracentrifugation, and the second is rate zonal ultracentrifugation. 
Equilibrium density ultracentrifugation uses a high density bed of sucrose, caesium 
chloride, (CsCl), iodixanol, Percoll
®
, or Nycodenz
®
 to separate virus material based on 
its buoyant density. Rate zonal ultracentrifugation separates based on size and density. 
Density gradient ultracentrifugation works by loading virus either manually into a 
stationary ultracentrifugation tube containing a high density bed as described above, or 
continuously into the bottom of a packed rotating rota, the latter being more common at 
large scale. Rotational speeds can reach ≥ 40,000 rpm, with a resulting relative 
centrifugal force (RCF) of ≥ 100,000g, The duration of the process can last from many 
hours to even days, while particles move down the bed from an area of low 
concentration of media to an area of high concentration until the buoyant density of 
each particle reaches that of the media. Rate zonal ultracentrifugation on the other hand, 
while similar, can be performed more rapidly. A smaller, often more concentrated 
volume of virus is loaded onto the top of a gradient bed, which is again rotated at high 
speeds. While the virus will still band once it reaches its buoyant density if left to settle 
for long enough, the different particles present in the sample will travel down the bed at 
differing velocities depending on their size as well as (to a lesser extent) any differences 
in density and overall viscosity. In order to take advantage of this phenomenon, the 
ultracentrifuge is stopped prior to density equilibrium being reached, so that each 
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volume fraction can be analysed.  This can be a high resolution technique used for viral 
purification due to the difference in size between virus particles and common 
impurities. However, as sample volume needs to be extremely small (~10% bed 
volume) scale up is challenging. At bench scale, typical bed volumes scale to ~250 mL. 
When using density gradient ultracentrifugation, vaccinia virus will often require 
around 12 hours (typically overnight) to band; smaller viral particles such as AAV can 
take up to 3 days. The operation is typically performed at 2-8⁰C to reduce the risk of 
viral inactivation. 
The general disadvantages of density gradient ultracentrifugation are that the technique 
is very time consuming, requires skilled operators and is very labour intensive. At 
production scale it commonly takes two operators to setup and clean the system. This, 
coupled with the fact that in the past recovery of infectious viral particles was shown to 
be low, between 33% to 63% being fairly liberal estimates (Joklik 1962), demonstrates 
the need for a more optimal and scalable purification processes for viruses.  
There are several companies that produce density gradient ultracentrifuges for 
production scale processing. A relevant example is Alfa Wassermann which 
manufactures a KII ultracentrifuge that has a maximum process capacity of 200 L (Alfa 
Wassermann 2013) (Figure 2.3). 
Density gradient ultracentrifuges are not run in the same way from bench to 
manufacturing scales. Bench-scale ultracentrifuges are designed to be run in batch mode 
while larger manufacturing scale ultracentrifuges are often run in a semi-continuous 
mode. At bench-scale, an ultracentrifuge tube is filled with a packing matrix such as 
sucrose at differing concentrations from top to bottom. High concentrations are loaded 
into the tube first and then lower concentrations are added on top. This produces a 
sucrose concentration step gradient from the top to the bottom of the tube. Alternatively, 
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instead of sucrose, salts such as caesium chloride can also be used. These form linear 
concentration gradients when run under high centrifugal forces due to the high density 
of caesium salt (CsCl). In both cases, virus is loaded into the top headspace of the tube, 
which is then placed into the ultracentrifuge rotor and rotated at high g force (~RCF x 
100,000). 
Once the run is complete, the tubes are removed and harvested using a sterile needle 
which is used to pierce the bottom of the tube. Fractions are then removed and analysed 
for viral particles. This process is time consuming and prone to human error. 
Semi-continuous ultracentrifugation works slightly differently to batch 
ultracentrifugation as shown in Figure 2.2. 
 
 
Figure 2.2 A graphical representation taken from (Sandra Merino 2015) to show how 
large scale ALFA WASSERMAN KII ultracentrifuges work. 
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Each step (1-7) as indicated in Figure 2.2 is listed below: 
1. Ultracentrifugation gradient matrix is pumped into a stationary rotor (maximum 
volume 3.2 L) 
2. Rotor is slowly accelerated and the bed aligns vertically on the walls. 
3. Virus material is loaded into the bottom of the rota and particles are captured at 
the top of the bed – towards the middle of the rotor. Effluent flows out the top of 
the rota. 
4. Viral particles move down the bed from the centre of the rota to the outer walls 
until their buoyant density is equal that of the media. 
5. The rotor is decelerated until stationary. 
6. The bed reforms horizontally but the gradient remains in place. 
7. Fractions are pumped out the bottom of the rotor and passed through a UV cell 
to determine where virus has banded. Fractions can also be sampled for further 
analysis. 
 
One of the major limitations of ultracentrifugation is volumetric throughput. Bench 
scale centrifuges are limited to a few hundred millilitres. Large scale ultracentrifuges 
can process more material, but this is still limited to a maximum of ~200L depending on 
the virus being purified. According to Alfa Wassermann this can be as low as 5 L for 
Hepatitis B, while in the case of influenza process volumes can reach up to 150 L. After 
a run the bed is collected in fractions between 15 and 500 mL. Each fraction is analysed 
for infectious virus particles. There have been some issues reported when using 
ultracentrifugation related to the removal of genomic DNA, which has a similar density 
to many viral particles. Alfa Wassermann suggests the use of benzonase if this is found 
to be the case; however, it should be noted that this is an expensive processing option as 
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nucleases and assays to test for their removal are costly and require validation. (Alfa 
Wassermann, 2013).  
Another possible disadvantage of ultracentrifugation is that the machines can be 
difficult to clean as they need to be taken apart manually. It can take two operators, 
working together, several hours to clean and shut down a single system. This means that 
even if several machines are used in parallel in order to process a large volume of 
material, a bottleneck in terms of time and labour is experienced. 
Ultracentrifuge rigs are also very expensive with prices greater than 300,000 USD for a 
process scale rig. Costs associated with ultracentrifugation will likely increase further 
when validation qualification and infrastructure requirements for GMP use are taken 
into account.  
 
Figure 2.3 Picture of a KII Ultracentrifuge from Alfa Wassermann (Sandra Merino 2015). 
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There are a number of challenges to large scale ultracentrifugation making many 
industrialists keen to find alternatives. What is important to keep in mind, however, is 
that ultracentrifugation also has some advantages which can be difficult to find in other 
emerging technologies; these, together with some disadvantages, are summarised in 
Table 2.2. 
Table 2.2 Advantages and disadvantages of ultracentrifugation 
Advantages of Ultracentrifugation Disadvantages of Ultracentrifugation 
 
- Not reliant on changes in pH or salt 
concentrations to generate a 
separation. These can inactivate 
some viruses 
- Low sheer environment  
- Well tried and tested technique 
requiring little process development 
- Rotas can be steam sterilised  
- Some processes give high 
percentage recovery and purity 
 
- High capital expenditure 
(CAPEX) and labour costs  
- Relatively low throughput - 
difficult to scale up 
- Can be very manual and 
laborious  
 
2.2.3.2 Alternatives to ultracentrifugation  
 
There are a number of scalable alternatives to ultracentrifugation. Comparison studies 
dating back to the 1980’s have shown that many can outperform bench scale 
ultracentrifugation. 
The issue is that in order to replace ultracentrifugation, in which significant investments 
have already been made, results from other technologies need to show significant 
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improvements in purity and yield as well as productivity. Techniques such as 
chromatography, aqueous two phase and precipitation are not straightforward to 
develop. Complex multifactorial experiments need to be performed in order to generate 
process knowledge and understanding. This is not the case with ultracentrifugation, or 
with TFF. Many factors that affect the separation efficiency of an ultracentrifuge cannot 
be modified; therefore relatively little process development is required. Experienced 
operators are needed to run manufacturing campaigns, and a significant amount of 
capital is required to purchase equipment, but once these are in place, there is often not 
much of a driver to switch technologies.  
The main and most commonly developed alternatives to ultracentrifugation are 
summarised in Table 2.3. 
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Table 2.3 Alternatives unit operations to ultracentrifugation  
Unit Operation Viral purification applications References  
Tangential Flow 
Filtration 
(TFF) 
 
- Both flat sheet (FS) and hollow fibre (HF) filters have 
been used to concentrate and purify viral feed streams 
and can be used to remove cells, cell debris, proteins, and 
DNA from crude lysate. 
- Relatively low molecular weight cut-off (small pore) 
filters are used to remove proteins and DNA.  
- Large pore diameter filters are typically used for the 
removal of cells and larger debris.   
- Filters are commonly manufactured using either 
polyethylene sulfone (PES) or regenerated cellulose 
(RC). 
- Nominal channel diameters range from <100KD to 
>0.45µm  
- One potential drawback is that shear forces need to be 
well controlled to prevent membrane fouling and viral 
degradation. This can be easier to control and measure 
when using HF filters rather than FS. 
- Flux vs TMP studies are required during process 
development in order to generate understand of critical 
process parameters (CPPs). 
- In general TFF is considered as a relatively low 
resolution technique, but easily scalable to large process 
volumes. 
 
(Negrete et al. 
2014;Wickramasin
ghe et al. 2005)  
 
  
 
Gel Filtration  
- Size exclusion chromatography also known as gel 
filtration (GF) has been shown to achieve higher yields 
than density gradient ultracentrifugation, although 
sometimes struggles to remove large contaminants such 
as genomic DNA.  
- Typical issues associated with GF often relates to 
volumetric throughput. Good separation requires low 
load volumes, typically ~2% of the total column volume.  
- Due to load volume restrictions GF is often found 
towards the end of the process once volume is reduced. 
- GF benefits by allowing isocratic elution often in 
physiological buffers such as PBS. 
- In general GF is regarding as high resolution, low 
volume technique. 
 
(Andreadis et al. 
1999;McGrath et 
al. 1978) 
Precipitation  
- Precipitation using PEG, ammonium sulfate and calcium 
phosphate has been used to aggregate viral particles 
allowing removal by low speed centrifugation.  
- Variable recovery of infectious viral particles has been 
reported in the literature likely due to changes in osmotic 
pressure. Reported for Retrovirus, but thought likely to 
affect other particles.  
- A combination of PEG 6000 followed by Sepharose Cl-
4B (GF) has been reported to achieve a good recovery 
and purification efficiency of both extracellular and 
intracellular moloney murine leukemia virus. This was 
reported as being especially true for larger volumes as 
the PEG 6000 was able to pellet virus from bulk fluid 
prior to chromatography. 
- Potential issues regarding large scale manufacturing are 
solubilising viral pellets formed, and removal of co-
precipitated impurities. 
(Morenweiser 
2005) (Aboud, 
Wolfson, Hassan, 
& Huleihel 1982)  
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Unit Operation Viral purification applications References  
- The mechanisms of viral precipitation are generally not 
well understood. This leads to challenges in process 
development. 
 
Aqueous Two 
Phase (ATPS) 
 
- Aqueous two phase has been attempted with chemicals 
such as PEG, dextran and polyvinyl alcohol to separate 
virus material from cellular components, An example 
being a dextran-polyethylene glycol system successfully 
used to concentrate and purify HIV-1 along with external 
gp120 protein.  
- Scale up is generally considered possible using 
convention extraction equipment used in the chemical 
industry, however requires investment. 
- ATPS requires a lot of process development as phase 
equilibrium and protein partitioning is not well 
understood 
- Raw material costs (polymers) is also a concern. 
(Morenweiser 
2005) (HAMMAR 
and GILLJAM 
1990) (Cunha and 
Aires-Barros 
2000) 
Chromatography  
- Packed bed systems and continuous polymer monoliths 
and membrane sheets have been used successfully to 
purify a range of viral particles for clinical use. 
- Common types of chromatography used include Affinity 
(AF), Cation and Anion exchange, (IEX), Hydrophobic 
interaction, (HIC), Immobilised metal affinity (IMAC) as 
well as Pseudo-affinity and mixed modal resins. 
- Use  of chromatography to purify viruses is discussed in 
more detail in Section 2.3. 
 
(Cheng et al. 
2001;Gagnon 
2008;Wolff et al. 
2010b) 
 
 
New generation chromatography using membranes, fibres, and monoliths are perhaps 
the most widely published alternatives to ultracentrifugation for capture and purification 
of viral particles. Advances in resin design have paved the way to some very promising 
process designs with some impressive results.  The next section of this introduction will 
concentrate on chromatographic history, theory, applications and results. 
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2.3 Chromatography 
2.3.1 Overview 
 
Chromatography was first developed by the Russian botanist M.S. Tswett, who has 
often been described as the father of modern chromatography. He published his first 
paper in 1903 on the separation of xanthophylls and chlorophyll on an inulin column. 
His second paper in 1906, on the insolubility of chlorophyll in petrol and ligroin, 
resulted in an early description of adsorption (Ettre and Sakodynskii 1993a;Ettre and 
Sakodynskii 1993b). Chromatography can, in general terms, be described as “a 
separation procedure for resolving mixtures and isolating components” by a process of 
“differential migration”(Doran 2005).  
Chromatography has been used for the separation of a large number of biological agents 
from proteins, vitamins, and amino acids, to viruses, virus-like particles (VLPs) and 
plasmid DNA (pDNA). 
A solvent otherwise known as the mobile phase, typically a liquid in liquid 
chromatography or a gas in gas chromatography, travels down a column and interacts 
with a stationary phase at different rates depending on its affinity for the matrix (Doran 
2005). This is traditionally a solid support, although it can also be a liquid in liquid-
liquid chromatography. 
For most preparative bioprocess applications, the stationary phase consists of a solid 
inert compound. These structures are typically either porous beads, of ~40-100 µm, 
which have small micropores of around 100 nm on their surface, or solid porous 
materials with highly crosslinking channels. These channels can have very large 
diameters ranging from 0.4 to 100 µm, and are therefore often used for separation of 
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large macromolecules such as viruses and virus like particles (VLPs) or even cells 
(Dainiak et al. 2006). 
Examples of typical bead materials, often used for protein purification, are highly cross 
linked agarose (MabSelect SuRe LX®, GE Healthcare Life Sciences), polystyrene 
divenyl benzene (POROS ® Applied Biosystems), polyacrylamide, (Bio-Gel, Bio-Rad), 
and hydrophilic cross-linked vinyl polymer (Toyopearlm TosoH Biosep). 
There are a number of single rigid porous chromatographic structures on the market. 
The most common are membrane adsorbers and monoliths. 
An example of a membrane that was commonly used in bioprocessing, although now 
discontinued, was ChromaSorb (EMD Millipore, Darmstadt, Germany) made from 
polyethylene. Another example is Sartobind
® 
(Sartorius, Gottingen, Germany) which is 
made from stabilised reinforced cellulose. This product is available as a strong CIEX 
with sulphonic acid ligands, a strong anion exchange (AIEX) with quaternary 
ammonium ligands, and a HIC that uses a phenyl ligand. A salt tolerant addition, 
Sartobind STIC
®
 designed for HCP, DNA and endotoxin removal is also available, and 
it consists of primary amine ligands. The other main membrane adsorbers on the market 
are Mustang filters (Pall, NYC, USA). from which Mustang S and Q are both made 
from polyethersulfone (PES) and come with sulphonic acid and quaternary ammonium 
ligands respectively.   
Convective interaction media (CIM) monoliths are also single rigid open channel 
chromatographic structures commercially made at large scale from 
poly(glycidylmethacrylate-co-ethyleneglycoldimethacrylate, (BIA Separations, 
Ajdovscina, Slovenia). In general, charged, hydrophobic, affinity or active groups are 
chemically synthesised on the surface of the solid methacrylate support and interact 
with solutes via hydrophobic or electrostatic interactions, hydrogen bonding and/or Van 
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der Waals forces. The two modes of adsorption-based chromatography to be discussed 
in this thesis are preparative ion exchange and hydrophobic interaction chromatography.  
 
2.3.1.1 Ion exchange chromatography (IEX) 
 
In ion exchange chromatography adsorption is initiated by electrostatic interactions 
between a solute and the stationary phase. Ion exchange columns can be either 
positively charged, known as anion exchangers (AIEX), or negatively charged, known 
as cation exchangers (CIEX). Typical AIEX ligand chemistries include quaternary 
amine groups (QA) or diethylaminoethyl groups (DEAE). These chemistries represent 
strong and weak anion exchanges respectively. Primary amines are also common, 
although in preparative AIEX they are more often used for single use negative capture 
polishing steps, which are designed to capture residual impurities such as HCPs and 
DNA. 
Common strong CIEX ligands are sulfate groups (SO3) in the form of sulphonic acid or 
sulfopropyl groups. Weak CIEX ligands often consist of carboxymethyl groups (CM) 
Separation is dependent on the difference in net charge between solute molecules, and 
the subsequent affinity of the solutes to the adsorbent. pH and ionic strength can be 
manipulated to bring about adsorption and elution depending on the isoelectric point of 
the solute of interest. 
Increasing the salt concentration (often a neutral salt such as NaCl) allows smaller 
charge dense ions to compete with the often larger solute molecules for binding sites.  
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2.3.1.2 Hydrophobic interaction chromatography (HIC) 
 
Hydrophobic interaction chromatography relies on the interaction between hydrophobic 
patches on the surface of a solute and the often non-polar ligands on the stationary 
phase. Butyl or phenyl groups are commonly used as preparative ligands, although 
hydroxyl and epoxy groups can also be used if a weaker interaction is desired. 
Adsorption is thought to be driven by an increase in entropy as a result of a reduction in 
the Gibbs free energy of the solute in solution. This occurs by increasing the 
concentration of kosmotropic salts such as ammonium sulfate in the load material. In 
addition to this, hydrophobic amino acids present close to the surfaces of proteins are 
thought to form surface hydrophobic cavities, due to the reduction in free water 
molecules. These cavities are then able to bind to hydrophobic ligands. A reduction in 
salt concentration and changes in pH are typically used to bring about elution, although 
organic solvents are sometimes required. 
 
2.3.2 Practical considerations when developing viral chromatography 
steps  
2.3.2.1 Trade-offs when evaluating process performance 
 
A common trade-off needing to be considered when developing chromatographic 
processes for the majority of products is “recovery versus purity”. 
In order to increase the optimum performance of a process, both the percentage 
recovery of the product of interest as well as the removal of impurities need to be 
maximised. It is here that process developers come across a common problem. When 
factors influencing process performance are varied, whether numerically or 
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categorically, optimum conditions favouring one response or the other are often found 
rather than both together. A compromise between the two responses thus becomes 
unavoidable. As a result, the relationship between each individual individual factor and 
overall process performance is often nonlinear. It is also common that areas of local 
optima can be found in a design space. This can be helpful in giving process developers 
more flexibility, especially when considering scale up challenges to achieving a certain 
criteria, since not all factors are as easy to accomplish at large scale as they are at bench 
scale, but can also make the determination of global optima difficult. 
When developing processes for infectious viruses, the complexity of the problem 
increases further. Trade-offs relating to infectious viral processes need to take viral 
infectivity into account as well as total particle recovery. Conditions that are able to 
recover all viral particles loaded without any impurity contamination would only be 
acceptable if the viral particles recovered were infectious. 
For this reason viral stability during processing and storage is of paramount importance 
and needs to be characterised. In order to do this, stability studies need to be performed 
over time at a range of temperatures and conditions that best represent those of a 
process. 
Many viral particles are thought to be labile, although the exact mechanism of 
inactivation is not described in the literature in detail. Viral sample handling needs to be 
planned with stability data in mind. If viral infectivity crashes at room temperature for 
example, then samples will need to be put into controlled temperature storage as soon as 
possible after a fraction has been collected.   
Sample handling needs to be consistent so that researches can rule out the possibility 
that any loss in infectivity is the result of a variation in the experimental protocol.  
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2.3.2.2 Resin screening considerations 
 
Both ion exchange and hydrophobic interaction chromatography have been used to 
purify viral particles (Banjac et al. 2014;Gerster et al. 2013a;Opitz et al. 2008;Wolff et 
al. 2010a). What is interesting is that many viruses, especially enveloped viruses, have 
been shown to bind to both CIEX and AIEX at either side of their supposed isoelectric 
points (Banjac, Roethl, Gelhart, Kramberger, Jarc, Jarc, Strancar, Muster, & Peterka 
2014;Wolff, Siewert, Lehmann, Hansen, Djurup, Faber, & REICHL 2010b). This has 
been demonstrated in protein separations in the past; however it appears to be 
particularly commonly in viral chromatography. This is perhaps due to the size and 
complex physicochemical properties of viral particles (Yamamoto and Ishihara 1999). 
For this reason, both strong and weak CIEX, AIEX, and HIC resins should be included 
in initial screening experiments. 
There are a number of bottlenecks that need to be considered when setting up extensive 
screening experiments. Virus process development takes time, one of the major time 
bottlenecks being the infectivity assays. Assays can take anywhere from several days to 
several weeks to run; so unless high throughput screening technologies can be utilised, 
it is imperative to design experiments in a sequential manner in order to give as much 
information as possible per experiment. It can be difficult to generate enough virus 
material to perform extensive screening studies, thus experimental designs need to take 
this into account. The goals of screening studies in viral bioprocessing need to be 
clearly defined from the offset.  
One of the attributes of using chromatography is that there are a lot of factors that can 
be manipulated in order to maximise the productivity and separation achievable. The 
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advantage of this is that there is a lot that can be done to optimise a separation process 
should this be required. Examples are changes in pH, salt concentration, type of buffer 
system in the load, wash and elution buffers, stationary phase and ligand chemistry, and 
type of matrix. The matrix could be a packed bed, monolith or membrane as previously 
mentioned.   
When dealing with complex feed streams such as viruses, this can also be a 
disadvantage as to fully optimise, even a single step, can require a very large number of 
runs. In practical terms, it is impossible to screen every possible factor that might 
influence a separation. Therefore factors to be considered need to be prioritised based 
on previous experience, theoretical understanding and considerations, published 
literature, and often finite resources.  
The use of multifactorial designs such as DoE and Simplex analysis can be useful, and 
have been used successfully in the past to find areas of optima within complex design 
spaces (Konstantinidis et al. 2016). Variability in viral analytics and time taken to 
analyse virus samples, however, make both of these approaches challenging. 
The best process development techniques to utilise for viral separations will vary 
between laboratories and will not only depend on the product, but also on the situational 
constrains such as time available for process development, and equipment availability. 
For this reason a general statement on this topic is of limited use. A lytic virus such as 
vaccinia (which requires infectivity assays to determine viral titre, being developed in a 
laboratory with many other projects and with no high throughput capabilities), will need 
to consider DoE and intelligently designed one-factor-at-a-time approaches rather than 
high throughput screening (HTPD) and simplex analysis. On the other hand, a 
laboratory optimising an AAV separation, which requires qPCR as its major 
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quantitation assay, may well be able to utilise HTPD and Simplex methodologies as 
well as DoE if the resources are available. 
Process developers need to take into account the amount of complexity inherent in the 
feed stream, time required to asses product concentration and impurity profiles, and 
assay variability. 
As described later in this thesis, stability data, refined experimental design and the use 
of a large variety of orthogonal analytical methods can be used to generate reasonably 
robust conclusions on process performance. However, chromatographic process 
development is likely to be more time consuming and expensive compared to other 
techniques such as ultracentrifugation. 
 
2.3.3  Use of chromatography for virus and other macromolecular 
separations  
2.3.3.1 Membrane adsorbers and packed bed columns 
 
Membrane adsorbers have been used to purify viruses and other large macromolecules. 
They have some of the same advantages as monoliths in terms of mass transfer and flow 
independent adsorption; however, the achievable resolution is not as high due to a 
shorter bed length and a less interlinking channel structure. 
 
Figure 2.4 is an illustration of the comparative strengths and weaknesses of membrane 
adsorbers (MA), monoliths and packed bed columns for viral separations. As it can be 
seen in Figure 2.4, membrane adsorbers benefit from high capacity and flow rate, but 
limited resolution. Packed bed columns can achieve high resolution, but need to be run 
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at lower flow rates and cannot achieve as a high capacity as membranes or monoliths. 
Monoliths benefit from being able to run at high flow rates without compromising 
capacity or resolution. 
 
 
 
Figure 2.4 Visual comparison between packed bed, membrane adsorbers and monolith 
chromatography, adapted from (Ales Strancar 2011). 
 
There have been a number of studies that have used membrane adsorbers to purify 
viruses such as vaccinia, influenza, retroviral vectors, adenovirus and others (Peixoto et 
al. 2008;Wolff and Reichl 2008;Wolff, Siewert, Hansen, Faber, & Reichl 2010a). 
(Wolff, Siewert, Hansen, Faber, & Reichl 2010a) describe the use of pseudo-affinity 
membrane adsorbers (MA) combined with HIC resins from the ToyoScreen HIC mix 
pack (Tosoh Biosciences GmbH, Stuttgart, Germany) to purify modified vaccinia 
Capacity 
Resolution Flow rate 
MA 
Packed bed 
Monoliths 
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ankara (MVA) virus with the aim to reduce DNA levels to ≤ 10 ng per dose (as required 
by the WHO 1998). A combination of two membrane adsorbers were used, one with 
sulfated cellulose (SC) and the other with heparin ligands.  A protein present on IMV 
(A27L) is known to bind to heparin (Chiu et al. 2007) making this an attractive 
candidate as a pseudo affinity ligand. It was found that both strategies worked; HIC 
combined with SC-MA and Heparin-MA gave similar total virus particle yields of 
approximately 60 %. Both were able to reduce HCP levels to lower limit of 
quantification (LLOQ), and final DNA levels were comparable and as low as 
10ng/dose.   
It was concluded that nuclease treatment would still be required to robustly reduce DNA 
to specified levels; however, as the amount of DNA was reduced significantly compared 
to other technologies such as ultracentrifugation, the amount of nuclease treatment 
could also be reduced, resulting in a more cost effective process.  
 
SC-MA has also been utilised for MDCK cell culture derived influenza virus capture. 
H1N1 and H3N2 were both purified as described by (Opitz, Zimmermann, Lehmann, 
Genzel, Lubben, REICHL, & Wolff 2008). In this study, commercially available CIEX-
MA and column-based cellufine sulfate were compared to SC-MA. SC-MA showed 
higher infectious virus recovery as well as increased DNA removal when compared to 
both technologies. High flow rates (15 mL/min) coupled with a higher binding capacity 
(13 µg HA/cm
2
) were achieved in comparison to column-based cellufine sulfate 
chromatography, also resulting in an added process productivity benefit over this 
technique.  
It is clear from both studies that pseudo-affinity-based membrane adsorbers are an 
attractive option for capture and polish of large enveloped viruses. It should be noted 
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that neither of these supports are available as catalogue items from Sartorius. But the 
technology shows potential and clearly has advantages over packed bed 
chromatography. There is still room for development to increase vaccinia virus yield 
from 60 % and remove more DNA to achieve concentrations below 10 ng DNA/dose, 
however; if GMP compliant columns are available then pseudo-affinity membrane 
adsorbers might be an attractive process option.  
 
2.4 Monoliths  
2.4.1 History and Overview 
 
There are now several types of monolithic materials on the market. Originally monoliths 
were made from N,N’–methylenebisacrylamide; however, this was replaced with 
piperazine diacrylamide and methacrylamide when it was found that these compounds 
allowed for higher flow velocities (Svec 2008). Process scale commercial monoliths are 
now made from poly(glycidylmethacrylate-co-ethyleneglycoldimethacrylate) or 
Styrene-divinylbenzene (CIM® BIA separations, Ajdovscina, Slovenia), and currently 
BIA Separations are the only company that can make up to 8000 mL columns (Ales 
Strancar 2011). 
Larger scale columns are currently in R&D phases, as manufacturing hurdles are 
encountered during the polymerisation reaction due to the heat released across the 
structure, potentially causing structural distortion if not kept within a certain range. The 
polymerisation reaction which combines glycidyl methacrylate and ethylene 
dimethacrylate in a free radical bulk polymerisation reaction with benzoyl peroxide as 
an initiator has an activation energy Εa,app of 81.5 kJ/mol with a heat of reaction (∆Hr) of 
190 J/g (Mihelic et al. 2001). 
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All monolith columns produced by BIA Separations from 1 mL up to 8000 mL are run 
in radial rather than axial flow as this reduces their footprint whilst maintaining a 
minimum bed length required to ensure a low pressure drop (∆P). Smaller commercially 
available columns from 0.1 mL to 0.34 mL are run in axial flow as this is mechanically 
easier to fabricate at small scale, owing to their smaller cross sectional area to bed 
length ratio. As a result of this difference in area to bed length ratio, it is advised by the 
manufacturer to perform scale up studies using 1 mL columns as a minimum. 
Other manufacturers of monoliths are BioRad (Hercules, CA, USA) who have produced 
polyacrylamide UNO columns. These are advertised for their high resolution at high 
flow rates for protein separation. Merck have produced a silica-based monolith called 
Chromolith, but have concentrated on the analytical ability of the columns taking 
advantage of their high number of theoretical plates compared to packed bead resins of 
an equivalent bed length. GE Healthcare has produced monobeads, which are made 
from polyvinyl alcohol and polystyrene-coated. These can be packed into traditional 
chromatography columns and are marketed for their high resolution and flow rate 
capabilities.  
2.4.2  Theoretical Considerations when using Monoliths 
 
Purification of large macromolecules such as viruses, VLPs and pDNA, is typically 
restricted by very low dynamic binding capacities (DBC) when using conventional 
packed bed chromatography. For this reason chromatography has not conventionally 
been the first method of choice for macromolecular separation.  
Vaccinia virus, which is one of the largest known viruses, has an approximate diameter 
of 300 nm. The pore opening on the surface of commercially available chromatography 
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media tends to be around 100 nm in diameter. Most viruses, therefore, can only bind to 
the outer surface of these beads and so cannot utilise the full surface area available.  
Packed bed columns are designed for the purification of relatively small molecules such 
as therapeutic proteins, mAbs and peptides. These molecules can easily diffuse into the 
micropores on the surface of typical bead-based resins, so the surface area available for 
adsorption is very large and hence not a limiting factor. Manufacturers can further 
optimise capacity as well as increase the number of theoretical plates of their resins by 
reducing bead diameter and increasing ligand density. Efficiency is directly related to 
particle diameter and is described by the number of theoretical plates or equilibrium 
stages in a column per meter. The height of each theoretical plate (HETP) measured in 
meters can be determined by the equation below, 
𝐻𝐸𝑇𝑃 =  𝐴 +  
𝐵
𝑢
+ 𝐶. 𝑢         2-1
        
where A is eddy diffusion (m), B is longitudinal diffusion (m
2 
s
-1
), C is the resistance to 
mass transfer (s), and u is linear velocity (m s
-1
). 
This expression can also be expanded for process IEX chromatography as described in 
(Jungbauer 2005;Lettner et al. 1995). 
𝑯𝑬𝑻𝑷 =  
𝟐𝜺𝒃 𝑫𝑳
𝒖
+  
𝟐𝒖
𝟏−𝜺𝒃
 [
𝒌′
𝟏+𝒌′
]
𝟐
[
𝒓𝒑
𝟑𝒌𝒇
+
𝒓𝒑
𝟐
𝟏𝟓𝜺𝒑𝑫𝒑
]     2-2 
 
where  𝜀𝑏 is bed porosity, 𝜀𝑝 is particle porosity, 𝐷𝐿  is the axial dispersion coefficient 
(m
2 
s
-1
), 𝐷𝑝 is the particle diffusivity (m
2 
s
-1
), 𝑘′ is relative retention factor, 𝑟𝑝 is particle 
radius (m), and 𝑘𝑓 is the particle film mass transfer coefficient (m s
-1
). 
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Due to mechanical constrains, limitations do exist regarding scale up of packed bed 
columns (Jungbauer and Hahn 2008). High back pressures due to bed compression 
towards the centre of a packed bed, as well as areas of non-linear flow distribution, 
particularly at the column walls, can occur if the column diameter is increased above a 
certain point. This is not thought to be a serious limiting factor for protein separations in 
terms of productivity, due to the high binding capacities now achievable with 
commercially available resins, 40-100 g/L in some cases. If packed bed columns were 
to be used for viral separations, however, especially for high dose applications, column 
size may become a bottleneck as capacity will be significantly lower, potentially by 
orders of magnitude. 
When considering the purification of viruses monoliths are becoming extremely useful 
tools (Jungbauer & Hahn 2008).  Monoliths have excellent mass transfer properties, as 
reviewed and demonstrated by a number of authors including (Gritti et al. 2003;Hahn et 
al. 2002;Jungbauer & Hahn 2008;Zou et al. 2002). However controversy exists as to 
whether the observed mass transfer characteristics are due to the open pore structure and 
subsequent convective flow or the small size of particles used in the polymerisation 
process (Hahn, Panzer, Hansen, Mollerup, & Jungbauer 2002). The generation of an 
open pore structure seen in CIM monoliths is due to the polymerisation process; small 
particles ~1 µm in diameter agglomerate into a single, rigid polymeric homogeneous 
structure called poly(glycidylmethacrylate-co-ethyleneglycoldimethacrylate). While the 
overall surface area of monoliths is smaller than that of a conventional packed bed 
chromatography column, the surface area available to large macromolecules for 
adsorption is much higher. The three dimensional structure of monoliths has been 
described as similar to membranes, which have in turn been described as very thin 
monoliths (Ales Strancar 2011). They are highly porous and contain a vast amount of 
cross-linking. This allows them to exhibit very low back pressures at high flow rates, 
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even at process scale. The HETP and dynamic binding capacity observed are almost 
completely unaffected by velocity; therefore monoliths can in theory give very fast, 
efficient separation of large macromolecules.  
As Illustrated in Figure 2.5 the velocity profile in monolithic structures is important 
when discussing their performance in comparison to packed bed chromatography and 
especially membrane adsorbers. 
 
Figure 2.5 An illustration to show the cross linking wide channel structure, and almost flat 
velocity profile achievable using monoliths. The red arrows represent directional flow and 
their size represents relative velocity.  This picture was adapted from (Gagnon 2008). 
 
A phenomenon known as eddy diffusion and axial dispersion occurs between the beads 
of packed bed chromatography columns, causing band broadening and reduced 
performance due to inter-particulate mixing. The velocity profile through a monolith on 
the other hand is incredibly flat and relatively constant across the whole structure. This 
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eliminates eddy diffusion and axial dispersion, and hence, minimises band broadening 
as there is no mixing occurring within the column. Mass transfer in monoliths, is 
therefore not limited by diffusion like in a packed bed column. 
NA = ka ∆ CA = ka (CAo – CAi)      2-3
       
where NA is the rate of mass transfer (kg s
-1
), k is the mass transfer coefficient (m s
-1
), a 
is the area available for mass transfer (m
2
)  ∆ CA is the change in concentration of 
component A between the phase boundary and the interface as described by (CAo – CAi). 
CAo  is the concentration at the phase boundary of component A (kg m
-3
) and CAi  is the 
concentration at the interphase of component A (kg m
-3
). 
In a packed bed column, which is limited by diffusion, this equation can be rewritten as 
NA = kL a (CAo – CAi)        2-4 
where  kL is the liquid-phase mass transfer coefficient (m s
-1
). 
The main resistances to mass transfer in a packed bed column are shown in Figure 2.6 
for reference. 
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i) Convective mass transfer from bulk liquid to boundary layer 
ii) Diffusion across liquid boundary layer 
iii) Diffusion into micropore 
iv) Adsorption at solid liquid interface 
v) Surface diffusion  
 
Figure 2.6 An illustration showing the resistances to mass transfer involved in the 
adsorption of a solute molecule to a ligand within a micropore of a resin bead in a 
packed bed system adapted from (Bak et al. 2007).  
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A typical adsorption isotherm for a short bed monolith is highly favourable and often 
fits with Langmuir isotherms, as shown in Equation 2-5. 
q = 
𝑞max  𝑐
𝐾𝐷+𝑐
          2-5 
 
where qmax is the maximum solute binding capacity (kg m
-3
), KD is the dissociation 
constant (m
3
 kg
-1
), c is the concentration of solute in the mobile phase (kg m
-3
), and q is 
the concentration of solute bound to the adsorbent (kg m
-3
).  
The generation of adsorption isotherms is challenging when using infectious virus as a 
starting material. This is due to the complex nature of the analytics. Viral quantification 
assays tend to be incredibly variable with percentage coefficients of variance of >30% 
routinely. This is a challenge when making any process development decisions, but 
when attempting to create isotherms to describe adsorption equilibrium for modelling 
applications a higher degree of certainty is required. Efforts to model mass transfer 
properties of monoliths have therefore been performed using model proteins such as 
BSA, lysosyme and IgG (Hahn, Panzer, Hansen, Mollerup, & Jungbauer 2002), which 
can be quantified easily using UV absorption-based techniques. 
As previously described, monolith porosity is very high (ε > 0.5). In practical terms this 
makes it possible to operate monoliths at high flow rates without significant pressure 
drops which, coupled with high binding capacities for large macromolecules, results in 
significant advances in productivity compared to packed bed chromatography. CIM 
monoliths from BIA Separations can be operated at >10 column volumes (CVs)/min at 
small scale (1 mL) and ~ 1 CV/min at large scale (8000 mL). In comparison, the 
majority of packed bed columns are run at between ~0.2 – 0.5 CV/min. 
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2.4.3 Purification of large complex macromolecular entities using CIM 
monoliths  
2.4.3.1 Introduction 
 
Monoliths have been used for a large range of applications, such as the capture and 
purification of viruses, VLPs, and bacteriophage, which are discussed in this section. 
Besides this, literature from BIA Separations shows that CIM monoliths have also been 
used for purifying transfection grade pDNA, IgG, IgM, His-tagged proteins, and His-
containing proteins (BIA separations 2010).  
 
2.4.3.2 Virus purification using monoliths 
 
In this section the following will be reviewed: 
 Vaccinia virus 
 Tomato mosaic virus 
 Potato virus Y 
 ∆NS1-Influenza A + B virus 
 Baculovirus 
 Adeno-associated virus (AAV) 
 Lentivirus 
 Adenovirus type 3 dodecahedric virus-like particles 
 VLPs generated in Saccharomyces cerevisiae 
 Staphylococcus aureus bacteriophages 
 Bacteriophases, Lambda, T7, and M13 
 
Following a review of the literature, there has been some recent work on MVA 
purification using CIM monoliths, but authors have indicated severe challenges in 
removing DNA to the required specifications of 10 ng/dose (Yang 2013). The authors 
suspected a strong association between MVA and genomic DNA, which appeared to 
prevent viral enrichment during IEX or HIC chromatography.  What is interesting is 
76 
 
that this interaction appeared to be reversed after the addition of certain chaotropic 
agents. 250 mM NaBr and 150mM KCl were added to CR.pIX avian cell culture 
infected with MVA prior to lysis. Diatomaceous earth was then added post lysis and 
incubated for 20 minutes at room temperature before being removed by filtration using 
0.2 µm glass fibre disks. Subsequent IEX monolith chromatography was able to yield a 
concentration of DNA/dose (assuming a relatively low dose of 1x10
8
 plaque-forming 
units (pfu)) of 2 fold above the acceptable levels for clinical applications (Jordan et al. 
2015a). The percentage yield of infectious virus achieved is not available. This work 
clearly outlines the challenges and complexity of removing contaminating DNA from 
viral feed streams and indicates a clear unmet need to develop a process capable of 
removing DNA and other impurities in order to develop vaccinia virus at the required 
levels of purity in an economically feasible way. This will become particularly urgent if 
clinical trials currently involving the development of vaccinia virus for oncolytic 
applications are successful. 
A study by (Kramberger et al. 2004) used CIM quaternary amine (QA) monolith disks 
to concentrate tomato mosaic virus (ToMV) by several orders of magnitude. This 
technique was intended to be, and hence optimised, for the concentration of ToMV in 
irrigation waters, which are typically well below the limits of detection by standard 
ELISA quantification assays. It was shown that even low concentrations of virus in 
irrigation water can infect plants and cause losses to crops, particularly in a greenhouse 
environment. The method development focused around viral concentration, with the 
main optimisation criteria being percentage yield. This was so that the total amount of 
virus eluted from the column could then be measured for a given volume of water so as 
to determine the relative concentration of virus in the water system. The yield achieved 
from CIM QA monoliths after two parallel experiments was 90% and 89% by ELISA, 
respectively. Virus was eluted in 1.5 M NaCl in sodium acetate buffer pH 5.5. 
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ToMV was also purified using CIM QA monoliths as described by (Kramberger et al. 
2007) for the development of a preliminary quantification technique to replace ELISA 
and reverse transcriptase PCR (RT-PCR) technologies, which are labour intensive and 
take a long time to complete. The study describes the generation of a standard curve by 
loading five samples on the CIM QA monoliths at different concentrations of between 
0.1 mg/mL and 0.43 mg/mL. The virus was eluted from the column using a linear 
gradient between 0-1.5 M NaCl in sodium acetate buffer, and the corresponding peak 
height was measured by UV absorbance at a wavelength of 280 nm. This data was then 
used to generate a standard curve for the assessment of unknown virus concentrations 
using the same method. 
At preparative scale CIM QA was able to purify ToMV removing >99% of the 
contaminating DNA and all quantifiable protein. The percentage viral recovery was 
shown to be as high as 90%. Virus was elution between 0-1.5 M NaCl in sodium acetate 
buffer using a multi-stepwise elution schedule. This is comparable to conventional 
ultracentrifugation-based purification of ToMV; however, the authors point out that the 
process can be shortened from 5 days to 2 hours when using monoliths. 
 More recently, CIM QA 0.34 mL monoliths disks were used to purify Potato virus Y 
(PVY) produced from inoculated leaves from N tobacum cv White Burley and both 
leaves and stems from Solanum tuberosum cv Pentland plants in a study by (Rupar et al. 
2013). This was the first time that a filamentous virus had been purified using monoliths 
and showed a number of purification challenges due to its size, shape and flexibility. 
The dimensions of PVY are 700 nm x 11 nm. Impurities originating from the plant cell 
lysate material such as cell wall components, pigments, poly-phenols and a variety of 
host cell plant proteins and organelles posed challenges to purification due to their 
variety and complexity.  PVY is also known to aggregate, causing reduced yields during 
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purification. As with all infectious viruses, PVY presents an analytical challenge with 
regards to the quantification of infectious virus particles and contaminants. To combat 
this, the authors used a number of different analytical techniques in order to build a 
complete picture of process performance.  Transmission electron microscopy was used 
to measure viral integrity, RT-PCR was used to measure PVY RNA, SDS-PAGE and a 
260 nm/280 nm UV absorbance ratio was used to estimate viral purity. In the presence 
of 0.5-1M urea, which was added to the load to prevent protein-induced aggregation, 
99.9% of plant nucleic acids were removed as well as all quantifiable protein. Up to 
50% of the viral RNA loaded was recovered across the elution factions, which after 
inspection using TEM contained integral PVY. The infectivity of the recovered virus 
was tested by infecting healthy N. tobacum plants with purified PVY, and it was found 
that infectivity was not significantly affected by CIM monoliths. Elution was performed 
in two parts, first a stepwise elution was run from 0.1 - 0.25 M NaCl and then a linear 
gradient was run between 0.25–1 M NaCl over 100 column volumes with Tris buffer 
containing EDTA. 
Ion exchange CIM monoliths have been used to purify Vero cell derived ∆NS1 live 
replication deficient influenza virus A and B (Banjac, Roethl, Gelhart, Kramberger, 
Jarc, Jarc, Strancar, Muster, & Peterka 2014). ∆NS1-H3N2, ∆NS1-H1N1, ∆NS1-H5N1, 
and ∆NS1-Influenza B were all tested. ∆NS1-Influenza A virus strains were found to 
adsorb to both strong and weak AIEX monoliths, DEAE and QA respectively, as well 
as strong CIEX CIMSO3 monoliths all at neutral pH. Interestingly, this was not the case 
for ∆NS1 Influenza B virus which did not adsorb to CIMSO3. The dynamic binding 
capacity measured for ∆NS1-H1N1 was 1.9x1010 pfu/mL on CIM QA monoliths, 
1x10
10
 pfu/mL on CIM DEAE, and 8.9x10
8
 pfu/mL on CIMSO3. After scale up to 8 
mL CIMQA monoliths, process reproducibility was tested on all viruses. Average 
infectious virus recovery was between 70.8% ± 32.3% and 87.9% ± 30.8%. Percentage 
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removal of contaminating protein was between 93.3% ± 0.4% and 98.6% ± 0.2% and of 
DNA between 76.4% and 99.9%. All viruses were eluted in HEPES buffer in 500 mM 
NaCl pH 7.5. 
A study by (Gerster et al. 2013b) mentions the use of Benzonase (Merck KgA, 
Darmstadt Germany) to reduce DNA load challenge going onto CIM monoliths.  The 
study deals with the development of CIM QA monoliths to purify infectious baculovirus 
produced by Spodoptera frugiperda cells (Sf-9) using a stepwise elution schedule. It 
also illustrates the potential use of epoxy monoliths for the removal of lipids from the 
feed stream run in flow through mode. The percentage recovery of infectious virus was 
shown to be highly dependent on the age of the load and its composition; DNA 
concentration, levels of aggregation, and ratio of infectious to inactivated virus. The 
recovery of infectious virus in the main elution pool was between 20% and >99%. The 
total protein removal was reported to be between 92% and 99%, and DNA removal 
between 52% and 62%. Virus was initially eluted over a linear NaCl gradient between 
0.2–1 M, however, this was later redesigned and virus was eluted using a multi-stepwise 
elution schedule. This paper stresses the difficulty to report a full picture due to the 
complex nature of the system, but does use a range of orthogonal assays in an attempt to 
generate process understanding. These studies illustrate the reduced time needed to 
purify large amounts of virus using monoliths compared to ultracentrifugation, and the 
authors suggested that further scalability studies would be worthwhile in order to 
develop a viable large scale process. 
A range of recombinant Adeno-Associated Virus serotypes (rAAV) have been 
successfully purified using CIM QA monoliths. AAV1 capture using CIM QA 
monoliths has been shown to yield between 40% and 72% prior to affinity-based AVB-
Sepharose (GE Healthcare, Uppsala, Sweden) as a second step (Wang et al. 2009). 
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Virus was eluted using a stepwise elution schedule in Tris buffer containing 260 mM 
NaCl. In a separate article, separation of full and empty AAV8 capsids using CIM QA 
monoliths was performed on 0.34 mL disks (Lock et al. 2012). Virus was eluted over 
shallow gradients from 80-115 mM NaCl over 20 column volumes. Two peaks were 
reported over the elution, the first containing empty capsids, these are vectors lacking a 
genome, and the second containing up to 99% full, genome containing capsids. Results 
were confirmed both by negatively staining TEM, which showed empty capsids with an 
electron dense core, and qPCR. This was originally developed as an analytical 
technique, however, BIA Separations now market CIM QA as both an analytical tool to 
estimate full/empty ratios and as a preparative method to remove empty capsids from 
purified AAV material.  
CIM DEAE weak AIEX monoliths have been used to purify HIV-1-derived lentiviral 
vectors (LVs) (Bandeira et al. 2012). LV is known to be very unstable. This is likely 
due to the degradation of its envelope surrounding the capsid causing loss of infectivity. 
This often occurs over typical processing conditions during both ultracentrifugation and 
chromatography using membrane adsorbers, which have been shown to recover ~30% 
of infectious LV. CIM DEAE achieved a recovery of up to 80% and removed up to 
88.8% of contaminating DNA prior to the addition of Benzonase. After Benzonase 
treatment the whole process was shown to remove 99.9% of contaminating DNA, with 
an overall infectious LV recovery of 36%. This included losses over depth filtration, 
chromatography using CIM DEAE, ultrafiltration, and size exclusion chromatography 
as a final polishing step. LV was eluted in Tris buffer using a stepwise elution schedule 
at 0.65 M NaCl. A pre-elution wash step contained 0.1 M NaCl was also employed to 
remove contaminating protein. 
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In the examples shown above, the main recurring challenge has been to remove 
genomic DNA from viral feed streams. The main reason why DNA is a problem is that 
many viral processes require cell lysis. This means that high concentrations of cellular 
DNA are present in the harvest prior to purification. The exact amount will depend on 
the cell density and type of primary recovery steps being used.  CIM monoliths have 
shown the ability to efficiently adsorb infectious virus material. Over 50% of virus 
material loaded is commonly eluted without significant loss in infectivity, and DNA and 
protein can be removed to an acceptable level with the addition Benzonase. One of the 
main attributes that will likely drive the industry away from ultracentrifugation is 
productivity, as many authors have reported significant gains in terms of time when 
using monoliths with comparable or improved purity and yield. There is clearly more 
work to be done to improve process performance with monoliths; however, as often 
shown in the literature, it is currently difficult to draw conclusions due to analytical 
challenges. 
 
2.4.3.3 Virus like Particle VLP purification using monoliths 
 
CIM monoliths have been successfully used to purify a number of VLPs from partially 
purified and crude cell lysate. Work by (Urbas et al. 2011) has shown that CIMac QA 
columns, which are 0.1 mL analytical monoliths supplied by BIA Separations, are able 
to purify recombinant adenovirus type 3 dodecahedric virus-like particles (Ad3 VLP) 
expressed in a baculovirus / insect Sf21 cell systems. The recovery of biologically 
active VLP achieved by CIMac QA monoliths was shown to be 52%, with levels of host 
cell DNA removal greater than 99%. The monolith process also allowed the purification 
to be reduced from 5 days, when using ultracentrifugation, to 1 day when using 
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monoliths. VLPs were eluted between 0-1 M NaCl initially using a linear gradient, and 
then latter using a multi-stepwise elution schedule in Tris buffer containing EDTA and 
glycerol. While CIMac columns are primarily used for quantification, this work 
demonstrated that they can also be used to screen and optimise preparative purification 
processes.  
Work done as part of an EngD collaboration between University College London and 
BIA Separations as described by (Burden et al. 2012) uses CIM OH monolith to purify 
VLPs produced in Saccharomyces cerevisiae. This study is another good illustration of 
the potential of monoliths to purify large macromolecules as an alternative to either 
ultracentrifugation or conventional packed bed chromatography. The author describes 
problems associated with lipid contamination in the feed stream and outlines a 
methodology for the removal of lipids prior to the purification process, which was 
shown to double the DBC and increase the life time of the monolith column. Amberlite 
/ XAD-4 beads were used to remove 70% of the lipids, whilst recovering 80% of the 
VLP. This increased the CIM OH DBC from 0.11 mg/mL to 0.25 mg/mL. In 
comparison to Butyl-S Sepharose 6 FF, CIM OH monoliths achieved a DBC of 
approximately 3-4 fold higher. The recovery of VLP was comparable, 85% from CIM 
OH and 90% from Butyl-S Sepharose 6 FF. CIM OH load buffer contained 1 M 
Ammonium sulfate, while Butyl-S Sepharose 6 FF only required 0.6 M. Elution was 
achieved by a stepwise schedule in phosphate buffer from both columns without 
ammonium sulfate.    
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2.4.3.4 Bacteriophage purification using monoliths  
 
A study by (Kramberger et al. 2010) focuses on the purification of Staphylococcus 
aureus bacteriophage (phages) VDX-10 using CIM QA monoliths. This was developed 
as a one-step purification process, and was scaled up from 0.34 mL CIM QA disks to an 
8 mL column. Viable phage recoveries were recorded between 54% and 65%, DNA 
removal was between 99.4% and 99.8%, and total protein removal was between 90% 
and 91%. Phage was initially eluted in a linear gradient between 0-1M NaCl over 100 
columns volumes. When the process was scaled up, a step wise elution schedule was 
used at 0.6 M NaCl.  
In a separate study (Smrekar et al. 2011) three different phages, T7, lambda and M13 
were purified using CIM QA monolith disks. The binding capacity of M13 was found to 
be very high, 4.5x10
13
 pfu/mL. T7 and Lambda phages both showed lower capacities 
closer to 1x10
13
 pfu/mL. All three phages were eluted in a linear gradient between 0-1M 
NaCl over 20 column volumes with 100% recovery of all phages recorded. Lamda 
phage, however, required the addition of 0.2 M NaCl in the load in order to reach 100% 
recovery and maximum DBC. 
In conclusion, commercially available CIM monoliths are able to remove impressive 
amounts of host cell DNA and protein from viral feed streams without compromising 
viral infectivity. Monoliths offer significant advantages in terms of productivity over 
traditional unit operations like ultracentrifugation, although differences in infectious 
virus recovery and purity between the two technologies depend on the virus in question. 
For example, the percentage recovery of Baculovirus has been reported to be less than 
1% following ultracentrifugation (Chen et al. 2009), while human respiratory syncytial 
virus can reach infectious recoveries of 69% according to (Gias et al. 2008). 
84 
 
The next section will focus on viral analytics, which is a massive challenge and 
bottleneck in process development. For chromatography to become indispensable for 
the purification of virus material, conclusions drawn during process development 
regarding process performance need to be accurate. This is currently not possible in 
many cases as viral analytics are too variable, and no one assay is able to tell the whole 
story.  
 
2.5 Virus Bioprocess Analytics  
2.5.1 High Level Analytical challenges faced during virus bioprocessing  
 
There are a number of reasons why viral analytics can be a challenge. Prior to the 
commencement of process development, a precise understanding of exactly what the 
starting material is and what impurities are present is crucial. The answer to these 
questions, however, is complex. Many assays are needed in order to generate a realistic 
approximation of viral titre as questions relating to the number of infectious viral 
particles, number of transducing units, number of whole, integral viral particles, number 
of empty viral particles, number of full viral particles, and number of full particles 
containing the correct genetic material all need to be answered depending on the virus in 
question. All of these assays add layers of complexity and all of this information needs 
to be put together in order to generate robust conclusions.  
To complicate this further, viruses, unlike most proteins, are generally expressed 
intracellularly. This means that cells need to be lysed in order to release the virus into 
the supernatant. Some viruses are lytic, meaning they can be left to lyse the cells 
themselves, others require chemical or mechanical treatment in order to lyse the cells. 
During this process, cellular components such as host cell DNA, proteins, and lipids, if 
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using mammalian, insect or avian expression systems, or cell wall components, 
pigments, and poly-phenols if using plant cells (Rupar, Ravnikar, Tusek-Znidaric, 
Kramberger, Glais, & Gutierrez-Aguirre 2013), are released into the supernatant along 
with the virus. Assays need to be developed that are able to quantify all of these 
contaminants, especially if they are considered to be critical quality attributes (CQAs). 
One of the major contaminants in viral therapies is dsDNA. According to the WHO, 
Technical report series, No 926, 2004, (World Health Organisation 2004) a smallpox 
vaccine needs to have less than 10 ng of cellular DNA per dose.  
The Host Cell Protein concentration in a final drug substance is often defined as a CQA, 
however, typical specifications for viral therapies in terms of mass of HCP per viral 
dose is not as specifically defined as it is for dsDNA.  
The reason for this is that acceptability criteria for HCPs will often depend on the 
production cell line used, specific HCP populations known to be present, and any 
clinical safety data available. The regulators typically suggest an open dialog with 
manufactures and require evidence of HCP removal across the process using sensitive 
and qualified assays. A justification for in-house acceptability criteria is then put 
forward by the manufacturer.  
According to International Conference on Harmonization (ICH) guidelines Q6B: “For 
host-cell proteins, a sensitive assay (e.g., immunoassay, capable of detecting a wide 
range of protein impurities) is generally utilized. In the case of an immunoassay, a 
polyclonal antibody (pAb) used in the test is generated by immunization with a 
preparation of a production cell minus the product-coding gene, fusion partners, or other 
appropriate cell lines.(…) “Clearance studies, which could include spiking experiments 
at the laboratory scale, to demonstrate the removal of cell substrate-derived impurities 
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such as nucleic acids and host cell proteins may sometimes be used to eliminate the 
need for establishing acceptance criteria for these impurities”. 
The FDA and EMA have similar wording each requiring the use of sensitive and GMP 
qualified assays to monitor HCPs according to ICH guidelines. According to (F.Wang 
et al. 2015) the actual speciation of HCPs is determined on a case by case basis but is 
often between 1 and 100 ng/mg of protein. It should be noted that this range in 
specification is likely taken from the biopharma sector, and therefore relevant for 
products such as a mAbs and therapeutic protein rather than ATMPs. 
1-100 ng/mg does not translate well to viral vectors as 1 mg of vaccinia would be 
approximately 5x10
12 
viral particles; this is assuming the mass of 1 vaccinia virus 
particle is 5 fg. A dose of vaccinia virus is likely to be around 1x10
9
 infectious particles 
per injection so if the specifications were set to 100 ng/mg of virus then the total mass 
of HCPs per vaccinia dose would need to be 0.02 ng. This is unlikely to be achievable.  
For this study total protein has been recorded across each unit operation and shown to 
be reduced to LLOQ levels based on the BCA assay. An immunoassay such as an 
ELISA would be more appropriate for a GMP compliant process to show protein 
removal, however, it was decided that data from the BCA assay would be good enough 
to generate process knowledge and understanding while working with vaccinia at UCL. 
The main reason for this was cost and availability. 
When conducting process development of viral vectors for gene therapy applications in 
industry both PicoGreen and BCA assays are routinely used to test in process samples 
to show removal of dsDNA and total protein. This is particularly true during early phase 
development. More specific ELISA assays are then developed, qualified and used for 
product release testing and as required for in process control following dialog with the 
regulators. 
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2.5.2 Current analytical methods used in virus bioprocessing 
 
It is relatively straightforward to get a measure of the total number of particles, 
assuming equipment availability, in a pure viral sample. Harvest samples are very 
difficult to analyse without specific assays such as ELISAs as the majority of particles 
are not viral. Dynamic light scattering (DLS) using a Zetasizer, and Nanoparticle 
Tracking Analysis (NTA) using a NanoSight, both supplied by Malvern Instruments 
(Malvern Instruments, Worcestershire, UK), can be used to generate particle size 
distribution data. DLS is not able to reliably estimate the concentration of particles 
especially in polydisperse samples due to bias caused by large particle in the solution. 
NTA does not suffer from this issue as the instrument measures individual particles 
separately. Neither of these techniques are specific to viral particles. Both the DLS and 
NanoSight measure the movement of particles and calculate size based on Brownian 
motion. 
NTA works as follows: 
A laser is passed into a chamber containing the sample in suspension at between 1x10
6
 
and 1x10
9
 particles/mL. The particles scatter the laser beam which is detected by a 
video camera mounted on top of a microscope permanently set at 20x magnification.  
The camera records frames of the particles moving under Brownian motion at lengths of 
time determined by the operator. The particles are then tracked and the hydrodynamic 
diameter is calculated based on specified temperature and viscosity inputs according to 
the Stokes Einstein equation shown below. 
𝑑𝐻 =
𝑘𝑇
3𝜋𝜇𝐷
         2-6 
where dH is the hydrodynamic radius of a particle (m), k is the Boltzman constant (J/K), 
T is temp (K), µ is viscosity (Pa.s) and D is the diffusion coefficient (m
2
s
-1
). 
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Tunable Resistive Pulse Sensing (TRPS) equipment supplied from IZON (IZON 
Oxford, UK) is an alternative system that uses impedance measurements rather than 
Brownian motion to estimate particle size. A voltage is placed across a tuneable 
nanopore at constant pressure, and a measurement is made by recording the resistive 
pulse generated as a particle traverses through. As particles traverse they block the flow 
of ions through the nanopore and the resulting voltage impedance is measured. The 
magnitude of the resistance pulse in proportional to the particle size and velocity. TRPS 
can also measure the zeta potential of individual particles in a sample. This is calculated 
from the electrophoretic mobility according to the Smoluchowski equation. As the 
magnitude of the resistive peak is independent of the zeta potential the size and zeta 
potential can be measured simultaneously for each particle traversing the nanopore. 
Flow cytometry, specifically the Virus Counter 3100 from Virocyt (Virocyt CO USA) is 
a fourth option, this system using general nucleic acid and protein stains to tag viral 
particles containing both DNA and protein. Particles are then passed through a laser 
probe region one by one and those emitting florescence from both stains are counted as 
integral viral particles.  
All four systems described above will approximate the total particle concentration in a 
sample, but each has a very low specificity. What this means in practice is that all four 
assays will overestimate total virus concentration in a sample, even if only taking into 
account particles within the specific size range corresponding to the virus. This will be 
especially true when analysing impure samples. 
In order to quantify total particle concentrations more specifically, ELISAs are 
commonly used. ELISAs use antibodies to bind to conformational epitopes on viral 
surfaces. Conjugated antibodies are then used to generate a colour change that can be 
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detected by absorbance plate readers. A common example (AAV2 Titration ELISA, 
Progen Biotechnik GmbH, Heidelberg, Germany) uses a biotin-conjugated antibody to 
generate a colour change when streptavidin and a substrate are added. 
In order to quantify infectious titre, infectivity assays need to be performed. Examples 
are Tissue culture infectious dose (TCID50) assays and plaque assays. Transduction 
assays can also be used, although only for virus that can transduce cells in culture. 
These assays are cell-based and require trained personal to perform, often taking 5-6 
days to obtain a reading. One of the most challenging aspects, however, is the 
variability commonly seen between replicates. This is routinely above 30% (RSD), but 
can be as high as an order of magnitude. 
The use of a large variety of orthogonal analytical methods to help build a quantitative 
picture of the system in question is currently thought to be the best option when 
analysing virus material. This is generally accepted as best practice amongst industry 
professionals and academics within the field. As previously mentioned, there is no one 
assay that can provide all the information.   
The following table, while not exhaustive, gives a detailed overview of some of the 
more commonly used techniques for analysing virus material.  
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Table 2.4 Commonly used analytical methods for the quantification of viral CQAs  
Assay Application Advantages Limitations 
 
Quantification of total viral particles and related impurities  
 
Analytical 
Chromatography  
 
- Total viral particle 
quantification 
 
- Fast 
- Sensitive 
- Fairly high precision 
 
 
- Requires base line resolution 
- Relatively low specificity unless affinity-based 
- Indirect measure of viral particles / based on 
standard curve 
 
ELISA (direct or 
sandwich)  
 
- Total viral particle 
quantification 
 
 
- Sensitive 
- Specific 
- Fairly high precision 
 
- Indirect measure of viral particles / based on 
standard curve 
- Fairly time consuming 
- Expensive 
 
Electron 
Microscopy  
 
- Visualisation of 
virus integrity 
morphology and 
polydispersity  
 
- Very high resolution 
- Generates a visual image 
 
- Expensive  
- Requires significant expertise 
- Prone to artefacts 
 
Dynamic light 
scattering (DLS) 
 
- Particle size 
distribution / 
aggregation profile 
- Quantification of 
total particles 
 
- Very Fast 
- Sensitive 
 
- Low resolution 
- Struggles with polydisperse samples 
- Non-specific  
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Assay Application Advantages Limitations 
 
NanoSight 
(NTA) 
 
- Particles size 
distribution / 
aggregation profile 
- Quantification of 
total particles 
 
- Very Fast 
- Relatively high resolution 
- Generates a visual image 
 
- Non-specific   
 
 
qPCR 
ddPCR 
RT-PCR 
 
- Quantification of 
total viral genomes 
 
- Fast 
- Specific 
- Sensitive 
- (ddPCR generates absolute 
quantification) 
- Fairly high precision 
 
- Indirect measure of viral particles 
- Requires complex pre-treatment of sample to 
remove residual viral DNA 
 
Viral counter  
InDevR 
 
- Quantification total 
particles (some 
comparisons made 
to infectious titre)  
 
- Fast  
- May give infectivity data 
 
- Expensive equipment 
- Low specificity 
 
 
Quantification of infectious viral particles   
 
Infectivity assays  
(eg TCID50 
Plaque Assays  
 
- Quantification of 
infectious viral 
particles 
 
- Specific (Infectious virus) 
 
- Time consuming 
- High variability 
- Laborious 
- Requires experienced operators 
 
Cell-based 
reporter gene 
assays 
 
- Quantification of 
infectious 
replication 
 
- Specific (Infectious replication 
competent/ transducing units)  
 
- Time consuming 
- High variability 
- Requires experienced operators 
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Assay Application Advantages Limitations 
/transduction 
assays 
competent virus 
Or 
- Quantification of 
transducing units 
 
Quantification of process related impurities  
 
Protein 
Absorbance 
Assays 
BCA (or similar) 
 
- Quantification of 
total protein 
 
- Fast 
- Sensitive 
- Fairly high precision 
 
- Non-specific 
- Relatively high LLOQ 
 
 
 
RP HPLC  
 
- Quantification of 
lipids  
 
- Sensitive 
- Fast 
- Can give high resolution 
especially if coupled with mass 
spec (LC/MS) 
- Fairly high precision 
 
- Requires base line resolution 
- Relatively low specificity  
 
 
DNA Florescence 
Assays 
(PicoGreen) 
 
- Quantification of 
total dsDNA 
(ssDNA also 
available) 
 
- Sensitive 
- Fast 
- Fairly high precision 
 
- Non-specific 
- Reagent may be able to detect encapsulated viral 
DNA 
 
HCP (ELISA) 
 
- Quantification of 
host cell protein 
(HCP) 
 
 
- Sensitive 
- Specific 
- Fairly high precision 
 
- Indirect measure  
- Fairly time consuming 
- Expensive 
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2.5.3 Quantification of viral infectivity 
 
Common assays utilised for the quantification of infectious virus particles are often 
slow, laborious and prone to high variability and human error. The most common is the 
plaque assay redeveloped from an early method designed to quantify bacteriophage in 
1952 by Renato Dulbecco (Flint et al. 2004). The plaque assay works by incubating 
adhering cells with a virus preparation and allowing it to be absorbed by the cells. The 
inoculum is then replaced with a gel that prevents viral infection of other cells once the 
infected cells on the plate are lysed. Circular zones are then formed around infected 
cells called plaques, which are assumed to be the result of infection from one virus 
particle.  There are a number of variations of the plaque assay including the 
Fluorescent-Focus assay and the Infectious Centre Assay. 
The Fluorescent-Focus assay is very similar to the plaque assay but rather than adding a 
gel, such as agar, cells are permeabilised with a solvent, such as acetone, and incubated 
with an antibody against a specific viral protein. A second antibody with an attached 
fluorescent marker is then added, which recognises the first. Infected cells can then be 
examined using a fluorescence microscope. This technique is often used for viruses that 
are not able to kill and lyse cells. The Infectious Centre assay on the other hand is 
utilised to determine the number of cells in a culture that are infected with virus. It 
works by growing the cells and allowing viruses to propagate for a short period of time 
before taking an aliquot of the cell suspension and re-infecting known dilutions of the 
harvested cells onto fresh adhering cells which are covered in a gel in the same way as 
when performing a plaque assay. The number of resulting plaques formed is then a 
measure of how many cells in the original sample were infected with the virus.  
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The TCID50 assay, derived from a statistical method for deriving 50% end points by 
(Reed and Muench 1938), works in a similar way to the plaque assay, however, does 
not require the addition of a gel to quantify infection. Instead it relies on the 
identification of cytopathic effect (CPE) when the cells are observed under a 
microscope after the infection has taken place. Serial dilutions of the initial virus sample 
are performed in a 96 well plate containing a monolayer of adhering cells in each well. 
Plates are then incubated for 5-6 days, depending on the virus, at 37 ⁰C and 5% CO2.  
There has been a lot of work in recent years to develop fast and effective reporter gene 
assays for the quantification of infectious virus particles. The application of such assays 
can be within a clinical setting, for example used for diagnostic testing, or can be a 
process analytical technology (PAT) for virus bioprocessing. There are a number of 
examples in the literature of reporter gene assays being used for virus replication 
detection. A study by (Lutz et al. 2005) shows the use of both green fluorescence 
protein (GFP) and firefly luciferase reporter genes to detect replication of Influenza 
virus A in 293T cells. RNA polymerase I promoter/terminator cassettes expressing 
RNA transcripts of either GFP or luciferase flanked by untranslated regions of the 
influenza A were constructed and transfected into 293T cells. It was shown that after 
infection with Influenza A the cells started expressing the reporter gene within 6-24 
hours. The study used two different methods to detect expression of each protein, GFP 
was detected using a dual laser excitation FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA, USA), whilst luciferase activity was measured in 293T cell 
lysate using the Luciferase Assay System (Promega, Madison, WI, USA).  
Reporter genes have typically been cloned into the backbone of viruses themselves 
rather than into cell lines used for titre estimation. An example of how this has been 
done is given in (Cosma et al. 2004). While this approach has been shown to work, 
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there are some associated safety concerns. Viruses are known to drop large genes, if a 
replicating virus was to drop a reporter gene in a patient cells it is unknown whether this 
might be incorporated in the cellular DNA, and what the effects might be. This risk is 
that residual DNA might contain oncogenes or infectious agents (Yang 2013).  
To get around this issue there are a number of examples of virus induced cell-based 
reported gene assays where genes are expressed in cell lines under the control of viral 
promoters that express the gene of interest during infection. A study by (Levy et al. 
2010) has used a strong poxvirus promoter 7.5-kDa-STR upstream of luciferase cloned 
into a pGL4.10 vector and transfected into HeLa cells. The study also used green 
fluorescence protein (GFP) for live cells assays. When virus infects the cell the 
promoter sequence is activated by viral transcription factors that are able to pass though 
the nuclear membrane. Infection causes translation and expression of the reporter gene 
by the cell.    
2.6 Summary 
 
It is clear that vaccinia and other oncolytic viruses hold immense potential to enhance 
the lives of global populations. Many companies are working with vaccinia and other 
oncolytic viral vectors to achieve desirable patient outcomes, which could significantly 
enhance survival rates for patients with difficult and hard to reach tumours.  If this 
potential is to be brought forward to a commercial setting, however, then affordable, 
safe and well validated manufacturing regimes need to be established.  
Vaccinia virus purification remains a challenge. While some work on vaccinia and other 
large infectious virus particles has shown that monoliths and membrane adsorbers are 
able to outperform unit operations such as ultracentrifugation in terms of productivity, 
work to remove DNA and other contaminants whilst demonstrating a robust recovery of 
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infectious particles is still limited and needs to be understood and developed further. 
Companies have already made significant investments in ultracentrifugation. 
Ultracentrifugation is a tried and tested technique requiring very little process 
optimisation. Recovery and purity of infections virus generated from most 
ultracentrifugation processes is reasonably high and is acceptable for clinical 
applications. As a result of this, the industry is cautious not to completely move away 
from ultracentrifugation. Chromatography does have some significant advantages. 
There are significantly more factors that can be optimised in order to generate superior 
process performance. This makes it likely that chromatography will be able to 
outperform ultracentrifugation.  The problem is that as a result of the large number of 
factors available for optimisation, chromatography requires a lot of process 
development time, resources and expertise. This is made even more problematical due 
to analytical challenges associated with estimating total and infectious virus, as robust 
conclusions on process performance are difficult to generate.  A large number of 
orthogonal assays are needed in order to build up a picture of how a viral process is 
performing.  
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  Chapter 3
 
Materials and Methods 
 
3.1 Introduction 
 
All experimental methods undertaken during this work have been explained in a single 
Materials and Methods section. This chapter is not intended to act as a list of standard 
operating procedures (SOPs), but has been written in order to allow a reader to be able 
to repeat any experimental procedure described in this thesis with appropriate training 
and access to relevant manufacturer’s instructions. 
 
3.2 Preparation of vaccinia virus load material  
3.2.1 Viral production 
 
Vaccinia virus was produced in Cercopithecus aethiops Kidney (CV-1) cells (ATCC) 
and cultured in Corning® 175cm
2
 cell culture flasks (Corning, NY, USA) in an 
incubator at 37⁰C, 5% CO2. Flasks were seeded at a cell density of 1x10
6 
cells/flask, 
measured by a haemocytometer. (All cell counts were measured in duplicate). 
The media used was Dulbecco’s Modified Eagle’s Medium (DMEM), high glucose 
(4500 mg/500 mL) containing Sodium pyruvate (110 mg/500 mL), and 4 mM L-
Glutamine. 5% Foetal bovine serum (FBS) was sterile filtered through a 0.22 µm sterile 
Millex® syringe filter (Merck Millipore, MA, USA) and added to the media along with 
1% penicillin/streptomycin purchased from (Sigma-Aldrich St Louis, MO). 
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25 mL of DMEM was used as a standard volume for all T175 flasks used. 
Cells were infected with vaccinia once they were ~80% confluent. Confluence was 
measured by eye; a single T175 flask was then trypsinised and the total number of cells 
counting using a haemocytometer. The resulting count was used to determine the total 
number of viral particles required per batch. 
The multiplicity of infection (MOI) was set to 0.01 pfu/cell. The total number of cells 
present per batch before infection was calculated as the total number of cells in a single 
T175 flask multiplied by all 30 flasks per batch. 
 
3.2.2 Primary recovery 
 
Cells were harvested 72 hours post infection using a Corning Cell Scraper purchased 
from (Sigma-Aldrich St Louis, MO). The resulting cell suspension was centrifuged at 
1500 rpm for 5 minutes to pellet the cells and remove the supernatant. The supernatant 
contains viral forms with an extra envelope derived from the cell membrane.  Pelleted 
cells were re-suspended in DMEM media containing 5% FBS and freeze thawed three 
times to lyse cells and release virus. 
Material was re-centrifuged at 2000 rpm for 5 minutes to remove cell lysate, collected, 
and stored at -80⁰C until further processing.  
It should be noted that the resulting material was freeze thawed 4 times, aliquots of 1 
mL were taken at final thaw in order not to continually freeze and thaw the bulk 
material prior to chromatographic or filtration experiments. 
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The size of a single batch of material was kept constant at 30x T175 flasks and yielded 
~3x10
10
 infectious virus particles. The final concentration of material, herein referred to 
as “harvest material” was 1.57x109 pfu/mL on average. 
 
3.2.3 Preparation of chromatography load material 
 
Harvest material was diluted 1:5 with equilibration buffer in order to achieve 
appropriate salt and pH conditions for adsorption.  Diluted material was then passed 
through a 0.8 µm cellulose acetate syringe Minisart filter (Sartorius Stedim Biotech, 
Sartorius AG, Goettingen, Germany) before being sampled and loaded onto the column.  
The 0.8µm filter was put in place to protect the column from potentially fouling 
materials such as large debris or viral aggregates. A process flow diagram is shown in 
Figure 3.1.  
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Figure 3.1 Process flow diagram showing method used to produce vaccinia virus 
throughout this work. 
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3.2.4 Chromatographic systems used 
 
A number of different chromatography systems were used during this work. Initial 
studies were performed using an AKTA Explorer (GE Healthcare, Uppsala Sweden).  
Due to resource limitations, all CIM SO3 stepwise elution optimisation runs were 
performed using a Pharmacia P-6000 FPLC pump connected to a Pharmacia 
conductivity monitor. As a UV monitor was not available, elution fractions were 
collected in fixed volumes and analysed for infectious virus, DNA, and total protein 
concentration offline. An image of this setup is shown in Figure 3.2.  
 
Figure 3.2 Chromatography system setup used for CIM SO3 stepwise elution optimisation 
runs.  
 
 
 
P-6000 Syringe pump 
Conductivity meter
CIM SO3 monolith
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CIM OH optimisation experiments were performed using an AKTA Pure (GE 
Healthcare, Uppsala, Sweden) with all fractions collected using a F9-R fraction 
collector. All monolith columns were run at 5 column volumes (CV)/min (195 cm/h) to 
ensure scalability and all fractions were collected and stored at -80 ⁰C prior to 
processing. 
As vaccinia virus requires BSL II containment all chromatography experiments were 
performed in dedicated CAT II laboratories in closed systems inside a biosafety level II 
cabinet. 
The chromatography method used for running each monolith chemistry is shown in 
Figure 3.3.  
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Figure 3.3 Chromatography run setup used for CIM monolith stepwise elution runs 
 
 
 
Removal of 20% ethanol storage solution 
10 CVs purified water (2 mL/min)
CIP
10 CVs 1 M NaOH 2M NaCl (2 mL/min) 60 min
Regeneration step
20 CVs Elution buffer (5 mL/min)
Equilibration step
20 CVs Equilibration buffer (5 mL/min) 
Product Load
Wash / Re-equilibration step
10 CVs Equilibration buffer (5 mL/min) 
Elution
10 CVs Elution buffer (5 mL/min)
Strip
10 CVs Strip buffer (5 mL/min)
CIP
10 CVs 1 M NaOH 2M NaCl (2 mL/min) 60 min
Removal of CIP buffer
10 CVs Equilibration buffer followed by purified water (2 mL/min)
Storage
3 CVs 20 % Ethanol (2mL/min)
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3.2.5 Monolith chemistries used 
 
Four different commercially available Convective Interaction Media
TM
 (CIM) 1 mL 
monoliths (BIA Separations GmbH, Villach, Austria) were evaluated as potential 
capture steps for vaccinia virus, each with a nominal channel diameter of ~6 µm. 
The chemistries evaluated are listed below; 
 CIM SO3-1mL columns, strong cation exchangers due the presence of 
sulfate groups, negatively charged between pH 2-13   
 CIM QA-1mL columns, strong anion exchanges, positively charged between 
pH 2-13 due the presence of quaternary amine groups  
 CIM DEAE-1mL columns, weak anion exchangers due the presence of 
diethylamine groups positively charged between pH 3-9 
 CIM OH-1mL columns, weak hydrophobic columns due to the presence of 
hydroxyl groups. These are generated by the hydrolysis of epoxy groups. 
Hydroxyl groups are negatively charged and are very hydrophilic 
Monoliths were equilibrated with >20 CV of elution buffer, followed by >20 CV of 
equilibration buffer after a 60 min sanitisation in 1 M NaOH 2 M NaCl. Wash and 
elution fractions were both collected in 5 CV fractions throughout. All buffers were 
sterile filtered prior to use using 0.25 µm membrane filters run in dead end mode at 
constant pressure. 
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3.3 Buffer preparation 
 
All buffers where purchased from Sigma – Aldrich unless otherwise stated. 
Sodium phosphate monobasic monohydrate (NaH2PO4.H2O) was purchased as a 
powder and has a molecular mass of 137.99 g/mol. 
HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) was purchased in powder 
form and has a molecular mass of 238.3 g/mol. 
The titrant used to pH HEPES and NaH2PO4 buffers was NaOH. This was also 
purchased as a solid and has a molecular mass of 40 g/mol. 
Tris base (2-Amino-2-(hydroxymethyl)-1,3-propanediol) was purchased as a powder 
and has a molecular mass of 121.14 g/mol. Titrant used was HCL ACS reagent, 37% 
purchased in liquid form with a molecular mass of 36.46 g/mol. 
NaCl was purchased as a powder and has a molecular mass of 58.44 g/mol. 
Benzonase® was purchased from Merk & Co Kenilworth, NJ, USA  
Buffer used to dilute samples containing ammonium sulfate was: 
 10 mM Tris 2 mM magnesium chloride pH 8. 
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3.4 Analytics  
3.4.1 Quantification of infectious titre 
 
TCID50 was the method of choice for the quantification of infectious vaccinia virus 
particles, and was calculated using the Reed and Muench method (reed and Muench 
1938) and expressed in pfu/mL. 
 
The logarithm of the TCID50 was calculated as follows: 
log 𝑇𝐶𝐼𝐷50 = 𝐿𝑜𝑔 (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑎𝑏𝑜𝑢𝑡 50% − (
% 𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑎𝑏𝑜𝑣𝑒 50%
% 𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑏𝑒𝑙𝑜𝑤 50%
)) 
           (3-1) 
This expression is a function of the dilution factor used in each row, and the percentage 
of infected wells at that dilution factor. The TCID50 can be directly found from this 
expression and this is then multiplied by the volume of diluted virus material added per 
well in a 96-well plate format in order to generate a TCID50/mL value. 
 
In order to then estimate the pfu/mL in a sample of a known TCID50, the Poisson 
distribution is used as follows: 
If we take the expression 
𝑃(0) = 𝑒(−𝑚)         (3-2) 
 
where p(0) is the proportion of uninfected wells, and m is the mean number of 
infectious units/volume. If we assume that the conditions for virus infection and 
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replication are the same in a plaque assay and a TCID50 plate then for any number 
expressed as TCID50, the following expression would be correct. 
 
𝑃(0) = 0.5         (3-3) 
 
This would then mean that,  
𝑒(−𝑚) = 0.5         (3-4) 
 
Therefore,  
𝑚 =  −𝐼𝑛 0.5 = 0.693147       (3-5) 
 
A value of 0.69 has been used in all infectivity calculations in this thesis to estimate 
pfu/mL as follows. 
 
𝑇𝐶𝐼𝐷50
𝑚𝐿
 𝑥 0.69 =
𝑝𝑓𝑢
𝑚𝐿
        (3-6) 
 
The TCID50 was performed by dispensing 10-fold sample dilutions down a 96-well 
plate onto CV-1 cells seeding at a density of 8000 cells/well. The plates were then 
incubated at 37 ⁰C,  5% CO2 for 6 days and read by visually inspecting for cytopathic 
effect (CPE) using a Leica DMIL LED bright field microscope (Leica Microsystems 
Inc, IL USA) as well as visually inspecting for red fluorescence protein (RFP). An RFP 
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gene had previously been inserted into the backbone of the virus under investigation; 
this was driven by a vaccinia virus (H5) promoter.  TCID50 generated from inspecting 
for CPR and RFP were equivalent as H5 is a stable promoter and vaccinia is unlikely to 
drop genes the size of RFP (approx. 401 bp). 
 
3.4.2 Quantification of total viral genomes by qPCR 
 
Relative total intact virus particles were measured using quantitative real time 
polymerase chain reaction, (qPCR) with Custom TaqMan
®
 QSY
®
 probes (Thermo 
Fisher Scientific Inc. Waltham, MA, US) which contains a QSY
®
 quencher and FAM
®
 
dye. 
The virus sample was diluted 1:10 in 20mM Tris buffer 2mM MgCl pH 8 and treated 
with 350 units of Benzonase® for 4 h at 37⁰C. Samples were then incubated at 90⁰C for 
1 hour in order to inactivate the nuclease and partially lyse the virus. Viral DNA was 
then purified using the DNeasy Blood and Tissue kit (Cat# 69504 + 69506) (Qiagen, 
Venlo, Limburg, Netherlands) in accordance with the manufacturer’s instructions. The 
protocol used was for non-nucleated blood.  
The total qPCR reaction volume was set to 50µL per reaction, 20 µl of template DNA 
was used. Forward and reverse primer concentrations per reaction were 900nM and 
probe concentration was 200nM.  
Sequence data was as follows: 
Probe: 6-FAM-ATTTTAGAACAGAAATACCC-MGB 
Primers: Sense 5’-AACCATAGAAGCCAACGAATCC-3’ 
    Antisense 5’-TGAGACATACAAGGGTGGTGAAGT-3’ 
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A standard curve was generated using chromatography load material purified DNA.  
qPCR recovery data is relative to the concentration of DNA in the chromatography load 
samples. 
 
Figure 3.4 qPCR standard curve generated from using chromatography load material  
 
3.4.3 Quantification of total protein 
 
The bicinchoninic (BCA) protein assay (Thermo Fisher Scientific Inc. Waltham, MA, 
US) was used to assay total protein. Samples were analysed in accordance with the 
manufacturer’s instructions. 
This assay works on 2 key principles. The first is the chelation of copper with protein in 
alkaline conditions in the presence of sodium potassium tartrate known as the biuret 
reaction. This results in the formation of a light blue complex. During this reaction Cu
2+
 
ions are reduced to Cu
+
. In the second reaction, two molecules of BCA form a complex 
with each monovalent cation to from a purple complex which strongly absorbs light at 
262 nm. As the levels of Cu
2+
 reduction is proportional to the levels of protein in the 
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R² = 0.9997 
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sample, a linear standard curve can be generated and used to estimate protein 
concentrations of unknown samples.  
Bovine serum albumin (BSA) was used as a standard for both the generation of a 
standard curve, between 0 and 2000 µg/mL, and for spiking samples with known 
quantities of protein to demonstrate the reliability of the assay. The diluent used was 50 
mM sodium phosphate (NaH2PO4) pH 7.0 and all samples were diluted at least 4 times 
to ensure appropriate buffer conditions and appropriate protein concentration. All 
samples were measured in duplicate. The lower limit of quantification (LLOQ) is 20 
µg/mL. 40 µg of BSA standard was used to estimate spike recovery. 
Micro BCA was used when LLOQ was reached using BCA. Samples were analysed 
according to manufacturer’s instructions. A standard curve was generated between 0 
and 200 µg/mL, LLOQ is 2 µg/mL. 
 
3.4.4 Visualisation of total protein by SDS-PAGE 
 
3.4.4.1 SDS – PAGE  
 
Non-reducing SDS-PAGE was used to visualise the total protein in selected 
chromatography fractions. 10µl of each fraction was diluted in NuPage MES loading 
buffer containing SDS. Precast NuPage Tris-Bis gels where used with MES running 
buffer in an XCell SureLock Mini gel tank and run at 100V for 40 min. The protein 
ladder used was the thermo scientific page ruler plus pre-stained protein ladder. All 
materials were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific Inc. 
Waltham, MA, US). 
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Gels were initially strained with SimplyBlue SafeStain, which is a safe Coomassie G-
250 stain for proteins; however protein bands in the elution were too low in 
concentration to be visible. A silver staining protocol was therefore used. 
 
3.4.4.2 Silver staining protocol 
 
1. Gels were fixed in 500mL of 40% methanol, 10% Acetic acid, in MilliQ for 1 h. 
2. Washed in MilliQ 3x for 5min each. 
3. Incubated in sensitizing buffer consisting of 5% (w/v) of sodium thiosulfate, 17g 
sodium acetate and 75mL of ethanol in 250mL with water (MilliQ) for 30 min. 
4. Washed in MilliQ 3x for 5min each. 
5. Silver stained in 2.5% (w/v) silver nitrate in 250mL of MilliQ for 20min. 
6. Washed in MilliQ for 45 s. 
7. Developed in sodium carbonate (12.5g) with 200 µL of formaldehyde in 500 mL 
of MilliQ until bands appears in elution fraction. 
8. Stopped in EDTA-Na2 (3.65g) in 250 mL of MilliQ for 20min. 
9. Washed in MilliQ 3x for 5 min each. 
10. Preserved in 5% Acetic acid at 2-8oC until imaging. 
 
3.4.5 Quantification of total dsDNA 
 
The dsDNA quantification was done using the Quant-iT
TM
 PicoGreen
®
 dsDNA reagent 
from Molecular Probes Inc. (Cat. # P7581, Eugene, OR, US). Samples were analysed in 
accordance with the manufacturer’s instructions.  Lambda DNA (Cat. # D1501, 
Promega Corporation, Madison, WI) was used as a standard for both the generation of a 
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standard curve, between 0 and 2000 ng/mL, and for spiking samples with known 
quantities of DNA to demonstrate the reliability of the assay. The diluent used for all 
dilutions was Tris EDTA (TE) and all samples were diluted at least 4 times (and up to 
200x) to ensure appropriate buffer conditions such as removal of salt and appropriate 
DNA concentration. All samples were measured in duplicate. The lower limit of 
quantification (LLOQ) is 250 pg/mL. 40 µg of λ DNA standard was used to estimate 
spike recovery. 
PicoGreen® is a proprietary asymmetrical cyanine dye, similar to SYBR Green I 
(Blotta et al. 2005). The dye binds specifically to dsDNA has an excitation wavelength 
of 485nm and emission wavelength of 530 nm. 
 
3.4.6 Calculation of total protein and total DNA purification factor 
 
A purification factor is a useful way to show the level of clearance of process related 
impurities such as DNA and total protein in relation to the product. This was calculated 
according to the equation below. 
 
𝑃𝐹 =
(𝐶𝐷𝑁𝐴𝑥 𝑉𝐿𝑜𝑎𝑑)/𝑑𝑜𝑠𝑒
(𝐶𝐷𝑁𝐴𝑥 𝑉𝐸𝑙𝑢𝑡𝑖𝑜𝑛)/𝑑𝑜𝑠𝑒
        (3-7) 
 
where a dose is assumed to be 1x10
9
 pfu and PF is purification factor. CDNA is the 
concentration of DNA in ng/mL and VLoad is the volume of the load in mLs and VElution 
is the volume in the elution in mLs. The PF for total protein was calculated in the same 
way in each case by substituting concentration of DNA for the concentration of total 
protein. 
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3.4.7 Quantification of total particles  
3.4.7.1 Nanoparticle tracking analysis (NTA) 
 
NTA (Malvern Instruments Ltd, Malvern, UK) was used to analyse viral particle 
distribution and total particle concentration. A NanoSight LM10 model was used in all 
experiments.  
The camera level was set to 11 and the screen gain was set to 1. During processing of 
the video frames, the detection threshold was set either 3 or 5 (stated in figures). Each 
sample was analysed 5 times and the mean concentration was processed in all 
evaluations. 
Samples were first diluted to within the dynamic range of the assay (1x10
6 – 1x109 
pfu/mL) using phosphate buffer without salt at pH 7. Dilutions made were typically 
between 10 and 100. Using a 1 mL syringe the sample was then loaded into the LM10 
chamber and progressed manually after every reading. In order to prevent any additional 
dilution in the LM10 chamber, the optical flat was cleaned and dried between all runs 
using water and compressed air. 
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3.4.7.2 Tunable Resistive Pulse Sensing (TRPS) 
 
The qNano, produced by (IZON, Oxford, UK) was used to measure chromatography 
load and elution fractions in order to determine levels of polydispersity as well as to 
determine an approximate Zeta potential.  
The system was calibrated with 200 nm ceramic beads (ID # CPC 200) in 300 mM 
NaCl diluted 1000 times.  
30-40 µL of virus sample was diluted 1000 times in PBS and loading into the top of the 
qNano using a p200 pipette. TRPS can measure the concentration of particles between 
concentrations of 1x10
5
 – 1x1012 particles/mL. 
 
3.4.8 Visualisation of virus and contaminants using electron microscopy 
3.4.8.1 Transmission electron microscopy (TEM) 
 
Virus was fixed with 0.5% glutaraldehyde before being loaded onto carbon coated 
copper grids. 20 µL droplets were left to partially dry at room temperature, washed with 
deionised water, and then stained with 2% uranium acetate solution. Grids were 
prepared in triplicate, and loaded into a Jeol 1010 transition electron microscope (with 
digital image capture). 
3.4.8.2 Scanning electron microscopy (SEM) 
 
Virus was fixed and loaded onto carbon coated copper grids in the same way as is 
described in Section 3.4.8.1. For SEM analysis grids were not negatively stained with 
uranium acetate. Once dry, grids where coated with gold palladium using a Gatan high 
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resolution gold beam coater. Grids were loaded into a Jeol 7401 high resolution field 
emission scanning electron microscope.  
 
3.4.9 Statistical analysis  
 
Throughout this work infectious virus concentration, total particle concentration and 
residual DNA and protein concentration measurements were performed in either 
duplicate or triplicate. In order to calculate error in these measurements relative 
standard deviation (RSD) was calculated as follows: 
The STDEV.S function in excel was used to calculate sample standard deviation, and 
the sample relative standard deviation. This was under the assumption that the assay 
measurements taken did not represent the entire population. The following equation is 
used to calculate sample standard deviation.  
𝑠 = √
1
𝑛−1
 ∑ (𝑥𝑖 − ?̅?)2
𝑛
𝑖=0           (3-8) 
where n is the total number of replicates for a single sample, xi is the value of each 
replicate and ?̅? is the mean of all the replicates. 
The RSD was then calculated as follows. 
𝑅𝑆𝐷 =
𝑠
?̅?
× 100         (3-9) 
Multivariate analysis was run using SAS JMP in order to test for correlations between 
multiple variables. The built in analysis tool uses the Pearson product moment 
correlation coefficient as a measure of the linear relationship between two variables 
(SAS JMP 12 2017a).   
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𝑟 =
∑(𝑋−?̅?)(𝑌−?̅?)
√∑(𝑋−?̅?)
2
√(𝑌−?̅?)
2        3-10 
This can be simplified and written as  
𝑟 =
𝑆𝑃𝑋𝑌
√𝑆𝑆𝑋 𝑆𝑆𝑌
          3-11 
 
where SPXY is the sum of products, SSX and SSY are the sum of squares for each 
variable. 
 
DoE was used to model the effects of pH and salt concentration for CIM SO3 
monoliths. The R
2 
values presented in the analysis shows how much the variation in 
response values can be attributed to the model (Rouiller et al. 2012). The R
2
 values were 
calculated as follows: 
𝑅2 = (
𝑆𝑆𝑚𝑜𝑑𝑒𝑙
𝑆𝑆𝑡𝑜𝑡𝑎𝑙
)                   3-12 
where SStotal, or total sum of squares, is the sum of the squared difference between the 
response values and the sample mean. This is the total variation in the response values. 
The SSmodel, or model sum of squares, is the difference between SStotal and the SSerror. It 
represents the variability explained by the model. SSerror is the error sum of squares and 
represents the sum of the squared differences between the fitted values and the actual 
values. This represents the variability unexplained by the fitted model (SAS JMP 12 
2017b). 
Throughout this thesis, the adjusted R
2
 has been used, which adjusts the R
2 
value for the 
number of parameters in the model. The Adjusted R
2
 
𝑅2𝐴𝑑𝑗 = 1 −
𝑀𝑒𝑎𝑛 𝑆𝑞𝑢𝑎𝑟𝑒 (𝐸𝑟𝑟𝑜𝑟)
𝑆𝑆𝑡𝑜𝑡𝑎𝑙 𝐷𝐹𝑡𝑜𝑡𝑎𝑙⁄
      3-13 
117 
 
where DFtotal is the degrees of freedom for the model and the error. The mean square for 
error is the sum of squares divided by its associated DF. It represents an estimate of 
population variance. 
 
In a fitted model the residuals, or difference between the predicted responses, 𝑌𝑚𝑜𝑑𝑒𝑙 , 
and the measured observations, xi,  is calculated in JMP using the root mean square 
error (RMSE). This should be a low as possible. 
 𝑅𝑀𝑆𝐸 =  √
∑ (𝑌𝑜𝑏𝑠−𝑌𝑚𝑜𝑑𝑒𝑙)2
𝑛
𝑖=0
𝑛
       3-14 
 
3.5 Sample handling  
 
Sample handling is a very important part of virus bioprocessing. 
Vaccinia virus stability will be discussed in some detail in Chapter 4. From the offset of 
experimentation, it was decided that all samples should be treated in as close to the 
same way as possible so as not to introduce any variability in virus infectivity as a result 
of handling. 
During every experiment, samples were taken of each fraction or stage needing to be 
recorded. Samples were then aliquoted into smaller volumes for each assay needing to 
be performed and all samples were left on the bench at room temperature until all 
experimental samples had been taken. All samples from an individual experiment, such 
as a chromatography run, were then frozen together at -80 ⁰C until required. 
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  Chapter 4
Material Characterisation  
 
4.1 Introduction 
 
Initial material characterisation is a very important first step when developing viral 
bioprocesses. Upstream processes are inherently variable thus an understanding of how 
much batch to batch variability is likely and why it occurs is crucial if its effects on the 
downstream process are to be understood.  
In many viral processes infectivity is a major critical quality attribute (CQA). 
Significant amounts of process knowledge and understanding need to come from 
infectivity assays, which, as discussed in the previous chapter, can have an error range 
of up to an order of magnitude. This makes it difficult to accept trends taken at face 
value unless the experiments can be repeated and trends identified many times. Often, 
due to time and material constraints, this is simply not possible without the availability 
of optimised high throughput processes and accompanying analytics.  
One way to combat this is to identify trends by using more than one analytical 
technique. These techniques need to be orthogonally coupled with infectivity data in 
order to generate a “picture” of what is happening in the system under evaluation. What 
is often challenging is that each technique provides a specific angle of insight into the 
often complex system, so they can often be misleading when individually evaluated.  
In this chapter, characterisation of the viral harvest and chromatography load material 
will be discussed in detail. The stage in the process in which this material is generated is 
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indicated in Figure 3.1, a process flow diagram is shown from cell culture to 
chromatographic capture.  
 
4.2 Harvest titre and residual impurity variability 
 
In an attempt to understand batch to batch variability in vaccinia virus harvest material 
the infectious titre, DNA concentration, and total protein concentration were measured 
across a number of batches. Figure 4.1 shows the raw data generated. The distribution in 
infectious titre is Gaussian and has a mean value of 1.57x10
9
 pfu/mL. Infectious virus 
was measured across 11 batches, DNA concentration measured across n=6 batches and 
protein concentration measured across n=3 batches. The distribution incorporates the 
variability in the analytics as well as inherent variability in the cell culture and primary 
recovery processes. Figure 4.2 reiterates these points, showing the range in the 
infectious viral titre, DNA, and total protein concentrations recorded in the harvest 
material.  
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Figure 4.1 Variability in infectious titre, DNA, and Protein concentration in vaccinia virus 
harvest material post freeze thaw and centrifugation measured across 11 batches. 
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Figure 4.2 Infectious titre, DNA, and total protein concentration range in the harvest 
material. (Vaccinia titre was measured across n=11 batches, DNA concentration measured 
across n=6 batches and protein concentration measured across n=3 batches. 
 
When taking a closer look at the data in Figure 4.1, there appears to be a correlation in 
the concentrations of infectious virus and the total DNA in the harvest material. This 
trend is also shown in Figure 4.3 after running a multivariate analysis on the raw data. 
The blue shaded area shows a 95% density eclipse assuming a bivariate normal 
distribution between each pair of variables. The red line and shaded area shows the 
fitted regression line and a 95% confidence interval for the fitted regression. The 
correlation between the virus and DNA concentration is shown to have an r value of 
0.8614. The value summarises the strength of the linear relationship between each pair 
of responses. The correlation between DNA and protein (r = 0.4029) and infectious 
virus and protein (r = 0.6106) is less significant. The R value is calculated using the 
Pearsons product moment correlation coefficient as shown in Equation 3-10.  
121 
 
 
Figure 4.3 Scatterplot matrix showing correlations between variations in concentration of 
virus, DNA and protein in vaccinia harvest material.  
 
It is possible that this may be linked to the number of cells per batch at the point of 
infection varying from batch to batch, due to the methods used to estimate the total 
number of cells per flask. It has been suggested in the literature when discussing 
indirect measurements for determining cell expansion efficiency that glucose, lactate or 
DNA concentration may be useful when dealing with cell culture systems in which 
direct measurements of cell concentration are challenging, such as in hollow fibre 
bioreactors (Wung et al. 2014). The reason this methodology was not evaluated in this 
case, was that significant optimisation would have been required as well as an increased 
amount of manual handling. Cell counting was performed either by using a TC20
TM
 
automated cell counter (Bio-Rad Laboratories, CA, USA) or a haemocytometer. The 
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total number of cells in a single T175 flask was then assumed to be the same across all 
flasks seeded at the same cell density (of ~1x10
6
 cells/flask). The total number of cells 
per batch prior to infection was then calculated as the number of cells in a single T175 
flask multiplied by the total number of flasks used. Batches of cells were infected with 
vaccinia once they became ~80% confluent.  
 
4.3 Determination of vaccinia harvest Zeta Potential  
 
The zeta potential of the viral harvest material was measured using a QNano devise 
designed by (IZON, Oxford, UK). The Zeta potential of each particle is calculated from 
the electrophoretic mobility using the Smoluchowski equation. The data is shown in 
Figure 4.4, and suggests that the majority of particles have a negative zeta potential of 
approximately -30mV. Similar to NTA the QNano is not able to measure particles of 
larger than 1µm depending in the nanopore used. This data is in agreement with 
literature values for vaccinia virus in terms of its isoelectric point, which is between 4 
and 5 (Michen & Graule 2010). 
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Figure 4.4 Zeta potentials of vaccinia harvest measured using the QNano showing 
calculated zeta potential values for individual particles. Average value shown to be -32 
mV. 
 
4.4 Virus stability 
 
Initially stability studies were performed in order to identify critical process parameters 
that might have an impact on the recovery of infectious virus during chromatography. 
The first study shown in Figure 4.5.A was designed to test whether vaccinia harvest 
material was stable at room temperature, as typical downstream unit operations are 
conducted without thermoregulation. A 1 mL aliquot of vaccinia harvest was left inside 
a biosafety level two (BSLII) cabinet and assayed for infectious virus every hour. 
The mean data shows an initial drop in the number of infectious particles, although the 
assay shows high variability in initial measurements. After the first 2 hours, the 
infectivity remains constant. After running an ordinary one-way ANOVA assuming a 
Gaussian distribution, no significance was found if a P value cut of 0.05 is used. (P 
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value = 0.0605, R
2
 = 0.5233) On this basis, it was concluded that vaccinia harvest is 
likely to be relatively stable at room temperature.  
  
The second experiment shown in Figure 4.5.B was designed to test whether increasing 
the salt concentration would have an impact on the infectivity of the chromatography 
load material. 50 mM sodium phosphate buffer was made up at pH 7 ranging from 0 to 
2M NaCl. Samples were incubated for 2 hours and then assayed for infectious virus. 
The rational for analysing viral stability in different salt concentrations was that typical 
load and elution buffers used for IEX and HIC chromatography vary in both 
concentration and type of salts required. It was decided that any understanding of the 
edges of failure in terms of loss in infectivity was important. 
The concentration of infectious virus is at its highest without NaCl. When 0.25 M NaCl 
is added, the total number of infectious viral particles decreases by almost 30%; 
however, as the concentration of NaCl further increases, from 0.25-2 M, the 
concentration remains constant.  
As a control and comparator, the stability of virus in cell culture media (DMEM) 
containing 5% FBS and hydrophobic interaction chromatography load buffer containing 
ammonium sulfate was also tested. Samples diluted in media (DMEM) were assayed at 
t=0 h and t=2 h and the concentration was not found to increase significantly. Given 
this, it can be inferred that vaccinia virus infectivity, both in media and sodium 
phosphate without NaCl, is relatively unaffected over a 2 h incubation at room 
temperature. There does appear to be an initial drop in infectivity in sodium phosphate 
buffer containing NaCl at concentrations typically seen in chromatographic separations. 
However, due to assay variability being as high as it is, this difference was not found to 
be statistically significant (P = 0.2030, R
2 
= 0.4314). 
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Figure 4.5 A) Vaccinia virus harvest stability time trail at room temperature. B) Vaccinia 
stability study with increasing NaCl concentration in phosphate buffer pH 7 at room 
temperature. Points refer to raw TCID50 replicate values (n=3), mean values shown as a 
horizontal line for each condition. 
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A design of experiments (DoE) was then performed in order to analyse the combined 
effects of both NaCl and pH on virus stability, again at room temperature, over a 2 hour 
period, in 25 mM sodium phosphate buffer. Given the inherent variability in the TCID50 
measurements, fitting correlations to the data is challenging. The ANOVA showed a 
significant individual P value for effects due to NaCl concentration (P = 0.0048). The P 
value for effects due to pH was relatively low, but above the 0.05 cut often used to 
demonstrate significance (P=0.0541). However, after fitting a partial least squared 
model to the dataset the adjusted R
2 
value was only 0.31, and the residuals were high, 
the RMSE was 1.453x10
9
. 
The data is shown in Figure 4.6. Each triplicate TCID50 reading is shown as a 3D 
histogram rather than the modelled data being shown as a response surface plot. There 
appears to be an apparent increase in stability as pH and NaCl concentration increases. 
It should be noted that the material used was purified by density gradient 
ultracentrifugation prior to analysis and so would have contained less DNA and host 
cell protein. This was due to material availability.  
Compared to the data in Figure 4.5 this result does seem to suggest a slightly different 
trend in terms of the effects of NaCl concentration on infectious virus stability; 
however, in both cases the variability is around 30%. Under close inspection, this 
variability appears even higher at high NaCl concentration and pH. While the material 
in the DoE appears slightly more stable as NaCl and pH increase, the control samples 
left in DMEM media remained fairly constant at 8.16x10
9
 and 1.41x10
10
 pfu/mL 
respectively. This shows that the sample diluted in sodium phosphate buffer without 
NaCl recovered only 5% of the infectious particles after 2 hours at low pH. 
As aforementioned, robust conclusions are difficult to generate when dealing with 
highly variable datasets. When considering future chromatographic development it 
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seems fair to assume that increasing the NaCl concentration will unlikely cause vaccinia 
infectivity to drop significantly. This makes both ion exchange and hydrophobic 
interaction chromatography possible candidates when screening different chemistries. 
As expected, low pH seems to have a negative effect on infectivity. Therefore, when 
optimising loading and elution conditions higher pH values have generally been used. 
 
Figure 4.6 3D histogram showing raw data values from vaccinia virus stability factorial 
design. Virus was purified using 2 consecutive sucrose density gradient ultracentrifugation 
runs prior to analysis. Study was performed at room temperature over a 2 hour period in 
25mM Sodium phosphate buffer. Replicate values (n=3) have been jittered by shifting the 
pH by 0.1 units. A control was run in DMEM media containing 5% FBS at the beginning, 
t=0, and after 2 hours t=1, the concentration of the control samples were 8.16x10
9
 and 
1.41x10
10
, respectively.  
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4.5 Physical characterisation 
 
While infectivity and residual impurity levels are vital to obtain in order to understand 
process outputs such as efficiency and productivity, not to mention being required for 
final product release, physical characterisation is also important.  
There are a number of techniques available that have either been designed or 
implemented to study viral integrity, morphology and characteristics such as levels of 
polydispersity. In this study vaccinia was analysed using transmission and scanning 
electron microscopy as well as NTA in order to investigate levels of aggregation.  
While it is unknown whether viral aggregates need to be considered as a critical quality 
attribute, it is considered possible that vaccinia aggregation may have an effect on 
process yield. Data from the literature also suggests that viral aggregation can influence 
infectivity measurements (Floyd and Sharp 1979). For these reasons it was decided that 
possible process parameters that could cause or prevent aggregation should be 
evaluated. 
 
4.5.1 Size distribution using nanoparticle tracking analysis (NTA) 
 
The size distribution of the chromatography load material overlaid with a null prep 
sample as measured using a NanoSight (Malvern Instruments Ltd, Malvern, UK) is 
shown in Figure 4.7. The null prep contained uninfected cell lysate prepared in the same 
way as the virus load. Both samples were diluted in 50mM sodium phosphate buffer pH 
7 (1:30) prior to analysis to ensure that the concentration of particles was within the 
correct working range for the instrument as specified by the manufacturer, (between 
1x10
6
 – 1x109 particles per mL). 
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A bimodal distribution is evident in both the load and the null prep samples. Both peaks 
can be seen to overlay (Figure 4.7) but are at a lower concentration in the null prep than 
in the virus load. It is speculated that host cell components and degraded viral particles 
make up the first peak in the load fraction. Vaccinia virus is around 300nm in diameter, 
which approximately corresponds to the size range of the second peaks. It is likely, 
therefore, that this population in the load sample contains intact viral particles. The fact 
that there is a second peak in the null prep sample leads us to the conclusion that there 
are particles of a similar size range to vaccinia generated during the primary recovery 
step. Based on this observation, it is expected that the NTA will overestimate the 
number of virus particles in the load fraction. Similarly, it would likely underestimate 
the recovery of virus across the column, assuming that a proportion of 300 nm particles 
derived from the host cell will be removed during chromatography.  
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Figure 4.7 Average size distribution data (n=5, 1min tracks, detection threshold 3). Load is 
vaccinia virus harvest material post dilution post filtration. Null prep is harvest material 
post dilution post filtration without virus, up and down stream steps treated in the same 
way throughout. 
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The effects of high and low salt concentration on particle size distribution were then 
tested, again using NTA. As this thesis is focusing on the development of a 
chromatographic process, it was decided to use IEX and HIC load buffers in the 
evaluation. 
Figure 4.8 shows the size distribution of the chromatography load material when diluted 
in cation exchange (CIEX) load buffer, 50mM sodium phosphate pH 7, and HIC load 
buffer 50mM sodium phosphate 1M ammonium sulfate 2M NaCl pH 7. The results 
show that buffer containing ammonium sulfate causes an increase in polydispersity. 
NTA is unable to identify particles larger than 1000 nm, which may result in some 
inaccuracy. However, it appears that the profile when diluted in high salt shifts to the 
right, suggesting self-association of particles in the sample. There also appears to be a 
slight increase in the number of particles at approximately 150 nm. The reason for this 
is not clear, however, it is speculated to be due to the aggregation of smaller particles 
such as fragments of DNA or proteins in the load that has previously been below the 
dynamic size range of the instrument. As it is unknown from looking at this data 
whether it is the virus material, contaminants, or a combination of both that are 
aggregating, the experiment was repeated and analysed using electron microscopy in 
order to gain more information. 
 
131 
 
0 3 0 0 6 0 0 9 0 0
0
2 .01 0 8
4 .01 0 8
6 .01 0 8
8 .01 0 8
1 .01 0 9
P a r t ic le  S i z e
(n m )
N
u
m
b
e
r 
o
f
 P
a
r
ti
c
le
s L o a d
1 M  (N H 4 ) 2 SO 4  2 M  N a C l
L o a d
N o  S a lt
E lu tio n
 
Figure 4.8 Effects of diluent salt concentration on particle size distribution.  (n=5, 1min 
tracks, detection threshold 5) Harvest material post dilution post filtration was diluted 
1:30 times in 50mM NaH2PO4 pH7 and 50mM NaH2PO4  1M (NH4)2SO4  2M NaCl pH7 
respectively. 
 
4.5.2 Visualisation of intact particles and evaluation of visible impurities 
 
Information in the literature does agree with initial findings from NTA data. It suggests 
vaccinia virus is prone to aggregate, especially in impure preparations (Kim and Sharp 
1966). 
Data generated using transmission and scanning electron microscopy was compared in 
order to visualise the extent of virus aggregation in DMEM media containing 5% FBS, 
IEX loading buffer, and as previously mentioned HIC loading buffer conditions. This 
was then compared to the NTA data previously discussed. 
Images generated from electron microscopy are not quantitative. They represent an 
extremely small fraction of a sample and require a partial drying and staining or gold 
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coating step depending on the methodology used. Images can therefore only be used to 
aid in our understanding of more quantitative measurements.  
Images generated from impure preps of vaccinia virus in both DMEM and sodium 
phosphate buffer without salt, appear to show relatively high levels of aggregation, as 
shown in Figure 4.9 and Figure 4.10. Viral clusters were evident across all grids 
analysed (n=3 for each sample). Stability data in Figure 4.5.B indicates that virus is 
relatively stable under both of these conditions. Data in Figure 4.5.A indicates that 
variability in infectivity is higher at t=0 h than at later time points. This may be due to 
aggregation. Floyd and Sharp showed that aggregation can impact on infectivity of both 
polio and reoviruses, (Floyd & Sharp 1979). If aggregation is time dependant, this may 
explain this initial variation. 
A TEM image, at high NaCl and ammonium sulfate concentration can be seen in Figure 
4.11. Virus is shown to be positively stained; perhaps due to the size of the clusters 
formed, nevertheless a large amount of aggregation is clearly visible. When compared 
to Figure 4.9, which is at the same magnification of 15,000x, the level of aggregation 
looks significantly higher. As it is difficult to make out individual particles, the sample 
was also analysed using SEM. This data can be seen in Figure 4.12 and Figure 4.13. 
Particles of a similar size to vaccinia virus can be seen in Figure 4.12 to form extremely 
large complexes. The aggregates formed are larger than 6 µm across and appear to be 
made of many virus like particles. It is speculated that these aggregates in reality are 
made up of other contaminants as well as vaccinia. This hypothesis is partially backed 
up in Figure 4.13. A smaller virus aggregate appears to be associated with another 
material. The image shows two proposed vaccinia particles with an associated structure 
possible resembling DNA complexed with positively charged histone proteins. It is 
speculated that this may represent heterochromatin as the structure appears to resemble 
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the “beads on a string” model often used to describe the complex between DNA and 
histone proteins. It is well documented in the literature as discussed (Wolff & Reichl 
2008) that the removal of DNA from viral feed streams is challenging. These 
observations, may partially explain why this is the case. DNA is likely to be difficult to 
remove as a result of the complexes it forms with virus particles. This view was also put 
forward and addressed in (Jordan et al. 2015).  
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Figure 4.9 Vaccinia virus harvest material in DMEM 5% FBS 15000x magnification, scale 
bar reads 1µm 
 
 
 
135 
 
 
Figure 4.10 Vaccinia harvest diluted in CIEX load buffer 8000x magnification, 
scale bar reads 2µm. 
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Figure 4.11 TEM micrograph of Vaccinia harvest in HIC load buffer 15000x 
magnification, scale bar reads 1µm 
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Figure 4.12 SEM micrograph of vaccinia virus material diluted in HIC load buffer 10000x 
magnification, scale bar reads 1µm Image shows an extremely large aggregated molecules 
potentially made up of many associated vaccinia virus particles. Rod-like structures are 
thought to be ammonium sulphate crystals. 
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Figure 4.13 SEM micrograph of vaccinia virus material diluted in HIC load buffer, 25000x 
magnification, scale bar reads 1µm  
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4.6 Conclusions 
 
Batch to batch variation in infectious viral titre as well as residual impurity 
concentration has been investigated in this chapter along with virus stability, 
morphology, and aggregation.  
The use of a variety of orthogonal analytical methods has allowed a number of 
conclusions to be drawn that are important to take into account when developing 
downstream unit operations. These conclusions are that: 
 Vaccinia virus infectivity is relatively unaffected by elevating NaCl and 
ammonium sulfate concentrations, but appears to drop off over time at room 
temperature, especially at low pH.  
 High levels of aggregation have been identified in impure viral preparations, 
especially at elevated ammonium sulfate concentration.  
 High batch to batch variability in infectious titre and residual DNA and protein 
concentrations identified, possibly due to variation in the total number of cells 
prior to infection per batch as well as variability in the TCID50 assay. 
A full characterisation of viral starting material is a never ending process. What is 
important is to generate enough product knowledge and understanding to be able to 
generate and work to understand mass and particle balances generated during process 
development activities. Without this information troubleshooting activities become 
impaired, and the generation of robust conclusions on process performance, ultimately 
contributing to patient safety, is impossible. 
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  Chapter 5
Ion Exchange Chromatography Process 
Development 
 
 
5.1 Introduction 
 
As described in Section 2.4.3, ion exchange (IEX) monolith chromatography, and 
especially anion exchange (AIEX), has been demonstrated in the literature as being 
capable of capturing and purifying infectious viral particles, virus like particles (VLPs) 
and other large macromolecular entities. The design of an efficient adsorption-based 
separation process for vaccinia virus, however, is complicated by its large size and 
complex physicochemical properties. Enveloped viruses in general are also known to be 
fairly labile, which has further complicated the development of chromatographic 
separations. An important constraint is to prevent loss in infectivity post purification. 
The large size of vaccinia virus excluded many popular IEX adsorbents and attention 
has been focused on large pore adsorbents. In this chapter, the process development of 
vaccinia virus using three commercially available ion exchange monoliths for initial 
capture and purification will be described. The aim was to generate a capture step able 
to bind and elute infectious vaccinia virus from crude lysate removing double stranded 
DNA (dsDNA) and proteins. The plan was to start with a screening study designed to 
test a selection of IEX chemistries, CIM QA, CIM DEAE, and CIM SO3 (each with a 
nominal channel diameter of 6 µm). The chemistries were chosen based on previously 
published data on the use of CIM monoliths to purify viruses described in Section 
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2.4.3.2. It was decided that the most promising chemistry would then be taken forward 
to start optimising load and elution strategies.    
5.2 IEX Monolith Screening Study 
 
Initial screening studies were primarily designed firstly to determine which IEX CIM 
monolith chemistries vaccinia was able to adsorb to at neutral or weakly basic pH, and 
then secondly to determine if there were any major differences in viral recovery or 
impurity removal capabilities from any of the monoliths. Approximately 1x10
10
 pfu of 
virus (10 mL fractions) were diluted 1:5 in IEX load buffer, as shown in Table 5.1, and 
passed through a 0.8µm cellulose acetate syringe filter, as described in Figure 3.1, before 
being loaded onto each column. The rationale for choosing the conditions outlined are 
listed below: 
1. Typically low pH is used to remove infectious viruses from biological products 
(WHO 2004). It was thought that loading vaccinia at low pH would likely cause 
unacceptable losses in infectivity.  
2. Cell culture pH is around neutral (pH 7) therefore it was thought sensible to test 
both CIM SO3 and CIM QA at pH 7. The rationale here is that vaccinia is likely 
to be stable at physiological pH.  
3. CIM DEAE was run at pH 8.5 as the capacity was speculated to be lower than 
that of CIM QA at pH 7. HEPES was used in place of Tris for CIM QA when 
run at pH 7 
4. CIM QA was then also tested at pH 8.5 in order to compare directly with CIM 
DEAE. 
5. Tris has a pKa of 8.07 and is therefore cationic at neutral pH. pH 7 is also at the 
bottom of its buffering capacity. Sodium Phosphate was used in place of Tris for 
CIM SO3.  
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Table 5.1 DNA and total protein purification factors recorded during initial screening 
studies on CIM SO3, CIM QA, and CIM DEAE. Buffer systems used are as shown, a 
concentration of 50 mM was used in each case. Equilibration buffer did not contain NaCl. 
Elution buffer contained 1.5 M NaCl. Purification factors calculated according to 
Equation 3-7.  
Monolith 
Chemistry 
Buffer System 
(used for equilibration, wash, 
and elution) 
Protein Purification 
Factor 
DNA Purification 
Factor 
SO3 Sodium phosphate pH 7 7.63 0.58 
QA Tris pH 8.5 2.09 0.18 
QA HEPES pH 7 2.18 0.40 
DEAE Tris pH 8.5 2.99 0.16 
 
 
1 mL radial monolith columns were used in all experiments. The volumetric flow rate 
used was 5 mL/min (linear velocity = 195.08 cm/h).  A process flow diagram indicating 
each unit operation from cell culture to chromatographic capture is shown in Figure 3.1. 
Representative chromatograms for each chemistry are shown in Figure 5.1. UV 
absorbance at 280 nm and conductivity values shown in mS/cm are presented for CIM 
SO3, CIM QA and CIM DEAE monoliths.  
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Figure 5.1 Representative chromatograms from CIM S03 in Sodium Phosphate pH 7.0 
(A), CIM QA in Tris pH 8.5 (B), CIM QA in HEPES pH 7.0 (C), and CIM DEAE in Tris 
pH 8.5 (D). 
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Figure 5.2 A) Box and whiskers plot (median & range) showing infectious vaccinia 
recovery data from CIM SO3, CIM QA, and CIM DEAE at pH 7 and pH 8.5. Red plots 
show the percentage of infections virus in the flow through fraction relative to the load, 
blue plots shows percentage of infectious virus in the elution fraction relative to the load, 
and black plots show the percentage infectious virus in the elution minus the total number 
of particles lost in the flow through relative to the load. B) Box and whiskers plot (median 
& range) showing the number of viral particles loaded vs the capacity achieved on CIM 
SO3, CIM QA, and CIM DEAE.  
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After analysing the results, the vaccinia virus concentrations in each stream are shown 
in Figure 5.2, it can be seen that vaccinia is able to adsorb to both AIEX and CIEX 
monoliths even though it has a zeta potential of approximately -32 mV (Figure 4.4), and 
an isoelectric point of between 4 and 5 (Michen & Graule 2010). After a review of the 
literature it was found that viral adsorption onto IEX resins at both sides of their given 
isoelectric point has been reported for a number of viruses before (Banjac, Roethl, 
Gelhart, Kramberger, Jarc, Jarc, Strancar, Muster, & Peterka 2014;Wolff & Reichl 
2011;Wolff, Siewert, Lehmann, Hansen, Djurup, Faber, & REICHL 2010b); however, a 
definitive conclusion as to why it occurs so commonly has not been reached. As with 
proteins, it is likely that viruses are sufficiently heterogeneous to form electrostatic 
interactions on the "wrong" side of their isoelectric point (Yamamoto & Ishihara 1999); 
however, complex interactions between charged viral particles and contaminating 
impurities of opposite charge may also play a role, especially in crude feed streams. 
The recovery of virus in the elution fractions for all IEX monoliths is shown to be 
comparable indicating that the capacity of each column is similar. However, infectious 
virus was also found in the flow through fractions, indicating that the columns may have 
been overloaded (Figure 5.2A). 
Residual impurity removal data is shown in Table 5.1. DNA purification factors can be 
seen to be less than 1, indicating that the net recovery of infectious virus was lower than 
the recovery of DNA relative to the load for each chemistry. Protein purification factors, 
on the other hand, show some encouraging results. The AIEX monoliths (CIM QA and 
CIM DEAE) are able to achieve a protein purification factor of between 2 and 3, while 
the CIEX monolith (CIM SO3) achieved a protein purification factor of 7.63. This 
suggests that the majority of proteins in the load are acidic. The experiments were not 
designed to test for removal of residual DNA or protein, as the elution buffer NaCl 
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concentrations used were too high (1.5 M). This concentration was picked in order to 
maximise the recovery of infectious virus.  
 
Following on from the screening studies on IEX monoliths there are a number of 
conclusions that can be drawn prior to moving on to the next stage in process 
development. 
 
1. DNA removal will likely be dependent on resolution being achievable in the 
elution fraction.  
2. Protein removal will likely by easier to achieve than DNA removal, as some 
base-line clearance is seen even without elution buffer optimisation. This is 
especially true for CIM SO3, as the majority of proteins loaded are recovered in 
the flow through fraction and so do not bind to the column. 
3. Vaccinia virus is able to adsorb to both CIEX and AIEX monoliths at neutral 
pH. 
4. Binding capacity and percentage recovery of infectious virus is similar across all 
chemistries tested. 
5. AIEX monoliths, especially CIM QA, appear to show a double breakthrough in 
absorbance during the load (as seen in Figure 5.1.B & C). It is unlikely that this 
phenomenon is due to vaccinia breakthrough, as it does not occur in any of the 
CIM SO3 chromatograms. It is thought possible that it may be DNA and/or 
protein as both adsorb to AIEX. The fact that QA is a stronger AIEX than 
DEAE would also support this theory, since the double breakthrough occurs 
earlier in DEAE suggesting a lower capacity. 
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It was decided at this point that only two chemistries would be taken to the next stage of 
process development due to resource limitations. CIM SO3 was chosen as the main 
candidate because of its potential to remove protein. More than 60% of the total protein 
loaded onto CIM SO3 monoliths during the screening study was recovered in the flow 
through fractions.  It was speculated that this would allow elution step design to focus 
on DNA removal and infectious yield. Based on the data from the screening study, it 
was not possible to fairly distinguish between CIM QA and CIM DEAE as both showed 
comparable recovery of infectious particles and achievable capacity as well as removal 
of DNA and protein. As only one could be taken forwards, however, it was decided that 
CIM DEAE would be put aside and CIM QA would be developed further.  Due to the 
presence of infectious virus in the flow through fractions from both CIM SO3 and CIM 
QA it was decided that a dynamic binding capacity study (DBC) needed to be 
performed. A DBC was completed on CIM SO3 (Figure 5.4D Run 1) and showed 
breakthrough at approximately 3x10
9
 pfu/mL of monolith. This was taken as an 
approximate binding capacity for both CIM SO3 and CIM QA monoliths, based on the 
capacities achieved in the screening studies (Figure 5.2B). The DNA and total protein 
concentration in the virus load material, prior to running the DBC study, was ~1000 
ng/mL and ~700 µg/mL, respectively. 
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5.3 Evaluation of DNA and Protein Elution Profiles from CIM SO3 
and CIM QA Monoliths 
 
A linear gradient elution was run on CIM SO3 as it can be seen in Figure 5.3.A and B 
and CIM QA monoliths (Figure 5.3.C). The gradient was run over 20 CVs between 0-
1.5M NaCl in 50 mM sodium phosphate and 50 mM Tris for CIM SO3 and CIM QA, 
respectively.  Both columns were challenged with approximately 3x10
9
 infectious viral 
particles. 90% of the virus loaded adsorbed to each chemistry, with only 5-10 % of the 
infectious virus found in the flow through fractions. The CIM SO3 chromatograms 
(Figure 5.3.A and Figure 5.3.B) show that the majority of infectious virus is eluted 
before the DNA. 40% of the DNA in the load is adsorbed to the column, and greater 
than 90% is removed with a 50% recovery of infectious virus in the first 10CVs.  Virus 
starts to elute after 2 CVs, which corresponds to approximately 150 mM NaCl. DNA is 
then co-eluted with a smaller viral peak after 10 CVs, corresponding to approximately 
750 mM NaCl.   
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Figure 5.3 Data shows the infectious viral particles (pfu) mass of protein (µg) and mass of 
DNA (ng) in elution fractions A) Linear gradient elution run on CIM SO3 monolith loaded 
to approximately 3x10
9
 pfu/mL run over 20 CV. B) Linear gradient elution run on CIM 
SO3 monolith loaded to approximately 3x10
8
 pfu/mL and run over 25 CV. Conditions for 
CIM SO3 Buffer A: 50mM sodium phosphate pH7, Buffer B: 50mM sodium phosphate 
1.5M NaCl pH 7. C) Linear gradient elution run on CIM QA monolith loaded to approx. 
3x10
9
 pfu/mL monolith run over 20CV between 0 and 1.5M NaCl. Condition for CIM QA 
Loading Buffer: 50mM Tris pH 8.5. Elution Buffer: 50mM Tris 1.5M NaCl pH 8.5 
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The results indicate that CIM SO3 monoliths are able to resolve most of the virus from 
the adsorbed DNA. CIM QA is not able to achieve this without heavy losses in virus 
yield, as DNA co-elutes with the main infectious viral peak as seen in Figure 5.3.C. As 
DNA was identified as a critical quality attribute (CQA), it was decided that the CIM 
SO3 linear gradient should be repeated but that the column should be challenged with 
an order of magnitude less infectious virus (approximately 3x10
8
 viral particles per mL 
of monolith) and eluted over a longer gradient (25 CVs rather than 20 CVs) in order to 
maximise the resolution achievable, The results can be observed in Figure 5.3.B. It 
shows the same trend and percentage removal of DNA across the elution peak as 
illustrated in Figure 5.3.A. 
The reason why virus and DNA co-elute towards the end of the gradient is unclear. It 
has been speculated that this may be due to a complex interaction between the virus and 
DNA molecules. SEM images of CIM OH fractions, presented in Figure 6.9, show virus 
associated with long DNA-like structures resembling “beads on a string”. It has been 
speculated that this structure may represent heterochromatin, which, due to the positive 
charge of the histone complexes, might enhance the interaction between the virus and 
the monolith. Other groups have also experienced difficulty in separating vaccinia virus 
and DNA, and experimented by adding chaotropes to disrupt potential viral-DNA 
complexes prior to nuclease treatment (Jordan, Weimer, Iarusso, Bernhardt, Lohr, & 
Sandig 2015b). 
A positive charge may also come from viral coat proteins even though the overall 
charge across the surface is negative. It has been suggested, based on work with 
influenza virus, which is also able to adsorb to CIM QA and CIM SO3 monoliths, that 
buffer condition dependent variation in charge distribution across the viral surface may 
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give viral vectors enough net charge to bind to both cationic and anionic chemistries 
(Banjac, Roethl, Gelhart, Kramberger, Jarc, Jarc, Strancar, Muster, & Peterka 2014).  
Another possibility might be the presence of a cationic bridging molecule in the feed 
stream that adsorbs to the stationary phase and is able to retain enough positive charge 
to interact with the virus, DNA, and any viral-DNA complexes present. Based on the 
screening studies, there is protein in the flow through fraction from both the CIEX and 
AIEX monoliths, suggesting that while the majority of host cell proteins in the load are 
acidic, there are also basic proteins present. The issue with this hypothesis is that it is 
difficult to envisage a species of host cell protein that would be able to retain enough 
net charge while bound to CIM SO3 to hold a large viruses like vaccinia on the surface.  
What is evident from the data in Figure 5.3 is that DNA is more retained at high NaCl 
concentration than the majority of infectious viral particles. This indicates that either 
DNA on its own, or DNA complexed with other particles in the feed stream, forms a 
stronger interaction with the column than the infectious viral particles on their own. 
It is clear that complex mechanisms underlie the retention of vaccinia on these resins. In 
the current context of developing a robust separation, it was decided at this point to 
design a stepwise elution scheme for CIM SO3 as this resin appeared to be able to 
separate infectious virus from contaminating DNA and protein. 
 
5.4 Development of a stepwise elution schedule for CIM SO3  
 
A central composite screening DoE was initially performed in order to sift through 
factors affecting the removal of DNA whilst maximising the recovery of infectious 
virus in the elution. Factors tested were sodium chloride concentration and pH. The load 
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challenge in each case was approximately 3x10
9
 pfu/mL of monolith. Based on the 
gradient elution results shown in Figure 5.3, ranges tested in the DoE were set between 
250-750 mM NaCl pH 6-8 in sodium phosphate buffer. Initially only the corners of the 
design space and centre points were tested, however, as there was a large amount of 
noise in the TCID50 measurements, face centred and internal augmented points were run 
in order to generate more information, specifically on infectious virus recovery. 
Figure 5.4.A & B shows the effects of NaCl and pH on the removal of DNA and 
recovery of infectious virus in the elution pool. DNA purification factors are used here 
to show the effects of any trade-off between DNA removal and virus recovery. 
Modelled data showing the effects of NaCl concentration and pH on the removal of 
DNA is portrayed in Figure 5.4.C. The black solid lines show the modelled data points 
while the blue dotted lines indicate a 95 % confidence interval. The red dotted lines 
show the points on the graph where the recovery of infectious virus was shown in 
Figure 5.4.B to be at its highest.  
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Figure 5.4 Data generated from CIM SO3 monoliths. A) 3D histogram illustrating the 
effects of NaCl concentration and pH on DNA purification factors measured from each 
run across a DoE central composite design. Raw data rather than modelled points are 
shown. B) 3D histogram showing the effects of NaCl concentration and pH on infectious 
viral recovery from each run across a DoE central composite design. Face centred and 
internal axial points are also shown as raw data rather than modelled points. C) DoE 
prediction profiler showing the modelled effects of NaCl concentration and pH on the 
removal of DNA from the load. (NaCl concentration leverage, P = 0.0007, pH leverage, P = 
0.0451, Adjusted R
2 
= 0.98) (n = 2). All TCID50 measurements were performed in 
triplicate, DNA and protein values measured in dublicate, mean values shown. D) Two 
dynamic binding capacity (DBC) runs on CIM SO3 with ~1000 ng and ~3000 ng of 
DNA/mL in the load. 
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 JMP Pro12 (SAS Cary NC USA) was initially used to model the data, and fitted a 
quadratic function suggesting curvature in infectious virus recovery due to sodium 
chloride concentration. The DoE suggested that 500 mM sodium chloride would give 
the highest recovery from CIM SO3; however, due to the levels of inherent variability 
in the TCID50 measurements, the adjusted R
2
 for the model fit was only 0.23. The 
model P-Value was fairly small at 0.0476 indicating significance in the model fit for 
curvature due to NaCl concentration, however, due to the size of the residuals (RMSE = 
18.6) it was decided that conclusions on optimal CIM SO3 elution conditions should not 
be drawn from the model. The raw data was therefore plotted without the regression as a 
3D histogram. An optimum salt concentration required to elute infectious virus would 
suggest a potential trade-off, perhaps between the number of viral particles desorbed 
from the column, and the stability of vaccinia in the elution buffers. When referring 
back to the stability data discussed in Chapter 4, there does appear to be some reduction 
in infectivity in 50 mM sodium phosphate as NaCl concentration is increased from 0-
0.75 M. However, the statistical significance of this data is low making it difficult to 
generate a conclusion. This is likely due to TCID50 assay variability.  Although the 
variation between replicates in Figure 5.4.B is high, there appears to be a general 
increase in infectious virus recovery as NaCl concentration in the elution buffer 
increases. An alternative hypothesis to an optimal recovery at 500 mM NaCl may 
therefore be that the recovery in actual fact plateaus between 500-750 mM NaCl, 
especially as pH increases from 7 to 8 (Figure 5.4.B). 
As expected, the recovery of DNA in the elution fraction from the CIM SO3 increases 
as the NaCl concentration and pH are increased. This supports the conclusions 
generated from the linear gradient elution data from CIM SO3 in the previous section. 
DNA is eluted from the column at approximately 750 mM NaCl while virus elutes at 
between 150 and 350 mM NaCl. 
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The trade-off in terms of DNA removal is that a relatively high salt concentration of or 
around 500 mM NaCl is required to recover between 68% and 84% of the infectious 
virus from the column, which leads to a relatively low 80% removal of DNA relative to 
the load. To confirm this, a lower NaCl concentration of 300 mM NaCl was tested at pH 
7. The results showed that 92% of the DNA was removed but the recovery of infectious 
virus was only 35 % resulting in a DNA purification factor of 4. A summary of this data 
is tabulated in Table 5.2 and shows the effects of decreasing NaCl concentration on 
percentage virus recovery and DNA removal. Some effect due to increasing pH can also 
be seen to increase virus recovery and reduce DNA removal. 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
Table 5.2 Overview of the data generated from CIM SO3 DoE showing effects of 
decreasing NaCl concentration on recovery and DNA removal and therefore purification 
factor. Data in bold represents the conformation run described above designed to 
maximise the DNA purification factor. *represents averaged data points. 
Elution 
condition 
Percentage 
virus recovery 
(Elution) 
Percent DNA 
removal 
(Elution) 
DNA 
purification 
factor 
Percent 
protein 
removal 
(Elution) 
Protein 
purification 
factor 
750mM NaCl 
pH 6 
31 % 69 % 1.0 90 % 3.0 
750mM NaCl 
pH 8 
*38 % *60 % *0.9 *81 % *2.3 
500mM NaCl 
pH 7 
68 % 80 % 3.6 85 % 4.5 
300mM NaCl 
pH 7 
35 % 92 % 4.3 92 % 4 
250mM NaCl 
pH 6 
6.0 % 94 % 1.0 80 % 0.3 
250mM NaCl 
pH 8 
30 % 90 % 3.2 81 % 3.4 
 
In terms of protein removal, this appears to occur mostly during the adsorption step as 
between approximately 60 – 90% of the protein loaded is recovered in the flow through 
fraction, and so does not bind to the column. Data from Figure 5.3 suggests that the 
majority of protein bound elutes at around 300 mM NaCl either co-eluting or eluting 
just before the main infectious viral peak. The DoE suggests that, unless the virus is 
eluted at low NaCl and low pH protein removal remains relatively constant across the 
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design space (Table 5.2). The reason the purification factor is so low when CIM SO3 is 
eluted at 250 mM NaCl pH 6 is that virus recovery is only 6%. In an attempt to visualise 
the removal of impurities, especially viral aggregates, transmission electron microscopy 
(TEM) was used at low magnification (8000x) to visualise CIM SO3 load and elution 
samples. The run analysed was eluted at 300mM NaCl at pH 7. This data is shown in 
Figure 5.5. A large viral aggregate is clearly seen in Figure 5.5.A as well as other debris 
and impurities. It is unclear what the origins of these impurities are. The approximate 
concentration of DNA and total protein in the load for this sample was 1364 ng/mL and 
337 µg/mL, respectively. The micrograph in Figure 5.5.B shows less aggregation, single 
vaccinia particles can be seen homogenously dispersed across the grid. Both images are 
representative of all grids analysed (n=3) and are shown at a magnification of 8000x.  
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Figure 5.5 TEM micrographs of A) CIM SO3 load annotated to show contaminating viral 
aggregate and debris B) SO3 eluate annotated to show vaccinia monomer. Virus was 
eluted in 50 mM sodium phosphate 300mM NaCl pH 7. 
A
B
L a rg e  a g g re g a te
C e ll o r v ira l d eb ris
V a c c in ia  m o n o m e r
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Another observation from the DoE was that there were more infectious viral particles 
recovered in the flow through fractions than expected. The numbers were variable, but 
averaged 44% (RSD = 62%). Throughout the DoE the columns were all loaded to their 
measured DBC, (3x10
9
 pfu/mL). A single batch of material was used for the initial 6 
runs, and a second batch was used for the augmented and axial points. As this result was 
unexpected, the DBC study on CIM SO3 run previously was repeated with the same 
batch of material as used for the initial DoE, and the results were overlaid with the 
original DBC curve. This can be seen in Figure 5.4.D. There is what appears to be a 
significant difference in the breakthrough curves between the two runs. The binding 
capacity of the initial batch of material was approximately 3x10
9
 pfu/mL of monolith, 
whilst that of the second run was three times lower, at approximately 1x10
9
 pfu/mL.  
There is a chance that this variability is due to the error in the TCID50; however, the 
coefficient of variance in the assay, as previously mentioned, is only found to be 
approximately 30%, which may not explain the whole discrepancy in terms of error in 
C/Co or percentage breakthrough. The difference in virus concentration in the flow 
through when comparing 0% and 100% breakthrough is greater than an order of 
magnitude; therefore it was speculated that the difference is due to, at least in part, the 
variability in the load material. Residual impurity concentrations were analysed in the 
two batches, and the main difference appeared to be the DNA concentration. In the first 
DBC run, the DNA concentration in the load was calculated to be approximately 1,000 
ng/mL, while the second batch had a DNA concentration of approximately 3,000 
ng/mL. This observation supports the above stated hypothesis that DNA is complexed 
with histone proteins resulting in competition for binding sites with the virus. Similar 
effects on CIM monoliths have been cited in the literature; however, they were 
explained as resulting from lipid fouling (Burden, Jin, Podgornik, & Bracewell 2012). It 
is unknown why the batches vary so much in DNA concentration. One possibility is that 
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there is variation in the total number of cells present in a single batch of cells prior to 
viral infection. As stated previously a single batch consists of 30x T175 flasks. Previous 
work on influenza virus (Banjac, Roethl, Gelhart, Kramberger, Jarc, Jarc, Strancar, 
Muster, & Peterka 2014) has also reported large variation in DNA concentration in the 
virus harvest material, suggesting a resulting effect on the reproducibility of virus yield. 
As mentioned elsewhere, this combination of variability in feedstock and assay 
complicates process development considerably. However, this is typical of infectious 
viral processes.  
In summary, the difference in the binding capacities (Figure 5.4.D) explains the 
increased recovery in the flow through, and therefore the overall lower recovery in the 
elution fractions observed. The trade-off between the recovery of infectious virus, and 
the recovery of DNA in the elution appears to limit the purification factor achievable in 
CIM SO3 monoliths under the conditions tested to around 4. Interestingly, even when 
the load was reduced to 1x10
9
 pfu/mL, the purification factor was not improved.  
 
 
5.5 Evaluation of CIM SO3 as a suitable capture step for vaccinia 
virus 
 
CIM SO3 does appear to be able to resolve most of the infectious viral particles from 
the contaminating DNA and protein in the load. It is not, however, able to remove 
enough DNA to achieve the required specifications for DNA removal specified by the 
WHO. It is assumed that this will remain at 10ng DNA/dose (World Health 
Organization 1998), and that vaccinia will be required at a dose of approximately 1x10
9 
pfu/dose. 
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5.5.1 Evaluation into the suitability of Benzonase® as a pre-
chromatographic treatment step. 
 
Benzonase® produced by (Merk KGaA, Darmstadt, Germany) is a CGMP compliant 
genetically engineered endonuclease, designed to digest DNA from biological feed 
streams. The disadvantage of using Benzonase® is that it is expensive, and its removal 
has to be validated. It is, however, the only effective biochemical method of removing 
DNA and RNA that is licenced for manufacturing use. 
In order to evaluate the suitability of Benzonase® for the use in the manufacture of 
vaccinia virus, an experimental protocol was designed to test different pre-treatment 
conditions with and without Benzonase® prior to CIM SO3 capture. The rationale here 
was to evaluate the effectiveness of different nuclease treatment schedules at removing 
DNA contamination. The idea was that this data could then be compared with an 
assumed process relying on two orthogonal monolith steps but without Benzonase®. 
The data in Table 5.3 shows the pre-treatment conditions used in each experiment. DNA 
purification factors are given, along with percentage DNA removal and percentage 
infectious virus recovery. The mass of DNA per dose in the elution is also shown, 
assuming a required dose of 1x10
9 
pfu (Heo, Reid, Ruo, Breitbach, Rose, Bloomston, 
Cho, Lim, Chung, Kim, Burke, Lencioni, Hickman, Moon, Lee, Kim, Daneshmand, 
Dubois, Longpre, Ngo, Rooney, Bell, Rhee, Patt, Hwang, & Kirn 2013), along with the 
number of uses each monolith has had including the experiment in question. Monoliths 
were loaded to a capacity of 1x10
9
 pfu/mL (5 mL) and eluted using a stepwise elution 
schedule in 50mM sodium phosphate 500mM NaCl pH 7 as shown in Figure 3.3. The 
same batch of virus was used in all experiment. DNA concentration in the harvest 
control runs showed variability of less than 10% (RSD 9.75%). 
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Table 5.3 Benzonase study showing experimental conditions including incubation time and 
temperature, DNA purification factor (PF) % DNA removal in the elution fraction, 
measured DNA per dose, % recovery of infectious virus, and number column reuses are 
shown. Concentration of Benzonase used in all experiments was 150 U/mL. Harvest 
material was all from same batch and thawed at 37 ⁰C. No additional Mg2+ Ions were 
added to harvest material prior to treatment with Benzonase. DMEM contains 0.81mM 
Magnesium Sulfate (MgS04). RT = Room Temperature. Control = Run performed without 
Benzonase® 
Conditions Total 
DNA 
Harvest 
(ng) 
(post-
treatment) 
DNA PF 
Elution 
% DNA 
Removal 
Elution 
DNA/dose 
Elution 
(1x10
9
 
pfu) 
% 
Infectious 
Virus 
Recovery 
Elution 
Number 
of 
Reuses 
Benzonase
® 
1 hr RT 
9703 1.56 88 5399 19 6 
Control 
1 hr RT 
19614 0.98 86 8442 14 8 
Benzonase
® 
6 hr 4-8 ⁰C 
8525 1.83 87 3537 24 3 
Control 
6 hr 4-8 ⁰C 
23857 0.96 93 13383 6 5 
Control 
New 
column, 
No 
incubation 
21781 2.83 70 3974 84 1 
 
What is immediately obvious when analysing the data in Table 5.3 is that Benzonase® 
does not remove the entire mass of DNA present in feed stream. It in fact removes 
approximately half of it. This phenomenon has previously been noted in the literature 
by other groups working with vaccinia virus (Jordan, Weimer, Iarusso, Bernhardt, Lohr, 
& Sandig 2015b), and has been suggested to be the result of complexes formed between 
the virus and contaminating DNA molecules. The data in this thesis shows that vaccinia 
forms large aggregates, especially in high salt conditions. It is perhaps reasonable to 
speculate, therefore, that Benzonase® would be unable to get close enough to the DNA, 
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especially if located towards the centre of a large aggregate molecule, to be able to 
hydrolyse it. 
 
5.5.2 Evaluation of CIM SO3 robustness 
   
The data in Table 5.3 also shows a reduced recovery of infectious virus from CIM SO3 
when eluted at 500 mM NaCl when compared to data generated when optimising the 
stepwise elution (Figure 5.4). It was originally thought that this could be the result of 
variation in DNA concentration in the load, however, there does not appear to be a trend 
when analysing the data in Table 5.3. As previously stated the RSD between the control 
runs in terms of DNA concentration was 9.75 %. The optimisation runs, as well as the 
Benzonase® control run, were performed on new columns suggesting that a residual 
foulant may have built up during the column lifetime. It was speculated that this may 
have changed the surface chemistry of the monolith sufficiently to affect the retention of 
virus on the column. As it is difficult to analyse the foulant layer itself, an experiment 
was designed with a column that had already been used twice, in an attempt to repeat 
the low recovery of infectious virus and then to regenerate the monolith performance 
using a variety of CIP strategies. The results can be seen in Table 5.4. 
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Table 5.4 experimental CIP buffers used in an attempt to regenerate a CIM SO3 
monoliths. Number of particles loaded, elution buffer conditions and batch of material 
used for each run was constant. Percentage infectious virus in the flow through fraction 
was less than 1% for each run. Note elution peak was collected from 100-100 mAu 
(Optical Path length 0.2 cm) CIP conditions shown for each run were performed on the 
run before, as so where the last CIP conditions  seen by the column prior to loading.  
means followed by. 
 CIP conditions 
performed on 
previous run 
Infectious virus  
% Recovery in 
500 mM NaCl 
Infectious virus  
% Recovery in 
2 M NaCl 
Number 
of reuses 
Run 1 
Normal CIP 
1M NaOH 2M NaCl 
1hr incubation 
27 34 3 
Run 2 
Experimental 
CIP 
80% IPA  
15 min incubation 21 6 4 
Run 3 
Experimental 
CIP 
Trypsin (5 min inc.) 
 2M NaCl  1M 
NaOH (1hr inc.) 
16 14 5 
Run 4 
Normal CIP 
1M NaOH 2M NaCl 
1hr incubation 
27 19 6 
 
 
It should be noted that the elution peak was collected from 100 mAu on its leading edge 
to 100 mAu on its tailing edge rather than using a 10 mL fixed volume elution as 
mentioned previously. This variance in the method does not appear to have affected the 
results. The recovery data matches that observed during the Benzonase® experiments. 
The recovery of infectious virus was lower when eluted at 500 mM NaCl than had been 
observed with fresh columns during the optimisation runs. The use of standard CIP 
conditions recommended by BIA Separations, 1M NaOH 2M NaCl, as well as 80% 
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IPA, and Trypsin do not appear to reverse this effect. What is interesting is that when 
the columns were further washed with 50 mM sodium phosphate 2 M sodium chloride 
pH 7 up to 34% of the infectious virus loaded was eluted as a separate peak; this was 
only observed after BIA Separations recommended CIP buffers where used.  
The data suggests that the affinity of infectious virus to the SO3 monolith may increase 
when a column has been used previously. It also appears that a higher salt concentration 
is required to elute the virus, suggesting that the mechanism of adsorption is still 
electrostatic. 
Without more data it is not possible to conclusively state that the columns are unable to 
be reused, but this data is sufficient to warrant later costing analysis to include number 
of monolith reuses into the sensitivity analysis shown in Section 7.4.2. 
 
NTA data from run 1 (Table 5.4) is shown in Figure 5.6. 5 mL of virus (1x10
9
 pfu) was 
loaded onto the column, the flow through was collected with the equilibration step in 15 
mL, the elution was collected in 1-3 mL, and strip was collected in 5 mL. The CIM SO3 
load polydispersity appears similar to previous measurements, although smaller 
diameter particles appear more variable. This is likely as the measurement was taken at 
a detection threshold of 5 rather than 3 in order to better analyse the larger (300 nm) 
particles in solution. Detection threshold is the minimum intensity value of an image in 
order for it to qualify as a particle and therefore be tracked and analysed by the 
software. It is clear that the elution fraction has a significantly smaller number of 
particles then the load. This was expected based on the analysis of the load and null 
prep samples shown in Figure 4.7. What is surprising is the area of each 250-350 nm 
peak in both the load and elution samples relative to the other peaks in the same sample.  
It appears that the smaller peak in the elution fraction is larger than the smaller peak in 
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the load fraction relative to the larger species in each distribution. It also appears that 
the larger, likely virus containing peak in the elution fraction has shifted to the left by 
approximately 10-20 nm. If it can be assumed that the smaller species in the load is an 
impurity, which is a reasonable assumption being that it is half the size of the virus, then 
this data would suggest that the purification factor of this impurity would be less than 1. 
In conclusion, the elution fraction appears to contain a relatively large population of 
particles of approximately 150 nm. It is not clear what this population consists of, 
although either a protein DNA aggregate or degrading virus particles seem the most 
likely. Another observation that can be made is that the number of particles in the load 
outnumbers the particles in the flow through, elution and strip fractions. This suggests 
that material is still bound to the column after the elution, which supports the argument 
in Section 5.5.2 that proposes that a foulant is adsorbing to the column and reducing 
yield after multiple injections.  
 
Figure 5.6 NTA data showing size distribution of SO3 load, flow through, elution and strip 
fractions. CIM SO3 monolith had been used 3 times; NTA data is showing mean values 
from 5 tracking experiments, Data from run 1 (Table 5.4) 
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5.6 An illustrative description of vaccinia virus adsorption on CIM 
SO3 monoliths 
 
It has been shown in this chapter that vaccinia virus is able to adsorb to CIM SO3 
monoliths at 2 pH units above its isoelectric point. 
Both the gradient and stepwise elution runs show that the DNA adsorbed to the 
monolith elutes at a higher NaCl concentration than the majority of the infectious viral 
particles. There are two hypotheses that might explain this: 
Hypothesis 1 is that the DNA is complexed with a strong cationic molecule which is 
able to interact with the monolith. 
Hypothesis 2 is that the DNA is able to associate with large viral aggregate molecules 
that have a higher affinity to the CIM SO3 stationary phase than smaller individual viral 
particles. 
 
5.6.1 Hypothesis 1 
 
It is known that the majority of the DNA in the load does not adsorb to the column as it 
was recovered in the flow through fractions collected during the CIM SO3 runs. It has 
been speculated, based on SEM images taken of both the DNA in the load and the flow 
through, that the DNA present is complexed with particles similar in size and 
morphology to histone proteins. As histone proteins are positively charged, this would 
explain why DNA is able to bind to the stationary phase and may also explain why 
DNA is able to form a bridge between the virus and the monolith. 
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5.6.2 Hypothesis 2 
 
In the second hypothesis, DNA is able to associate with large viral particles. There is a 
chance that a positive charge could come from the virus itself, but if this were true, and 
DNA was binding to positively charged regions on the viral surface, then it might be 
assumed that either the virus and DNA would co-elute, or the DNA would elute first. 
The reason for this assumption is that increases in the ionic strength of the mobile phase 
during the elution step would likely break the electrostatic interactions between either 
the virus and DNA, eluting DNA, or the virus and the column, eluting both DNA and 
virus. The fact that this does not happen suggests that the DNA is able to be retained 
without the majority of the infectious virus present. For this to be the case, DNA must 
either have a strong positive charge and so be able to adsorb directly to the CIM SO3 or 
be associated with large viral aggregates, likely made up of infectious and non-
infectious viral particles that do not break apart when NaCl is introduced and elute later 
in the gradient.  
Information in the literature on histone protein interactions (Rippe et al. 2008) is 
interesting. It shows that histone proteins, in the absence of DNA form aggregates 
which are stabilised at high salt (2 M NaCl). As the ionic strength decreases to 
physiological levels (100-150mM NaCl) the histone complexes begin to disassociate 
and at low ionic strength, histone proteins become soluble and unfold. In vitro 
reconstruction of nucleosomes is achieved by slowly reducing the salt concentration 
from 2 M to physiological ionic strength. This allows assembly of the nucleosome 
particles in an ordered manner and prevents histone-DNA aggregation. During CIEX 
experiments this would not have occurred and it seam conceivable that DNA-histone 
aggregates may have been formed in the harvest that were then able to interact with 
viral particles or aggregates and facilitate adsorption onto CIM SO3. In addition to this, 
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previous work performed on histone purification using CIEX chromatography  shows 
that histone proteins bind to SP ligands at 0.2M NaCl and require between 0.8 and 2 M 
NaCl to elute (Rodriguez-Collazo et al. 2009). Histone proteins are amongst the most 
basic proteins known with an isoelectric point of around 11 as discussed in (Chung et al. 
1978).  
While more supporting experiments need to be performed, the results generated when 
vaccinia was treated with Benzonase® endonuclease also support this theory. 
Benzonase® is not able to degrade all of the DNA in the load suggesting that large 
aggregates are present. This has been confirmed by TEM, as shown in Figure 4.10. It 
has also been shown, by SEM, that DNA is able to associate with vaccinia, suggesting 
that it may be responsible for the inter-particle interactions. This will be described in 
more detail in Chapter 6. 
An attempt at illustrating these molecules and their associated affinity to the CIM SO3 
is shown in Figure 5.7. The removal of viral aggregates in the CIM SO3 elution at 300 
mM NaCl supports the theory that the affinity of individual vaccinia particles for the 
CIM SO3 stationary phase is lower than that of large aggregates. The increased affinity 
of the DNA, potential complexed with positively charged histone proteins is supported 
by the linear gradient elution runs Figure 5.3 and the DoE Figure 5.4.A-C. 
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Figure 5.7 Schematic to show proposed binding affinity of vaccinia virus and Vaccinia-
DNA complexes on CIM S03 Monoliths. 
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5.7 Conclusion  
 
This chapter has illustrated that Vaccinia virus has some unusual properties in that it is 
able to bind to both CIEX and AIEX monoliths.  From the initial linear gradient elution 
runs performed, CIM SO3 appears to be able to separate a large proportion of DNA 
from crude vaccinia viral harvest. DNA appears to adsorb more strongly to the column 
than viral particles, suggesting the presence of a strongly cationic molecule in the feed 
that is able to form a bridge between the anionic stationary phase and the DNA. 
When using a stepwise elution schedule, the unit operation is still able to separate virus 
from DNA. However, as DNA binds more strongly than the virus a pre-elution wash 
step cannot be used to remove DNA. A trade-off appears to occur in terms of the 
recovery of infectious virus and subsequent removal of DNA as an increased NaCl 
concentration increases the recovery of both infectious virus and DNA. Greater than 50 
% recovery is achievable at NaCl concentrations around 500 mM, however 20% of the 
total DNA loaded is co-eluted at this molarity. Lower salt concentrations (300 mM 
NaCl) reduce the levels of eluted DNA to around 10%, but this also reduces the 
recovery of infectious virus to around 35%. The resulting DNA purification factor 
appears to remain at around 4. According to TEM data, 300mM NaCl is able to remove 
large viral aggregates present in the CIM SO3 load. This data is qualitative rather than 
quantitative but is useful of note especially if levels of virus aggregation are defined as a 
critical qualities attribute. CIM SO3 monoliths appear to require more NaCl to elute 
vaccinia after they have been used more than once. This potentially supports the 
hypothesis that histone driven DNA – viral aggregation occurs that increases the affinity 
of virus adsorption onto the SO3 ligand. With this in mind, the most efficient 
application of CIM SO3 is likely to be as a single use capture step, vaccinia would be 
loaded at low salt and eluted at around 500 mM NaCl in order to maximise recovery 
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and remove the majority of contaminating DNA.  A second step would then need to be 
performed to remove the residual DNA and protein to levels acceptable for clinical 
application.  
Benzonase® is able to reduce the levels of DNA in the load, but not by enough to 
remove all contaminating DNA without the need for another step. This conclusion is 
supported by previous work on vaccinia virus. 
At this stage in process development, it was concluded that no further studies would be 
done with CIM SO3 monoliths until other systems were considered. There are some 
theoretical advantages of using a HIC system, and as vaccinia is shown to be reasonably 
stable in high salt, in terms of infectivity, CIM OH monoliths were evaluated next.   
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  Chapter 6
 
Hydrophobic Interaction 
Chromatography Process Development 
 
6.1 Introduction 
 
CIM OH monoliths are produced by the hydrolysis of epoxy ligands on the 
polymethacrylate monolith surface to produce a high density of hydroxyl groups. This 
makes CIM OH monoliths hydrophilic and negatively charged. The high salt levels 
usually needed in hydrophobic interaction chromatography (HIC) can damage labile 
viruses. Nevertheless standard HIC resins with phenyl and butyl groups have been used 
previously in both virus and VLP capture and intermediate polishing steps (Burden, Jin, 
Podgornik, & Bracewell 2012;Jordan, Weimer, Iarusso, Bernhardt, Lohr, & Sandig 
2015b;Wolff, Siewert, Hansen, Faber, & Reichl 2010a). It is more common today to use 
ion exchange (IEX) monoliths to purify viruses, (Banjac, Roethl, Gelhart, Kramberger, 
Jarc, Jarc, Strancar, Muster, & Peterka 2014;Gerster, Kopecky, Hammerschmidt, 
Klausberger, Krammer, Grabherr, Mersich, Urbas, Kramberger, Paril, Schreiner, 
Nobauer, Razzazi-Fazeli, & Jungbauer 2013;Kramberger, Petrovic, Strancar, & 
Ravnikar 2004;Kramberger, Peterka, Boben, Ravnikar, & Strancar 2007;Kramberger, 
Honour, Herman, Smrekar, & Peterka 2010;Rupar, Ravnikar, Tusek-Znidaric, 
Kramberger, Glais, & Gutierrez-Aguirre 2013) although the low hydrophobicity of CIM 
OH coupled with the relatively high salt tolerance of vaccinia virus (Figure 4.5) may 
reduce or minimise losses in infectivity. CIM OH could also be able to offer unique 
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selectivity, especially for DNA clearance, and is therefore considered here for vaccinia 
purification. 
 
6.2 CIM OH monolith screening study 
 
In order to evaluate the suitability of CIM OH monoliths as an initial capture and 
purification step for vaccinia virus, a number of decisions needed to be made from the 
outset, prior to the generation of any data, and based on previous experience and 
information in the literature. It was decided to start by running initial bind-and-elute 
experiments at neutral or weakly basic pH in sodium phosphate buffer. The reason for 
this was that it was speculated that a lower pH would reduce the stability of vaccinia 
virus as well as potentially increase the binding affinity of the virus to the monolith and 
so reduce the recovery in the elution.  The mobile phase modulator used to drive 
adsorption was ammonium sulfate due to its high ionic strength and kosmotropic nature. 
1 mL monoliths were used in all experiments. Chromatography run setup is shown in 
Figure 3.3. A process flow diagram detailing how vaccinia was produced can be seen is 
shown in Figure 3.1. 
Three experiments were performed using the following loading condition: vaccinia 
harvest was diluted in 50 mM sodium phosphate pH 7 in both 1 and 2 M ammonium 
sulfate, and pH 8.5 in 2 M ammonium sulfate. Rather than initially optimising a 
diafiltration step, vaccinia was diluted 1:5 with each chosen load buffer in order to bring 
the pH and conductivity close to that of the buffer used. Table 6.1 shows the recorded 
conductivity and pH for each buffer and diluted load fraction. As the binding capacity 
of CIM OH was unknown at this point, a binding capacity of ≤ 1x1010 pfu of virus was 
assumed, and so 1x10
10
 pfu of viral harvest material was diluted in load buffer, filtered, 
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and loaded into each column. Viral harvest, chromatography load, flow through and 
elution fractions were collected in order to generate a mass balance. The columns were 
eluted at the same pH as the load, but without ammonium sulfate in the buffer. The strip 
buffer consisted of pure water and the column was cleaned with 1 M NaOH 2 M NaCl. 
 
Table 6.1 Equilibration buffer and diluted viral load material conductivity and pH 
conditions. Conductivity meter was uncalibrated, so it was used as a reference only. The 
Chromatography system was not equipped with a pH meter. (N/T- not tested). AS stands 
for ammonium sulfate.  
Equilibration buffer / Load 
conditions 
Conductivity (mS/cm) pH 
1 M AS pH 7         Buffer 143.17 7.00 +/- 0.09 
1 M AS pH 7         Load 122.70 N/T 
2 M AS pH 7         Buffer  231.52 7.00 +/- 0.09 
2 M AS pH 7         Load 205.78 N/T 
2 M AS pH 8.5      Buffer N/T 8.5 +/- 0.09 
2 M AS pH 8.5      Load 200.40 N/T 
 
The results of the screening study are presented in Figure 6.1.A and show the recovery 
of infectious virus in the flow through and elution fractions, as well as the calculated 
recovery assuming no loss in the flow through fraction. This additional analysis was 
performed in order to illustrate the total number of infectious particles unaccounted for, 
as infectious particle balances rarely close. The best explanation for why this occurs is 
that infectious particles are either inactivated during the unit operation, or remain on the 
column after the elution and strip steps and are likely hydrolysed when washed with 
NaOH during the CIP step. The data appears to show that in 1 M ammonium sulfate the 
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virus is unable to bind strongly to the column, because around 60% of the infectious 
particles loaded are recovered in the flow through fraction. As a result, only around 40% 
of particles adsorbed are recovered in the elution. It should be noted that the relative 
standard deviation (RSD) in the infectivity assay is approximately +/- 30%. 
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Figure 6.1 A) Histogram showing vaccinia virus loaded in 1 and 2 M ammonium sulfate at 
pH 7 and 2M ammonium sulfate at pH 8.5. Red bars show the percentage of infections 
virus in the flow through fraction relative to the load, blue bars shows percentage of 
infectious virus in the elution fraction relative to the load, and black bars show the 
percentage infectious virus in the elution minus the total number of particles lost in the 
flow through. B) Histogram showing the number of viral particles loaded vs the capacity 
achieved on CIM OH.  
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In 2 M ammonium sulfate virus is present in very low amounts in the flow through with 
approximately 50-80% recovered in the elution fraction. At first glance this appears 
promising, however, after a more careful look at the data it was discovered that the virus 
recovery across the 0.8µm pre-filter when loaded in 2M ammonium sulfate was only 
6%. This is graphically represented in Figure 6.1.B and is shown in Table 6.2. The 
number of virus particles in the harvest (pre filtration) and load fractions are shown for 
each of the three runs along with the estimated capacities achieved on CIM OH along 
with the estimated percentage recovery achieved across the pre-filter and in the CIM 
OH elution. It can be seen that the number of particles loaded when the experiment was 
run at 1 M ammonium sulfate is significantly higher than when run at 2 M ammonium 
sulfate. It also shows a higher capacity achieved when run at 1 M ammonium sulfate. 
The low capacity at 2 M ammonium sulfate is thought to be the result of the low load 
challenge due to the low recovery of virus across the pre-filter. The higher recovery 
across the pre-filter when run at 1 M ammonium sulfate explains the higher load 
challenge on the column. The increased number of infectious virus particles in the flow 
through for this run suggests that the column may have been overloaded. 
Chromatograms for runs with 1 M and 2 M ammonium sulfate pH 7 are shown in 
Figure 6.2.  
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Figure 6.2 A) Chromatogram for 1 M AS pH 7 run B) Chromatogram for 2 M AS pH 7 
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Table 6.2 Summary of CIM OH screening study. The number of virus particles in the harvest and post 0.8µm filtration is shown along with percentage 
recovery of virus across the filter and the column. Capacity achieved is calculated by number of particles in the load minus the number of particles in the 
flow through. (* = Indicates that a new batch of material with a lower tire was used for 2 M AS run at pH 8.5). N/T = not tested. 
Load 
conditions  
Number of 
viral particles 
in harvest  
(pre 0.8 µm 
filter) 
 (pfu) 
Percentage 
recovery 
across  
0.8 µm filter 
Number of 
virus particles 
loaded  
(post 
0.8 µm filter) 
(pfu) 
Capacity 
achieved 
(pfu/mL) 
Number of 
viral particles 
in elution 
(pfu) 
Recovery 
in elution 
relative to 
harvest  
Recovery 
in elution 
relative to 
load 
Recovery 
in elution 
relative to 
capacity 
achieved  
DNA 
purification 
factor 
Protein 
purification 
factor 
1M AS  
pH 7 
2.48x10
10
 36% 8.94x10
9
 3.51x10
9
 1.53x10
9
 6% 17% 44% 3.71 3.00 
2M AS 
pH 7 
1.56x10
10
 7.0% 1.08x10
9
 1.04x10
9
 5.52x10
9
 4% 51% 53% 1.72 2.35 
*2M AS 
pH 8.5 
2.09x10
9
 21% 4.38x10
8
 4.35x10
8
 3.43x10
9
 16% 78% 79% 3.31 N/T 
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The elution buffer conditions tested during the screening experiments were not designed 
to test the ability of CIM OH to remove DNA or total protein, but to examine whether 
virus was able to bind and be eluted from the column without losing infectivity. 
Interestingly however, DNA and total protein purification factors calculated during 
these runs show promising results, as shown in Table 6.2. This is comparable to 
purification factors achieved for CIM SO3 after elution step optimisation. CIM SO3 
achieves a DNA and protein purification factor of approximately 4 when eluted in 300 
mM NaCl. The majority of DNA and contaminating protein is not able to bind to CIM 
OH. This explains why relatively high purification factors are achievable without 
elution buffer optimisation.  
 
6.3 OH load buffer optimisation 
 
In order to evaluate HIC as a potential capture and polishing step for vaccinia virus, an 
experiment had to be designed to address pre-column filterability. 
It was hypothesised that the low recovery across the 0.8µm filter was a result of viral 
aggregation in the presence of kosmotropic salts in the HIC load buffer. Experiments 
were designed in order to confirm this, and were aimed at increasing the recovery across 
the filter by modifying the load buffer conditions. 
The filters used in all studies were surfactant free cellulose acetate (SFCA) 0.8µm 
syringe filters manufactured by Sartorius (Gottingen, Germany). Cellulose acetate 
membranes are hydrophilic, and, in theory, ideally suited for pressure driven filtration 
due to low protein adsorption properties.  
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In order to increase filterability, a study was designed to test the effects of ammonium 
sulfate and NaCl concentration on both the pre-column filterability of the virus, and its 
ability to then adsorb efficiently to CIM OH. The conditions tested are shown in (Table 
6.3).  
 
Table 6.3 CIM OH load buffer optimisation study showing different NaCl and (NH4)2SO4 
concentrations tested. Run 1 (bold) was taken from screening experiments. 
Run [NaCl] (M) [(NH4)2SO4] (M) 
1 0 2 
2 1 1.5 
3 2 1 
4 3 0.5 
5 4 0 
 
 
Ammonium sulfate concentration was reduced by 0.5 M per run (from 1.5 M to 0 M), 
while the sodium chloride concentration was increased by 1 M per run (from 1 M to 4 
M). A volume of 2.3 mL of virus with a titre of approximately 1x10
9
 pfu/mL was 
diluted 1:5 in load buffer and was loaded onto the (filter-column) units as described in 
Table 6.3. The results, as can be seen in Figure 6.3.A, show the recovery of infectious 
virus in the 0.8µm filtrate relative to the harvest, and the flow through and elution 
fractions relative to the load. 
Figure 6.3.B shows the DNA and total protein purification factors achieved in the 
elution fractions for each run. Table 6.4 also shows a summary of this data set and 
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includes the number of infectious particles recovered pre and post filtration as well as in 
the flow through and elution fractions. The data suggests that as the ammonium sulfate 
is reduced, the filterability of the material increases. This is evident by the increase in 
recovery across the 0.8µm filter. The recovery when loaded in 4 M NaCl, without 
ammonium sulfate, and when loaded without any salt (shown in Figure 6.4) are similar. 
This suggests that NaCl does not strongly affect filterability. 
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Figure 6.3 A) CIM OH load optimisation study showing the percentage recovery of 
infectious virus across the 0.8µm filtration step relative to the harvest, and the recovery of 
infectious virus in the flow though and elution fractions relative to the load. B) 
Purification factors achieved for DNA and total protein. Elution buffers used for all 
experiments were 50mM sodium phosphate pH 7. ~2x10
9
 pfu of vaccinia was filtered, and 
all virus in the filtrate was loaded onto the columns. (AS = Ammonium sulfate). 
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Table 6.4 CIM OH buffer optimisation study showing the number of infectious virus particles present before and after dilution and 0.8 µm filtration, in the 
flow through and elution fractions. The percentage recovery of infections virus in the flow through and elution fractions, and the DNA and protein 
purification factors in the elution fractions for each condition tested. Rows in bold represent original data from screening study (different batch of virus, 
higher load volume (10mL). Buffer optimisation study came from a single batch of virus, 2.3 mL virus was diluted and loaded onto filter-column system. 
Conditions Number of 
particles 
(Harvest) 
Number of 
particles  
(Post 0.8 µm 
Filter) 
Number of 
particles 
(Flow 
Through) 
Number of 
particles 
(Elution) 
Percentage 
recovery 
(Flow 
Through) 
Percentage 
recovery  
(Elution) 
DNA 
purification 
factor 
(Elution) 
Protein 
purification 
factor 
(Elution) 
1 M AS pH 7 2.48x10
10 
8.94x10
9
 5.43x10
9
 1.53x10
9
 61.0 20.0 3.71 3.01 
2 M AS pH 7 1.56x10
10
 1.08x10
9
 4.38x10
7
 5.52x10
8
 4.00 51.0 0.05 2.35 
1.5 M AS 
1 M NaCl pH 7 
4.80x10
9
 9.63x10
8
 1.93x10
7
 1.46x10
8
 2.00 15.0 2.82 3.06 
1 M AS 
2 M NaCl pH 7 
4.58x10
9
 1.53x10
9
 6.59x10
7
 1.22x10
9
 4.00 80.0 6.62 10.6 
0.5 M AS 
3 M NaCl pH 7 
3.46x10
9
 2.56x10
9
 2.75x10
9
 9.62x10
8
 108 38.0 5.74 7.84 
0.0 M AS 
4 M NaCl pH 7 
3.78x10
9
 2.36x10
9
 3.19x10
9
 4.60x10
8
 135 19.0 3.42 5.85 
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The trade-off is that as the ammonium sulfate concentration decreases, the adsorption 
efficiency of virus onto the CIM OH also decreases. This is shown by an increase in 
recovery in the flow through fraction, which is dramatic for ammonium sulfate 
concentrations of 0.5 M and below. The same relationship is also evident in the DNA 
and total protein purification factors achieved in the elution fractions from each run. 
This is the case as purification factor is a function of both viral recovery and 
DNA/protein removal as described in Equation 3-7. It can be seen that the total particle 
balance is greater than 100% when low concentrations of ammonium sulfate are used in 
the load buffer. This is most likely due to the variability in the analytics.  
 
Based on the data in Figure 6.3 it was concluded that the best load buffer condition 
tested was 50 mM sodium phosphate 2 M sodium chloride 1 M ammonium sulfate pH 
7. This will from now on be referred to as optimised HIC load buffer. 
In order to test the robustness of this conclusion, the percentage recovery of virus across 
the filter in different load buffers was tested with and without salt, and in optimised HIC 
load buffer as shown in Figure 6.4. Box and whisker plots are shown together with the 
raw data values for each condition tested. The box represents the interquartile range 
with the median shown in the centre. The whiskers show the range.  
The plot illustrates that when vaccinia is filtered in optimised HIC load buffer a 
reasonably robust recovery of infectious virus is achieved. This recovery is 
approximately 35%. The recovery when loaded with 2 M ammonium sulfate was 
unacceptably low at around 6%. Interestingly, when run without salt the filtration 
recovery is higher, but also more variable. This may be due to more dynamic 
aggregation patterns without the presence of ammonium sulfate as a mobile phase 
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modulator acting to promote aggregation. This would likely affect the TCID50 as the 
number of particles per unit volume would likely be more stable. 
Figure 6.4 also shows the filtration recovery of virus in 2 M ammonium sulfate at pH 
8.5 after high g centrifugation. All other fractions were centrifuged at a relative 
centrifugal force (RCF) of 440, however this sample was centrifuged at 771 to test 
whether removing more debris prior to dilution in HIC load buffer would prevent 
filtration fouling. This experiment was only performed once, and the data showed no 
change in the infectious viral recovery.  
In future work, an evaluation of alternative filters would be recommended as described 
in Section 9.2. This work was focused on the development of a chromatographic 
separation, so while not perfect, a median recovery of 35% was taken as an acceptable 
pre-filtration recovery and the optimised HIC load buffer conditions were taken forward 
for the development of a capture step for vaccinia virus.  
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Figure 6.4 Replicate data showing filterability expressed as percentage recovery of virus 
across the filter in different load buffers. (High g centrifugation was attempted to remove 
cell debris at an RCF of ~771 for 5 min; normal centrifugation conditions consisted of an 
RCF of ~440 for 5 min) (AS = Ammonium sulfate) 
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6.4 Evaluation of dynamic binding capacity 
 
Binding capacity studies were performed in optimised HIC load buffer at pH 7 and pH 8 
as shown in Figure 6.5. The load material at pH 7 was calculated to be 1.42x10
8
 pfu/mL 
and at pH 8 to be 1.66x10
8
 pfu/mL. While the exact breakthrough curve is hard to plot 
with certainty due to the error in the TCID50, it is clear that initial breakthrough occurs 
at approximately the same time in each experiment, corresponding to 1x10
9 
pfu/mL of 
monolith. The slope of the breakthrough curve appears to be fairly shallow suggesting 
that adsorption is relatively inefficient. Further work needs to be carried out to 
understand the exact mechanism of adsorption; however, the data in Figure 6.9 suggests 
that aggregation in the presence of ammonium sulfate may be reversible, dynamic and 
variable depending on the diluent used. It is likely that the relative affinity of viral 
aggregates to the CIM OH stationary phase is dependent on the hydrodynamic diameter 
of the particles. If the aggregation profile and therefore the average particle diameters 
keeps changing, then this could lead to different adsorption kinetics for each aggregate 
particle.  
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Figure 6.5 CIM OH DBC run in optimised HIC load buffer at pH 7 and pH 8. Error bars 
show error in TCID50 data and are generated from 1 DBC study at each pH measured in 
triplicate, error bars show 1 SD. Y-error bars are shown as shaded areas and X-error bars 
are shown as horizontal lines. 
 
6.5 CIM OH step wise elution design 
 
A linear gradient elution was run over 25 CVs and fractionated in order to evaluate 
when infectious virus particles of 250-350 nm, DNA and total protein eluted from the 
column. Buffer A consisted of optimised HIC load buffer and buffer B was the same 
elution buffer as used in the early screening studies, 50mM sodium phosphate pH 7. 
The results are shown in Figure 6.6.A. DNA appears to elute first after around 10 CVs, 
followed by the virus towards the end of the gradient. This data suggested that it might 
be possible to remove DNA in a pre-elution wash step by decreasing the salt 
concentration enough to elute the DNA without eluting the virus. In order to test this 
hypothesis and make the process more commercially viable a stepwise elution schedule 
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needed to be developed. Two runs were therefore performed, the first at pH 7 and the 
second at pH 8; virus was eluted over 25 column volumes using a multi-step elution 
schedule. This consisted of reducing the ammonium sulfate and NaCl concentrations by 
20% every 5 column volumes by increasing the percentage of buffer B. Each of the 
elution steps is shown in Table 6.5. 
 
Table 6.5 CIM OH Multi-Stepwise elution schedule design showing percentage buffer A 
and percentage buffer B for each step (Each step was 5 CVs) Row in bold (step 4) shows 
buffer molarity in which the majority of infectious virus was eluted. 
Step Percentage buffer A 
Equilibration buffer 
(Optimised HIC load 
buffer pH 7-8) 
Percentage buffer B 
Elution buffer 
(50 mM sodium 
phosphate pH 7-8) 
Approximate molarity of 
elution fraction 
1 80 20 0.8 M AS 1.6 M NaCl 
2 60 40 0.6 M AS 1.2 M NaCl 
3 40 60 0.4 M AS 0.8 M NaCl 
4 20 80 0.2 M AS 0.4 M NaCl 
5 0 100 0.0 M AS 0.0 M NaCl 
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The corresponding chromatograms are shown in Figure 6.6 B and C. Virus in each 
elution pool was analysed using TCID50 and NTA. The chromatograms show that both 
measurements agree in terms of where the virus is being eluted from the columns, 
although as expected, the NTA overestimates the total number of virus particles in each 
fraction.  
Figure 6.6C shows that loading at pH 8 gives a slightly better removal of DNA than at 
pH 7 therefore the 3
rd
 and 4
th
 steps when run at pH 7 were increased from 5 CVs to 10 
CVs in an attempt to maximise DNA removal in the 3
rd
 fraction and maximise virus 
yield in the 4
th
. The resulting chromatogram is shown in Figure 6.6D. It appears when 
analysing the chromatogram that this worked, however, the raw data in Table 6.6 shows 
that a lower overall removal of DNA relative to the load was achieved. This is due to a 
higher concentration of DNA in the starting material when compared to the initial 
experiments run at pH 7.  All CIM OH runs where performed twice. 
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Figure 6.6 CIM OH Linear and stepwise elution schedules A) Linear gradient elution over 
25 CVs B) multi-stepwise elution schedule run at pH 7 C) multi-stepwise elution schedule 
run at pH 8 (DNA and particle data only collected across elution peak 3 rather then 5 data 
points plotted) D) multi-stepwise elution schedule run with additional column volumes for 
3
rd
 and 4
th
 steps pH 7.  
 
Data in Table 6.6 shows that the total protein concentrations in all fractions were below 
the limits of quantification. This was the case when analysed with both BCA and micro 
BCA protein assays. It is understood that micro BCA, while having an LLOQ of 2 
µg/mL, is incompatible with ammonium sulate. The regular BCA assay has an LLOQ of 
20 µg/mL, so for this reason an SDS page gel, shown in Figure 6.7, was run in order to 
visualise the protein present in the elution. After staining with SimpleBlue
TM
 SafeStain 
(Life Technologies, Carlsbad, CA, USA) there were no visible bands, therefore the gel 
shown was silver stained. 10 µL of each fraction under non-reducing conditions was 
loaded into each well. The gel shows that protein is present in the elution fractions at pH 
7 and pH 8, however, at very low concentration. The majority of protein is collected in 
the flow through fraction. A null prep sample, which was filtered cell lysate without 
virus, was run as a control (lane 10). This appears to have a similar protein profile to the 
load material, suggesting that the majority of protein in the sample was contamination 
from the host cell.  
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Table 6.6 CIM OH multi-stepwise elution scheduals run at pH 7 and pH 8 (N/T = not tested) LLOQ = lower limit of quantification. % R = percentage 
recovery 
 * = CIM OH run with elution fractions 3 and 4 increased from 5 to 10 CV’s.  
** = CIM OH run without 1
st
 and 2
nd
 elution fractions and with 3 and 4 increased from 5 to 10 CVs.  
Conditions 
tested 
0.8 µm 
Filter 
(% R) 
Number of particles 
loaded 
(pfu) 
Mass of 
DNA loaded 
(ng) 
Flow 
Through 
TCID50 
(% R) 
Elution 
TCID50 
(% R) 
Elution 
NTA 
(% R) 
Elution qPCR 
(% R) 
Elution 
DNA 
Removal 
(%) 
DNA 
purificati
on factor 
Elution 
Protein 
 pH 7 Run 1 104 6.62x10
8
 7200 0.16 92 35 N/T 97 21 LLOQ 
 pH 7 Run 2 38 5.35x10
8
 6100 0.08 42 55 N/T 97 15 LLOQ 
 pH 7 Run 3* 39 5.07x10
8
 23000 0.58 36 25 25 95 7 LLOQ 
pH 7 Run 4** 34 1.12x10
9
 25000 0.46 50 37 44 94 8 LLOQ 
pH 8 Run 1 32 1.75x10
9
 29000 0.42 90 39 N/T 96 22 LLOQ 
 pH 8 Run 2 34 1.08x10
8
 18000 0.15 91 10 12 99 88 LLOQ 
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Figure 6.7 Non reduced SDS page gel after silver staining. Fractions are from CIM OH 
harvest, load, flow though, wash, and elution fractions run at pH 7 (Figure 6.6.B) and pH 
8 (Figure 6.6.C). Null Prep fraction was prepared in the same way as chromatography 
load material but did not contain virus material. FT = flow through, E=elution. 
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NTA size distribution data for load and elution fractions analysed from CIM OH runs at 
pH 7 and pH 8 are shown in Figure 6.8. The load material originates from the same 
source, although has been diluted 1:5 in optimised HIC load buffer at pH 7 (A) and pH 
8 (B). The elution fractions from each run are less polydisperse than the load material, 
and appear comparable in terms of particle size profile. The load fractions show 
considerable differences which may be related to the change in pH; however, it is also 
likely to be indicative of the high levels of variability seen in the starting material.   
What is encouraging is that the variable polydispersity in the upstream does not appear 
to affect the levels of polydispersity in the CIM OH elution fraction. 
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Figure 6.8 Size distribution of CIM OH stepwise elution schedule load and elution 
fractions. A) data includes elution fractions 3, 4 and 5 pH 7 B) data show load and elution 
pH 8. N=5 for all samples, curves represent mean values. 
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6.6 Evaluation of robustness and process variability  
 
The ability of CIM OH to remove contaminating DNA from the viral load material 
varies depending on the total mass of DNA in the load. However, it is shown to be as 
high as 99% resulting in a total mass of DNA/dose of less than 10 ng (depending on the 
dose specified). A second chromatographic step would likely be necessary if vaccinia 
was required at high dose. When compared to sulfated cellulose membrane absorbers 
(SC-MA) evaluated in the literature, (Wolff, Siewert, Hansen, Faber, & Reichl 
2010a;Wolff, Siewert, Lehmann, Hansen, Djurup, Faber, & Reichl 2010b) CIM OH 
monoliths appear to have a lower binding capacity than SC-MA, which has shown to 
adsorb up to 6.42x10
9
 pfu of MVA per capsule. Each capsule tested was 75 cm
2
. A 
direct comparison is difficult to make as the cell line, vaccinia strain and analytical 
measurements were all different, however, it appears that a higher percentage recovery 
of infectious virus was achieved using CIM OH. The authors measured virus recovery 
from SC-MA using an in-house ELISA, and achieved a recovery of 75%. The total 
infectious recovery across the whole process was reported to be approximately 34% 
although a pre-column filtration step was not included in the process stream and this 
was after a second chromatography step. Infectious recovery from CIM OH is variable 
but as high as 90%. CIM OH and SC-MA show comparable removal of total protein, 
which is below the lower limit of quantification (LLOQ) of the BCA assay used in both 
studies. Total DNA removal was slightly higher using CIM OH, although still 
comparable to SC-MA. The best result shown for SC-MA was a removal of 98% of the 
total DNA loaded while CIM OH removed up to 99%. This corresponds to an 
impressive purification factor of 88. 
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The data in Table 6.6 shows that the DNA and total protein removal capability of CIM 
OH is fairly consistent at both pH 7 and pH 8. The recovery of infectious virus, while 
variable, appears to be above 66% on average. The median infectious viral recovery 
when comparing all the runs at both pH values is 70%, while the mean recovery is 67%. 
The limited qPCR-based recovery data (only 3 data points are available, Table 6.6 ) is in 
close agreement with the recovery data generated using the NTA. The qPCR protocol 
was designed to quantify intact viral particles by adding a nuclease treatment step to 
remove free viral DNA from the sample prior to analysis. More data is required to make 
accurate conclusions; however, these results may indicate that CIM OH is able to 
remove intact but non-infectious virus particles from the feed stream.  
Figure 6.9 shows SEM images of the CIM OH load, flow through and elution fractions. 
Viral aggregation in the presence of ammonium sulfate can clearly be seen in the CIM 
OH load. Particles larger than 6 µm were present across all grids analysed. A large 
number of other particles, appearing to be associated with the virus, are present in 
Figure 6.9B. We speculate that this is DNA, as the particles resemble “beads on a 
string” which is often used to describe heterochromatin. The “beads” are nucleosomes 
which consist of DNA wrapped around eight histone proteins known as a histone 
octamers.  This hypothesis is supported by CIM OH mass balance data, as 60-80% of 
the DNA loaded onto the columns is recovered in the flow through fraction. The 
associated particles in the SEM images are shown again in Figure 6.9.C to be present at 
a seemingly high concentration in the flow through fraction. They do not appear to be 
present in the elution.  
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Figure 6.9 A) large virus aggregate in CIMOH load (post filtration) >6µm in diameter B) 
Potential Viral-DNA complex in CIM OH Load (post filtration) C) DNA type structure 
with associated protein in CIM OH flow though fraction D) smaller virus aggregate 
(approx. 1µm) with less DNA association in CIM OH. 
 
An illustration, based on the data available on CIM OH is shown in Figure 6.10. The 
image is attempting to simplify a complex system, but shows how the NTA and qPCR 
data may be able to agree on a low yield of total particles, while the infectivity assay 
shows relatively high but variable infectious viral recovery. The NTA is identifying 
particles of between 250 nm and 350 nm. The recovery appears to be less than 50%. 
Large viral aggregates do not appear to be present, although particles above 1000 nm 
are above the limit of quantification for the instrument. The fact that the NTA and 
qPCR agree in terms of percentage recovery is interesting. This may be due to large 
viral aggregates present in the load material binding to the column and then being 
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broken down and recovered in the elution fraction. These particles wouldn’t be 
detectable in the load by the NTA, as they would be larger than 350 nm, but would be 
detectable by qPCR as this is able to detect all encapsulated viral genomes. The 
particles would then be detectable by both assays in the elution. This theory only works 
if the majority of non-viral, host cell derived particles, of a similar size to vaccinia are 
removed prior to elution. However, data from BCA, PicoGreen and SEM suggest this 
may be the case. These assays show that that the concentration of contaminants in the 
elution is low. If this were not the case the NTA would yield a higher recovery than the 
qPCR as it is a non-specific step. Microscopy data suggests significantly less 
aggregation in the elution relative to the load, however, as only small sections of a 
sample can be analysed, many more images would be required in order to generate 
statistical significance, but this is still supportive data. TCID50 is shown to yield a 
variable but high recovery of infectious virus. It is not known whether a single 
infectious viral particle can infect a cell if aggregated with other non-infectious 
particles. It is speculated, however, that in a dynamic system this may be a high source 
of variability. This question has been raised before, (Floyd & Sharp 1979;Kim & Sharp 
1966) and it was concluded that aggregates are able to infect cells, however, how many 
cells an aggregate is able to infect and how the specific composition of the aggregate 
affects the infectivity is still unknown. What is worthy of note, is that aggregated 
vaccinia particles appear to be more resistant to UV radiation then single particles that 
have been sonic-treated to remove aggregates (Galasso and Sharp 1965). Based on the 
data presented in this thesis, aggregation in the presence of ammonium sulfate can be 
reversed by the addition of sodium phosphate without salt, as was shown in Figure 4.8. 
Based on the NTA and TCID50 data, the approximate total particle to infectious unit 
ratio (P:I ratio) in the CIM OH load is 100:1.  In the elution this is reduced to 10:1. This 
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suggests that the CIM OH column is able to remove approximately 90% of the non-
infectious particles from the load. 
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Figure 6.10 An illustration to show proposed feed stream complexity and purification 
output based on data from CIM OH. NTA is assumed to be able to count any particle of 
close to 300nm (red and green rectangle (viral particles), and circles (cell components)), 
qPCR will count all intact virus particles regardless of whether infectious or not, TCID50 
will only be able to count infectious virus particles, it is unknown whether infectious 
particles within an aggregate is able to infect a cell. TEM show an extremely small snap 
shot of the system. 
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6.7 Conclusions 
 
CIM OH monoliths have proven to be an effective capture and polish step for vaccinia 
virus lister strain.  The total protein concentration in the elution fractions were reduced 
to below LLOQ levels of the BCA assays used in this study. More specific host cell 
protein (HCP) ELISAs will be needed to confirm the results prior to clinical application, 
but the outcome of this study is encouraging. CIM OH monoliths are also able to 
remove an impressive amount of DNA without the use of Benzonase®. At pH 8 up to 
99% of the DNA loaded was removed and infectious virus recovery in the elution was 
approximately 90%. This corresponded to a purification factor of 88. This purification 
factor is significantly higher than that achieved with CIM SO3. It was found that when 
developing a capture step for CIM S03 monoliths, a trade-off existed between the 
recovery of infectious virus and the recovery of DNA. This meant that the DNA 
purification factor was limited to 4.3. To illustrate this, in order to remove 92% of the 
DNA only 35% of the infectious virus loaded onto the monolith was recovered in the 
elution. CIM SO3 monoliths were also not able to remove as much total protein. When 
eluted with 300 mM NaCl a maximum of 92% of the total protein loaded was removed. 
This corresponded to a total protein purification factor of 4. 
A potential downside of using CIM OH as a capture step is the loss of virus across the 
pre-column filtration step. The filtration step is necessary to prevent monolith fouling 
which can result in high backpressures. The recovery across the 0.8 µm filter in 
optimised HIC load buffer was found to be approximately 35%. This was increased 
from 6% by decreasing the levels of ammonium sulfate in the load buffer. In 
comparison the recovery across the same filter when loaded in CIM SO3 load buffer (50 
mM sodium phosphate pH 7) is around 60 – 70%. This will need to be addressed in 
future work. 35% recovery, while reasonable for the purpose of developing a capture 
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step, would make the whole process extremely expensive in terms of overall cost per 
dose. 
While there are many challenges associated with the development of viral processes, 
two stand out as being the most significant. The first is the complexity and incredible 
variability of the starting material in terms of infectious titre, concentration of DNA and 
protein, and levels of polydispersity in relation to particle size. The second is the poor 
quality of the available analytical assays. No single assay is able to tell the “whole 
story” in terms of virus concentration and many have a routine intra-sample variability 
greater than 30%. Both CIM SO3 and, in particular, CIM OH appear to be able to 
adsorb a relatively large number of viral particles, approximately 1x10
9 
pfu/mL of 
monolith. Both chemistries have demonstrated the ability to remove the majority of 
contaminants, both removing over 90% of DNA and Protein, and recovering a 
reasonably large percentage of infectious virus, up to 50% from CIM SO3 and up to 
90% from CIM OH.  
By employing a number of orthogonal analytical methods, simplified illustrations of 
each chromatographic system have been generated. These models are data driven and 
comparable to previous work. In order to increase the levels of certainty on the 
conclusions drawn, more replicates and an even greater variety of analytical 
measurements need to be performed. Resource limitations prevented these from being 
possible during this study; however, future work will need to include them. 
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  Chapter 7
 
An Economic Evaluation of Monolith-
based processes and Comparison to 
Parallel Technologies 
 
7.1 Introduction 
 
This chapter aims to compare monolith chromatography with ultracentrifugation for the 
purification of vaccinia virus feed streams. This comparison is designed to firstly, assess 
the feasibility of the industry moving away from ultracentrifugation. Secondly, it aims 
to identify the critical parameters that will need to be focused on during future process 
development of vaccinia virus in order to generate viable commercial processes. As 
described in Chapter 2, there are advantages and disadvantages to both 
ultracentrifugation and chromatography; hence in order to make decisions both of these 
need to be addressed. To assist with this process, a decision tool in the form of a cost of 
goods (CoG) model, built using BioSolve Process Enterprise Version 7 (Biopharm 
Services, Chesham, Bucks, UK) was used. The data used in the model is based on the 
chromatographic data generated during this EngD research project as well as published 
literature on the purification of vaccinia virus using large-scale ultracentrifugation. 
Process flow diagrams for the proposed ultracentrifugation and CIM monolith-based 
processes are show in Figure 7.1 (Section 7.3.2). 
Purification using small and large pore TFF filters has also been used previously to 
purify influenza virus (Wickramasinghe, Kalbfuß, Zimmermann, Thom, & Reichl 
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2005), however, this has not been focused on in this chapter as question marks arise 
over this unit operation’s ability to remove enough contaminates for high dose 
applications  (Greenberg and Kennedy 2008;Monath, Caldwell, Mundt, Fusco, Johnson, 
Buller, Liu, Gardner, Downing, Blum, Kemp, Nichols, & Weltzin 2004). 
 
7.2 Model Design and Setup  
7.2.1 Cost breakdown 
 
BioSolve Process Enterprise version 7 (Biopharm Services, Chesham, Bucks, UK) was 
used as a platform to build the whole process model. Cost data was taken from 
BioSolve’s own data base unless otherwise stated. Exact unit prices for cGMP 
monoliths cannot be disclosed. This information is considered proprietary by BIA 
Separations; however, an up-to-date price list supplied BIA Separations was used in 
building this model.  
The cost of goods breakdown considered in this study is shown in Table 7.1 
 
 
 
 
 
 
 
208 
 
 
Table 7.1 Breakdown of costs and their associated components  
Grouped Costs Components 
  
Capital    General equipment 
       Process equipment  
    Cost of works 
Materials + QC  
   
Media 
     Buffers 
  Direct Raw Materials 
  Bought WFI 
  CIP 
  QC tests 
Consumables 
  Monoliths Columns  
  Bags 
  Filters 
  Other 
Labour 
  Process 
  Quality 
  Indirect 
Other 
  Insurance/other 
  Waste management  
  Maintenance 
  Utilities 
 
7.2.2 Key equations and model rules  
 
During small scale studies in T175 flasks CV-1, cell productivity was measured at 
approximately 100 pfu/cell. It is unknown whether this would scale up when producing 
vaccinia virus using microcarriers in stirred tank reactors, however, as a starting point, 
this value was carried through.  
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The following equation was used to estimate viral titre: 
𝑇𝑖𝑡𝑟𝑒 = 𝑀𝑐 𝑥 𝑀𝑑 𝑥 𝐶𝑚 𝑥 𝑉𝑃𝑐                                                                         7-1  
where Mc is microcarrier surface area in cm
2
/g, Md is microcarrier seeding density in 
g/L, Cm is the average number of cells per microcarrier in cells/cm
2 
and VPc is the total 
viral particles produced per cell in pfu/cell. 
cGMP compliant monoliths are available in three sizes, 0.08 L, 0.8 L and 8 L. In order 
to determine the size of monolith capsule required the following rule was applied.  
𝐼𝐹 (
𝑃𝐿
𝐷𝐵𝐶 𝑉𝑐 𝑁
) => 1 … .use larger column 𝐸𝐿𝑆𝐸 𝑢𝑠𝑒 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑠𝑖𝑧𝑒.                7-2 
where PL is the number of vaccinia particles in the feed stream in pfu, DBC is the 
dynamic binding capacity of CIM monoliths, which is set to 1 x 10
12 
pfu/L, Vc is the 
monolith volume in L, and N is number of cycles allowed (set manually).  
This rule starts with the smallest monolith which is 0.08 L and will work up each 
available size until it gets to the largest of 8 L. 
Labour costs are broken down into direct hours, solution preparation, and cleaning. 
Process operator and supervisors also incur indirect costs to the total. 
∑ 𝑳𝒂𝒃𝒐𝒖𝒓 𝒄𝒐𝒔𝒕                         7-3 
= ((𝑑𝑖𝑟𝑒𝑐𝑡 ℎ𝑜𝑢𝑟𝑠 × 𝑟𝑒𝑚𝑢𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟 𝑤𝑜𝑟𝑘𝑒𝑟)
+ 𝑢𝑛𝑖𝑡 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑝𝑟𝑒𝑝 𝑐𝑜𝑠𝑡𝑠 
+ 𝑢𝑛𝑖𝑡 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑛𝑖𝑛𝑔 𝑐𝑜𝑠𝑡𝑠) + 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑐𝑜𝑠𝑡𝑠 
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where indirect costs are made up of logistics, engineering and ‘other’ costs and are 
assumed by BioSolve to be 38% of the total production operator and supervisors direct 
costs. 
Other costs, shown in Table 7.1, are made up of insurance, waste management, 
maintenance and utility costs. 
Insurance, utilities and maintenance are calculated as a percentage of the total facility 
costs, as being 1%, 3% and 5% respectively. 
Waste management is broken down into non-contaminated and contaminated, aqueous 
and plastic waste. The associated disposal costs of each are shown in the appendix.  
As shown in Figure 7.1 later in this chapter, both the ultracentrifugation and monolith-
based processes included two TFF steps. 
The surface area of the filter is determined using the following equation. 
𝐴 =
𝑉𝑝𝑇
𝐽𝑝
                                                                               7-4 
where 𝑉𝑝 is permeate volume in L,  𝐽𝑝 is flux in L m
-1
 h
-1
 and 𝑇 is process time in h. 
Total capital costs are made up of the components shown in Table 7.1. This number is 
assumed to be borrowed upfront. The capital cost per batch and per dose are then 
calculated from the estimate of capital costs per year. Annual capital is the amount 
needing to be paid back to the loan provider and is calculated using the following 
equation.  
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 =  
𝑃𝑅
1−(1+𝑅)−𝑁
                                                                            7-5 
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where P is the total capital cost, R is the fixed periodic interest rate, assumed to be 12% 
per year and N is the number of years required to pay back the loan. This is assumed to 
be 10 years.  
 
7.3 Model Implementation 
7.3.1 Key Assumptions 
The base case assumptions made in the model are shown in Table 7.2. 
 
Table 7.2 Ultracentrifugation and CIM Monolithic base case assumptions  
 
The capacity achievable on a KII ultracentrifuge using a K3 rota is reported by the 
manufacturer as being up to 200 L (Alfa Wassermann 2013). Previous work reported in 
the literature has shown that approximately 20 L of vaccinia broth can be processed 
with an RK-centrifuge in an RK3 rota with percentage recovery of approximately 60% 
 KII Ultracentrifugation Monolith 
 
Capacity 20 L/cycle 1x10
12
 pfu/L 
Flow rate 0.2 L/min 1 CV/min 
Hold time 1
st
 purification unit operation 12 hr 0 hr 
Hold time 2
nd
 Purification unit operation 1 hr 0 hr 
Number of reuses Infinite (cannot be cycled) 20 cycles 
Percentage Virus Recovery 
Bioreactor Volume 
60% 
100 L 
60% 
100 L 
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(Hilfenhaus et al. 1976b). The RK system is now obsolete, but the equivalent rota is 
available from Alfa Wassermann and has since been scaled up. It is likely that volumes 
greater than 20 L can be processed in the new rota as its volume has been increased 
from 1.6 L to 3.2 L. It is also assumed, based on data in the same publication, that two 
ultracentrifugation steps will be required. Virus material is pumped into the rota and 
then left for a set period of time for virus to band in the sucrose bed. In the base case 
scenario, the first banding occurs in 12 hours while the second takes 1 hour. Smaller 
viruses can take several days to band; therefore a maximum of 50 hours for each 
(ultracentrifugation) unit operation has been used in the comparative analysis section of 
this chapter (Figure 7.5). 
Based on work with CIM SO3 and CIM OH monoliths, a dynamic binding capacity of 
1x10
12
 pfu/L is a reasonable assumption for large-scale vaccinia processes. This 
assumes that the 1 mL monoliths scale linearly. As large-scale monoliths can be run up 
to a maximum velocity of 1 CV/min, this flow rate has been fixed for all sensitivity and 
scenario analyses. The percentage recovery of infectious virus was shown to be above 
60% from both CIM SO3 and CIM OH, therefore the base case infectious recovery was 
fixed at 60%. The production volume was set to 100 L. In reality this would depend on 
the therapeutic application, the efficacy of the therapy and the market demand. As these 
are unknown it was decided to indiscriminately set a limit and keep this constant during 
all comparative studies. A table of main costs is shown in Table 7.3. Key personnel 
remuneration costs are show in Table 7.4. 
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Table 7.3 Lists of key process costs. The “General process” costs category comprises costs 
specific (referring) to unit operations that are the same regardless of the purification 
strategy. This includes upstream, primary recovery and final formulation costs. * 
Monolith costs are confidential so have been approximated. 
Process  Step Unit cost 
General process  100 L bioreactor 200,000 USD 
 Depth filters  300 USD/m
2 
 UFDF filters  3000 USD/m
2 
 Bags 
• 20L 
• 50L 
• 100L 
• 200L 
 
420 USD 
450 USD 
520 USD 
660 USD 
 Media serum free 
(DMEM/F12) 
Buffers (DPBS) 
In vitro virus assay (infectivity) 
3.31 USD/L 
 
0.73 USD/L 
13,000 
USD/assay 
Monolith chromatography  
process 
Chromatography rig 220,000 USD 
Monoliths*  
• 0.08 L 
• 0.8 L 
• 8 L 
 
~5,000 USD 
~10,000 USD 
~30,000 USD 
 
Ultracentrifugation 
 process  
 
Ultracentrifuge 
 
350,000 USD 
 
 
 
214 
 
Table 7.4 Personnel remuneration costs per year (BioSolve Process Enterprise) 
Personnel Remuneration (USD/Year) 
QC 74,400 
QA 97,650 
Supervisors 100,750 
Operators 62,000 
 
A list of more general process assumptions made in relation to both monolith and 
ultracentrifugation processes are listed below. 
• Each process is able to generate material to the required regulatory standards in 
terms of purity. 
• Ultracentrifuges are not cycled. Ultracentrifugation cycling occurs when a single 
system is run multiple times in order to process the whole batch. If an 
ultracentrifuge reaches capacity and additional material requires purification, the 
batch will be split and run in multiple machines in parallel. The reason behind this 
assumption is given in Section 7.3.2  Process Flow and Facility Design. 
 
• Infectivity analysis (in vitro) is required after every unit operation. If a batch is split 
in two, each new feed stream is analysed independently before being pooled back 
together.  
• A new facility will be built with new equipment. Capex will be spread across a 10 
year duration in which it will lose 90% of its value. 
• Treatment requirements are five injections of 1x109 pfu/injection. This makes the 
total treatment requirements of 5x10
9
 pfu per patient. A dose is assumed to be the 
total 5x10
9
 particles. 
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• The bioreactor volume is fixed to 100 L in all scenarios unless otherwise stated. It 
was assumed that the treatment was for Head and Neck cancer which had an 
incidence of 58,293 patients in the UK between 2010-2013 (Public Health England 
2015). The base case process would produce enough material to treat 90% (17,580) 
of these patients each year.  
• Viral titer is assumed to be 1.6x1011 pfu/L based on the following assumptions 
(Simaria et al. 2014):  
 Microcarrier surface area (Mc) = 2,530 cm2/g 
 Microcarrier seeding density (Md) = 6.3 g/L 
 Total cells per microcarrier surface area (Cm) = 1x105 cells/cm2 
 Total viral particles produced per cell (VPc) = 100 pfu/cell 
• The cost of microcarriers has not been taken into account in the model but is 
assumed to be constant as bioreactor volume is fixed. 
• The model does not take into account the bioreactor seed train, but starts from 100L. 
• All prices have been converted to USD using exchange rates described in the 
Appendix. 
• All media and buffers are made up on a per batch basis. 
• Single use systems are used for the following: 
 Bioreactor 
 All filtration systems 
 Media, buffer and product hold tanks 
• A campaign is designed to last 12 months with 21 days of maintenance and 14 days 
set aside for validation.  
• Each shift is 9 hours long. 
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• The base case batch duration for the monolith-based process is 11 days. The 
ultracentrifugation process takes 10 days. 
• The number of batches produced per year for each base case is estimated to be 30. 
• Batch failure rate is set to 5%. 
• The final formulation buffer is assumed to be Tris-HCL plus sugars such as sucrose 
(Ungerechts et al. 2016). 
 
The default model parameters set out in BioSolve in terms of capital breakdown, waste 
management, solution preparation time, cleaning, facility and maintenance costs are 
kept as default and are all shown in the Appendix. 
 
7.3.2 Process Flow and Facility Design 
The model compares two proposed processes. The first has two chromatographic steps, 
both of which are CIM monoliths; the other has two ultracentrifugation steps. The two 
ultracentrifugation steps, as discussed in Section 7.3.1, are assumed to be carried out 
using a KII Alfa Wasserman ultracentrifuges fitted with a K3 rota. Proposed process 
flow diagrams are shown in Figure 7.1. Each process is the same, except for the two 
purification steps. The whole process sequence has not yet been tested, and so it is 
partially conceptual, nevertheless has been assumed to work. 
The model has been designed without specific costs associated with a full seed train in 
order to reduce complexity. As the main questions asked in the analysis are focused on 
determining the operational feasibility of using a chromatography-based purification 
process as opposed to ultracentrifugation, it was decided that accurate determination of 
exact costs per dose were not the primary concern. What was important was to 
accurately determine comparative trends and trade-offs associated with critical process 
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parameters known to be variable in both ultracentrifugation and chromatographic 
processes.  
The primary recovery steps in the processes described are based on unit operations 
being designed at UCL (Personal Communication 2016). The process uses a tangential 
flow filtration step to concentrate and lyse CV-1 cells (grown on microcarriers) in the 
presence of TritonX-100, a non-ionic surfactant commonly used to chemically lyse cells 
(Giard et al. 1977;Wang and Ouyang 1999). The model assumes that an average 
transmembrane flux of 50 LMH is achievable, the harvest is concentrated 20 times and 
then diafiltered 7 times in buffer containing TritonX-100. After the diafiltration step, the 
retentate is passed through a depth filter to remove the microcarriers and cell debris. 
Depth filtration is used in many processes to remove whole cells, and has been used for 
clinical grade vaccinia virus to remove cell debris in the past (Ungerechts, Bossow, 
Leuchs, Holm, Rommelaere, Coffey, Coffin, Bell, & Nettelbeck 2016). The primary 
recovery steps have been kept the same for each process so that any trends seen are 
known to be resulting from changes made to the purification steps.  
It is assumed that the first TFF step will buffer exchange the feed stream into the 
appropriate load buffer for the first chromatography step. The elution from the first 
chromatography step is then diluted 1:5 before the second column. Monoliths run at 
high flow rates (1 CV/min) so this increase in volume is not a limiting factor in the 
process, as it will only marginally increase the overall processing time of the second 
step. The reason why an additional UFDF step was not preferred over an inline dilution 
is that it was considered unnecessary. An additional UFDF step would likely reduce the 
overall process recovery and increase the processing time. This would decrease 
productivity and increase costs. The final TFF step is designed to concentrate and then 
buffer exchange the virus into its final formulation buffer.  
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Figure 7.1 A) Proposed ultracentrifugation process flow diagram B) Proposed CIM 
monolith process flow diagram  
A
B
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One of the main process assumptions is that ultracentrifuges cannot be cycled in the 
same way as chromatography columns. The reason for this is that system setup and shut 
down is a very manual process and takes most of a 9-hour shift. It is assumed that an 
operator would need to leave the system running overnight for approximately 12 hours, 
although some viruses can take longer than 24 hours to band. Shutting the system down 
and fractionating the bed, not to mention cleaning and sterilising the system ready for 
reuse, is assumed to take at least a day. This would imply a considerably long holding 
time for this labile viral product at 2-8 ⁰C. Vaccinia would likely start to lose infectivity.  
Instead, a batch is split and run in multiple machines in parallel. The downsides of this 
option are an increase in process equipment costs and an overall higher investment due 
to the requirement of larger facilities. The option of running ultracentrifuges in parallel 
needs to be taken into account in the design stage of the facility because a process 
change of this calibre cannot be easily retrofitted into an existing facility unless enough 
extra space existed into the DSP suite. Two example fit outs are shown for the 
ultracentrifugation process in Figure 7.2. As the majority of closed process DSP 
products are handled in grade C clean rooms, this would be very expensive and hence is 
unlikely. BioSolve Process Enterprise does not take the added design change into 
account when adding new equipment but calculates the total clean room space 
requirements based on equipment size. 
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Figure 7.2 A) Facility fit out with a single ultracentrifuge B) Facility fit out with four 
ultracentrifuges running in parallel.  
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7.4 Comparison between Chromatography using CIM Monoliths and 
Ultracentrifugation  
7.4.1 CIM Monolith and Ultracentrifugation Base Case Process Costs 
Breakdown 
 
The ultracentrifugation and chromatography base case processes described above have 
been modelled and compared against each other. Figure 7.3 shows a cost breakdown for 
the ultracentrifugation and monolith processes in terms of total annual cost of goods. It 
is immediately obvious that the overall costs are similar. The ultracentrifugation process 
is estimated to cost $8.3 million per year, while the monolith process is estimated to 
cost $8.2 million per year.  
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Figure 7.3 Costs breakdown of base case chromatographic and ultracentrifugation-based 
processes 
 
Capital is seen to be a major cost in both processes, a breakdown of which can be seen 
in Figure 7.3. The reason for this is that both base case processes require a similar 
amount of equipment so costs associated with build, purchase, fit out, installation and 
validation do not vary much between processes, but are in each case significant. The 
ultracentrifugation process requires an additional centrifuge whilst the monolith process 
design assumes the requirement of two chromatography rigs, therefore the capital cost 
of the former process is only slightly higher than that of the monoliths process.  
Materials and QC (which BioSolve groups together) is shown to be the other major cost. 
The majority of this cost comes from the QC. In vitro virus testing is required for each 
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in process product fraction, and is estimated by BioSolve to cost 13,000 USD per assay. 
Buffer and media costs are not particularly large as the bioreactor volume and total 
buffer volume requirements are relatively small.  
As the ultracentrifugation process splits the batch if the percentage utilisation of a single 
rota reaches over 100%, extra infectivity assays (one for each product fraction) are 
assumed to be required. For this reason, the materials and QC costs are slightly higher 
for the ultracentrifugation process than for the monolith process. Labour costs are 
shown to be slightly higher when using monoliths as 13 cycles are required in order to 
process all the material. A monolith process also results in a higher consumable cost as 
the resins are expensive. The most expensive consumable costs associated with the 
ultracentrifugation process are the TFF filters, the total surface area requirement of 
which being the same for both base case processes.  
As shown in Table 7.1, the costs labelled ‘other’ include insurance, waste management, 
maintenance and utilities. The reason why these are slightly higher for 
ultracentrifugation than for chromatography is the slightly higher capital cost. 
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7.4.2 CIM Monolith and Ultracentrifugation Process Sensitivity Analysis 
 
In order to test the assumptions made in the base case model, Section 7.3.1, a sensitivity 
analysis was run for a number of general and purification technology specific factors 
thought likely to influence the cost of goods. The rational here was to gain 
understanding of the significance of the effects the fluctuation of these factors have on 
CoGs. The factors tested are presented in Table 7.5. The results are shown in Figure 7.4. 
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Table 7.5 Factors changed in the Ultracentrifugation and Monolith sensitivity analysis.  Best case, base case and worst case scenario values are 
shown 
 
Factors 
Changed 
Range and Base Case Values  
Ultracentrifugation Process Monolith process 
  Low Base High  Low Base High 
        
Capacity  1 L 20 L 200 L  5x10
11 
pfu/L 1x10
12
 pfu/L 3x10
12
 pfu/L 
Flow Rate  1 L/h 12 L/h 60 L/h 1 CV/min 
Number of 
Reuses 
  
cannot be recycled 
 1 20 40 
Percentage 
Virus 
Recovery 
 
 
20% 60% 100% 
 
 20% 60% 100% 
Bioreactor 
Volume 
 
10 L 100 L 200 L  10 L 100 L 200 L 
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Figure 7.4 Tornado diagrams showing the effects of changes in the base case variables 
shown in Table 7.5 on the overall costs per dose. A) Shows factors affecting CoGs for 
ultracentrifugation processes. B) Show factors affecting CoGs for monolith processes.  All 
factors were changed independently with all other conditions remaining the same as in the 
base case. Blue bars represent a reduction in costs per dose while red bars represent an 
increase. 
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There were a number of reasons for choosing the factors shown in Table 7.5. Firstly, it 
was thought that they would have a significant effect on the CoGs. Secondly, they are 
all parameters that can theoretically be optimised during process development. Should 
trade-offs that include any of the factors analysed arise during process development, an 
understanding of their effects on the CoG relative to each other can also help when 
making process development decisions. A hypothetical example of this might be a 
trade-off between loading capacity and the number of possible reuses of a monolith 
column. The results of a sensitivity analysis can be used to set priorities in terms of 
which parameter to favour. 
The capacity achievable when developing ultracentrifugation or monoliths-based 
processes is likely to be one of the first major questions asked in process development 
(Hilfenhaus et al. 1976a;Hilfenhaus, Kohler, & Gruschkau 1976b). The ranges shown in 
Table 7.5 are based on both literature and vaccinia process development data. In terms 
of flow rate, large-scale monoliths can be run at a maximum flow rate of 1 CV/min. As 
mass transfer is not limited by diffusion, comparison studies looking at the effects of 
different flow rates on binding and resolution are unlikely to be on the critical path, 
therefore the decision was made not to include any variation on flow rate into the 
sensitivity analysis for monoliths. The range and base case values chosen for the 
ultracentrifugation process come from values specified by the manufacturer, and would 
need to be confirmed experimentally. The number of reuses possible when using 
monoliths are, again, based on the manufacturers best case assumptions. As described in 
Section 7.3.1, the model assumes that ultracentrifuges cannot be cycled. For this reason, 
ultracentrifugation cycling is also not included in the model. Percentage recovery of 
virus particles was assumed to have a large impact on CoGs for both processes. While 
results vary from virus to virus and from process to process, it is difficult to conclude 
that either one of the processes being compared would likely be superior to the other in 
228 
 
general terms when it came to percentage recovery. Data in the literature, as well as data 
generated for this thesis, shows that virus yield is extremely variable on both systems. 
Between 20-100% recovery of infectious virus is recorded in the literature (Gerster, 
Kopecky, Hammerschmidt, Klausberger, Krammer, Grabherr, Mersich, Urbas, 
Kramberger, Paril, Schreiner, Nobauer, Razzazi-Fazeli, & Jungbauer 2013b), therefore 
this range was used with a base case recovery in each case set at 60%. Bioreactor 
volume and virus titre were included in the analysis for two reasons. Firstly, for 
completeness but secondly, to act as a reference point in terms of relative impact. It is 
well known that titre has a massive impact on the overall CoGs per dose when varied, 
so the effects of other factors can be compared to this change to enable a thorough 
evaluation of potentiation impact. 
 
7.4.2.1 Factors Identified in the Sensitivity Analysis to Affect Cost of 
Goods 
As expected, changes in viral titre and bioreactor volume have the most significant 
effects on the CoGs as seen in Figure 7.4. The reason for this is that the number of viral 
particles produced per unit volume, as well as the total volume of starting material 
available per batch if the titre remains constant, directly affects the number of doses 
produced annually. This outweighs any increases in cost associated with handling the 
extra material.  
The cost of an ultracentrifugation process is significantly affected by the volumetric 
capacity of the machine. Batch ultracentrifuges have significant load volume limitations 
as each rota has a fixed volume and this cannot be surpassed. Continuous flow 
ultracentrifuges are designed to be continuously loaded at a pre-defined flow rate until a 
maximum capacity is reached. The machine is then typically left for periods of time 
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ranging from several hours to several days to allow virus to band. The overall 
volumetric throughput is dependent on the total mass of impurities with a similar size 
and buoyant density to the virus. When capacity is reached, the purification factor starts 
to drop off quickly as banded virus and impurities start to overlap. The reason why the 
volumetric throughput has such a significant impact on the CoGs is directly related to 
one of the primary assumptions being made about ultracentrifugation in the base case 
model. This is that an ultracentrifuge cannot be cycled when run at large-scale. One of 
the main reasons for this is that viral stability would become a limiting factor as the 
process would take a long time to run. If this assumption is acceptable, and a centrifuge 
is unable to process the whole volume in a single cycle, then a batch would need to be 
split and run in multiple machines in parallel. Consequently, in the case of low 
achievable volumetric throughput, this would result in a significant increase in the 
capital cost of the process.  
 
Depending on the stability of the virus being processed and the total cycle time of each 
ultracentrifugation step, the supposition that ultracentrifuges are not able to be cycled 
may become debatable. In order to evaluate the potential costs per dose of running an 
ultracentrifugation step in multiple cycles a scenario analysis was run assuming 
different processing times with and without cycling. The output was plotted as a 
function of volumetric throughput. This data is presented in Figure 7.5. 
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Figure 7.5 Effects of Ultracentrifugation cycling and process time on the CoGs per dose. 
Time periods represent the first and second ultracentrifuge step process times. Cycling 
Possible = batches are cycled on one machine. No Cycling Possible = batches are split and 
run on multiple machines if required. Base case is assuming a 20 L vol. throughput for 
12hr in the first system and 1hr in the second and cannot be cycled (Blue line in bold type 
script). 
 
In reference to the base case ultracentrifugation process (as shown in Figure 7.3) cycle 
times used in the model were taken as reported in the literature (Hilfenhaus, Kohler, & 
Gruschkau 1976b). In this paper virus was loaded into the KII ultracentrifuge at 12 L/h 
and left to band overnight. The next day virus was fractionated and processed once 
again but this time left to band for an hour only. 50 hours as an assumption is an 
exaggeration, but shows the effects of cycling on the cost of goods as the banding time 
increases. Other sources suggest that viruses such as Rabies will band in as little as 8 
hours (Kumar et al. 2002). 
The costs are shown to increase exponentially (Figure 7.5) when the volumetric 
throughput of an ultracentrifuge is low. This is seen to be the case even if the machines 
can be cycled, although the negative impact on cost is lower. This is illustrated when 
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comparing ultracentrifugation banding times of 12 hours followed by 1 hour with and 
without cycling (green and blue lines Figure 7.5). If an ultracentrifuge can be cycled, 
then the additional capital of purchasing multiple machines would not need to be spent, 
however, the downstream process would take significantly longer, and this would 
become a bottleneck (Morenweiser 2005). This point is emphasised when the 
volumetric throughout is below 20 L/batch.  
It can be seen in all cases that when volumetric throughput increases above ~25 L per 
batch (Figure 7.5) the costs become very similar. The reason for this is that a single 
ultracentrifuge is able to process all the material, therefore it makes little difference 
whether it can be cycled or not. As only a single bioreactor is used in the model, 
BioSolve schedules the campaign by taking the total number of weeks the facility is in 
operation and dividing that number by the total time taken to complete the longest stage 
of the process. This is then multiplied by the percentage facility utilisation. In most 
cases the bottleneck in terms of time is in the upstream process (197 h). The campaign 
is scheduled by running the time bottle neck unit operations in series. Even if the 
ultracentrifugation process takes 50 hours, this unit operation would not become the 
bottleneck unless the volumetric throughput was lower than 20 L. At high volumetric 
throughput, the only significant impact compared to base case assumptions would be 
labour. However, labour as shown in Figure 7.3, does not make up a significant 
proportion of the CoGs. Capital and raw material costs remain the same as a single 
ultracentrifuge is run once to purify all the material. The impact of cycling the 
ultracentrifugation step assuming a 50-h run time on whole process timelines is shown 
in Figure 7.6. All other base case assumptions are kept constant. 
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Figure 7.6 Production Gantt chart to show time requirement for each unit operation in 
days. This assumes each ultracentrifuge requires 50 h to band vaccinia. 
 
 
Variations in the infectious virus recovery have, as expected, a significant effect on the 
cost of goods per dose for both chromatographic and ultracentrifugation-based 
processes. In a similar way to the effects seen on costs when viral titre and reactor 
volume are increased, more doses are produced per batch when recovery increases. 
Interestingly, as shown in Figure 7.7, when costs are analysed as cost of goods per batch 
rather than per dose for the monolith process, the trends seen are reversed. This is 
because the lower recovery reduces the number of particles needing to be processed, 
which results in less media being required, or fewer cycles of a given amount of resin 
per batch being needed. This reduces both the consumable and labour costs. This is not 
the case for ultracentrifugation as throughput is based on volume, and therefore 
assumed not to be affected by the number of infectious viral particles in the load. 
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The reason why the increase in recovery still leads to a drastic decrease in the CoG/dose 
is that the increase in CoG/batch is fairly marginal. An increase in percentage recovery 
from 20-100% elevates the CoG/batch by approximately 10%. 
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Figure 7.7 Effects of percentage virus recovery from the first of the two chromatography 
steps analysed as total cost per dose and costs per batch 
 
Labile viruses have a tendency to lose infectivity during chromatographic processing, 
especially at extremes of salt concentration. The recovery of infectious virus from 
chromatographic systems is therefore an important performance attribute requiring 
attention during process development. 
One of the disadvantages of using chromatography is that resins are expensive, 
especially if a large volume is required in order to process the material required. Factors 
that influence this cost other than the amount of material required, which is often fixed, 
is how much material can be loaded onto the resin before its capacity is reached, and 
how many times the resin can be re-used. As shown in Figure 7.8, the effects of each 
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factor on the cost of goods are related. There is an inversely proportional relationship 
between the number of reuses and the cost of goods. This is shown under base case 
assumptions in Figure 7.8A. There are three cGMP compliant commercially available 
CIM monoliths, these include 0.08 L, 0.8 L, and 8 L units. The cost of goods model was 
designed to pick the smallest column that will process the whole batch. Figure 7.8B 
shows the effects of increasing DBC on the cost of goods per dose. The graph shows 3 
different values as the DBC is increased. An 8 L column is required for the lowest DBC 
tested; this then changes to an 0.8 L and eventually to an 0.08 L monolith. 
What can also be seen when analysing Figure 7.8B is that these values are also 
dependant on the number of times the monoliths can be recycled. The effect of a 
column’s inability to be recycled on the CoGs is much greater when the DBC is low, as 
significantly more resin is required. The data also suggests that when the columns can 
be recycled more than 10 times the DBC has little effect on the CoGs. This is because 
all the material can be purified using a single small 0.08 L monolith column. Moreover, 
the base case process requires 13 cycles on a 0.08 L monolith, however, as monoliths 
are run at high flow rates this has minimal impact on the overall batch processing time 
and so does not impact the total number of batches produced during a 12-month 
campaign. Based on this data it can be concluded that the number of reuses is more 
important than the relatively small changes in the DBC in reducing overall CoGs/dose. 
The cheapest processing option is to cycle smaller columns 10 or 20 times rather than 
run a single large column to capacity. 
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Figure 7.8 Effects of DBC and reusability of CIM Monoliths on CoG per dose. 
 
 
The experimental data in this thesis suggests that CIM SO3 monoliths may yield less 
infectious virus in the elution fraction after multiple uses. This might be the result of 
monolith fouling, and may be linked to the amount of total DNA in the load as 
described in Section 5.5.2. CIM OH monoliths by comparison do not appear to be 
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affected by the number of previous uses and yield a purer viral prep than CIM SO3, as 
described in Section 6.7. Both monoliths have similar DBCs for vaccinia virus, although 
CIM SO3 shows more variability in this respect with potential DBC values ranging 
from 1x10
9 
to 3x10
9
 pfu/mL, (Figure 4.6). In the event that either chemistry is assessed 
as an initial capture step for vaccinia virus, this cost data can be combined with the 
experimental data obtained in order to identify drivers for future process development. 
An example of this might be the decision to work on increasing the binding capacity 
and yield of CIM SO3 but accepting that this type of monolith might only give robust 
and reliable results once and will therefore need to be used as a single use resin.  
 
7.5 An Economic Comparison between Chromatography using CIM 
Monoliths and Ultracentrifugation. 
 
The data in Table 7.6 summarises the advantages and disadvantages of 
ultracentrifugation and chromatography in comparison to each other.  Both systems are 
able to remove impurities so purity is not generally a bottleneck. The reason percentage 
yield has been placed as an advantage for ultracentrifugation is that particles do not 
have anywhere to go. It has been reported that infectivity can be lost in some instances 
depending on the stationary phase used (Gias, Nielsen, Morgan, & Toms 2008), but 
recoveries equivalent to optimised chromatographic systems have been reported for 
many years (Hilfenhaus, Kohler, & Gruschkau 1976b). 
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Table 7.6 Advantages and disadvantages of ultracentrifugation and chromatography and 
filtration as purification unit operations for viral vaccines. Yield has been coloured red as 
the recovery of infectious virus from each unit operation is dependent on the type of virus. 
 Ultracentrifugation Chromatography 
Advantages  Purity 
 Yield 
 Purity 
 Scalability (DBC) 
Disadvantages   Cost 
 Scalability 
(Throughput) 
 Cost 
 Yield (requires optimisation, 
trade-offs exist) 
  
 
One of the major differences between chromatography and ultracentrifugation is the 
trade-off between ultracentrifugation throughput and chromatography percentage yield 
versus product purity. During chromatographic development conditions that maximise 
product recovery tend to also maximise the recovery of impurities which limits the 
purification factor achievable. Ultracentrifugation percentage recovery is dependent on 
banding efficiency. The separation of product from contaminating impurities is often 
high if there is a significant difference in buoyant density between the different 
components. When the difference is small, the bands can overlap which reduces the 
purification factor achievable. In practical terms, this will impact the amount of material 
that can be loaded onto the bed as increasing the loading capacity reduces the separation 
efficiency. The data in Figure 7.9 shows a direct comparison between the trends in 
CoGs/dose from the ultracentrifugation and monolith-based processes when the 
volumetric throughput of the ultracentrifuge, and the recovery of infectious virus from a 
monolith is varied. The graph shows that the costs overlap assuming that 60% recovery 
of infectious virus can be achieved without optimisation from a large-scale 
ultracentrifuge. This would need to be amended if not the case. When the percentage 
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recovery is below 50% from the monolith, the ultracentrifugation process is cheaper 
unless the volumetric throughput decreases below ~5 L. The cost increases 
exponentially when additional machines need to be purchased. This makes even lower 
yielding chromatography processes more cost effective than ultracentrifugation 
processes. A monolith process is shown to become less expensive than 
ultracentrifugation when percentage recovery increases above 50% regardless of the 
volumetric throughput achievable using an ultracentrifuge. It should of course be noted 
that the percentage recovery achievable from the ultracentrifuge will impact where the 
two graphs intersect. 
 
Figure 7.9 Overlay in overall CoG per dose to show how trade-offs in critical process 
parameters can shift the balance from chromatography to ultracentrifugation. Monolith 
percentage recovery is varied as trade-offs exist between virus recovery and purity. In 
continuous flow ultracentrifugation the trade-offs are likely to be between purity and 
volumetric throughput.  
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7.6 Conclusions  
Both ultracentrifugation and chromatography can become prohibitively expensive. 
Depending on the critical process performance attributes, which are likely to be highly 
specific to the virus in question, both could be the cheaper option. As a result, it is not 
possible to conclude that one technology should be used preferentially over another in 
general terms. Ultracentrifugation is a tried and tested technique, and with the advances 
in continues flow systems, it has become easier in theory to scale up. Chromatography 
is currently the work horse in the bio pharma sector and is increasingly becoming the 
method of choice to purify viruses and other large macromolecules. A major issue when 
using chromatography, however, is the large number of experiments required in order to 
generate optimal separation performance. This is also true when purifying proteins, 
except that there are significant analytical challenges associated with quantifying viral 
particles. This makes process development extremely time consuming and expensive 
with robust processes difficult to generate. Ultracentrifugation does not have this issue 
as there are fewer independent variables that affect the separation and that can be used 
to optimise the process.  
In many ways, a decision as to what technology to use will depend on the equipment 
already available, especially if manufacturing in house is preferred, as well as the time 
available for process development prior to cGMP material needing to be available. 
In an ideal world, optimised processes for chromatography and ultracentrifugation 
would be developed in parallel and then compared before a decision is taken, however 
in practice this is unlikely to happen due to bottlenecks in both time and resources. 
Decisions will therefore need to be made with incomplete data based on the specific 
project requirements at the time and estimated for the life of the facility in question.  
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  Chapter 8
 
Challenges associated with the 
development and manufacture of 
infectious vaccinia virus  
 
8.1 Introduction1 
 
There are a number of challenges that need to be addressed if vaccinia virus is to be 
licenced and validated as an oncolytic viral therapy. According to ICH guideline Q11, 
process validation involves “the collection and evaluation of data, from the process 
design stage throughout production, that establish scientific evidence that a process is 
capable of consistently delivering a quality drug substance” (EMA 2011). For this to be 
possible it is important to identify the critical quality attributes (CQAs) early on in 
process development. The ICH guidelines acknowledge that when dealing with complex 
biological material this is a challenge. They state that risk management strategies should 
be implemented to account for the lack of knowledge and characterisation related to the 
safety and efficacy of each CQA during the lifecycle of the product.  
Two of the specific challenges when dealing with infectious viral products are analytical 
sensitivity and variability (Darling, Boose, & Spaltro 1998;Sullivan et al. 2012). These 
characteristics make quantifying the CQAs challenging. The relative standard deviations 
across each unit operation are cumulative leaving the potential variation across a 
process to be as high as 60% based on the research presented in this thesis. The CQAs 
and associated analytical challenges for vaccinia virus are discussed below.   
                                                 
1
 This chapter is included as part of the UCL requirements for the award of Doctor of Engineering 
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 Vaccinia virus concentration 
Physical techniques such as NTA, TRPS, TEM and flow cytometry will 
quantify the total number of particles of a given size, shape or physical 
characteristic but are nonspecific and therefore are unable to give 
accurate concentration data unless the sample is pure. 
Specific assays include ELISAs, qPCR-based techniques, and Western 
Blots. Some ELISAs claim to be able to identify whole viral particles 
from associated viral proteins, but this is difficult to validate. qPCR-
based techniques require extensive sample pre-treatment to remove non-
encapsulated viral DNA which reduces the accuracy and precision of the 
measurement. Both ELISAs and qPCR require reliable reference 
standards, which are often difficult to source, and suffer from high 
variability and relatively low sensitivity. ELISA reference standards are 
validated using protein sequence data and TEM.  
 Vaccinia virus potency 
The potency of a virus relates to its biological activity. For vaccinia virus 
licenced as an oncolytic therapy, the simplest measure of potency is 
infectivity. The reason for this is that oncolytic viruses such as vaccinia 
need to be replication competent. In this thesis infectivity was measured 
by TCID50, however, there are a number of other cell-based approaches 
as outlined in Chapter 2. All suffer from relatively low sensitivity and 
high variability. 
Infectivity determines the ability of a virus to infect a cell but not 
necessarily to genetically modify it. If a therapy is required to transduce 
a cell and insert a gene of interest into the nucleus then transduction 
assays will need to be performed.  
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Transduction assays tend to be more specific than infectivity assays 
although variability associated with both techniques prevents robust 
conclusions from being generated for either in isolation. 
 Product related impurities such as: 
o Levels of vaccinia virus aggregation 
Presence of aggregates can be tested using physical techniques 
previously discussed, however, there is currently no way of 
measuring the origin, infectivity and quantity of viral aggregates. 
o Levels of vaccinia virus degradation 
Degraded viral particles can sometimes be visualised using TEM 
although quantification using this approach is challenging. It also 
requires specialist equipment which is likely to be too expensive 
to bring in-house. It may be possible to use a combination of 
ELISAs to quantify non-encapsulated viral coat proteins, but this 
capability would need to be developed and would be very 
difficult to validate in terms of accuracy. 
 Process related impurities such as 
o Concentration of contaminating DNA 
Florescence-based assays such as Quant-iT PicoGreen can be 
used for total DNA quantification but they are non-specific. The 
LLOQ of PicoGreen is 250 pg/mL, which may become limiting 
for some applications. 
qPCR can also be used, but this will quantify specific genes 
known to be conserved in the genome of the host cell. This will 
therefore require assumptions to be made regarding the total 
estimated mass of DNA in a sample based on the mass of DNA 
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used as a standard. High variability in impure fractions is also 
common when using qPCR. 
o Concentration of contaminating protein 
 Absorbance-based techniques such as a BCA assay or similar can 
be used to quantify the total concentration of protein in a sample. 
This is not specific to host cell proteins (HCPs) however. The 
reason why this could be a problem is that BCA assay also 
detects the proteins on the surface of viruses. Consequently, this 
assay tends to overestimate the total mass of protein in a sample 
especially if the concentration of HCPs is low and the 
concentration of virus is high. Furthermore, these assays also 
suffer from low sensitivity. 
 Specific HCP ELISA can be purchased for some cell lines, 
although these assays only quantify specific proteins species in a 
sample. If a specific HCP is defined as a CQA then this could 
work well as long as the ELSIA used is able to identify the 
concentration of the specific impurity in question. In the case of 
the process developed in this thesis for vaccinia, there are no 
commercial ELISA kits available for CV-1 cells, however there 
are for Vero cells which also support vaccinia virus production. 
o Contamination from media components such as serum, phenol red, 
and antifoam. 
If contaminants such as phenol red are defined as CQAs the 
easiest way of ensuring safe concentrations of these substances in 
the final material is to not use them. Commercial kits for the 
analysis of residuals such as phenol red are not commercially 
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available hence these would need to be developed at a cost and 
in-house using technologies such as mass spectrometry or reverse 
phase HPLC.  
o Concentration of common additives such as levels of residual 
Benzonase, or detergents 
The majority of process additives, Benzonase being a good 
example, come with an associated specific assay. Residual 
Benzonase can be quantified using an ELISA which is relatively 
sensitive. These assays can be expensive, however the advantages 
of adding materials such as Benzonase to ensure the removal of 
DNA, can often outweigh the negative implications such as cost. 
o Levels of contaminating endotoxin, mycoplasma  
Endotoxins are quantified using ELISAs. 
Mycoplasma can be semi-quantified using luminescence-based 
assays. A more sensitive technique used to quantify mycoplasma 
is qPCR. Mycoplasma can also be grown in culture and 
quantified by counting associated colonies although this is time 
consuming and variable. 
o Removal of adventitious viruses 
The removal of adventitious viruses is a challenge as common 
techniques used in the biopharma sector such as nanofiltration 
and low pH hold steps will remove and destroy vaccinia virus as 
well as any adventitious agents.  
Viral validation can still be performed on each unit operations in 
the process to test for viral clearance, but processes without 
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specific capture steps will be optimised to recover viruses and so 
the log removal of contaminating virus (LRV) will likely be low.  
o Concentration of leachables from process consumables such as 
chromatography columns and plastics. 
Manufactures will test and validate consumables for leachables 
prior to release. If leachables are biological in nature, analytical 
assays, often in the form of ELISAs, will likely be supplied from 
vendors. If the leachables are small molecules than gas 
chromatography/mass spectrometry (GC/MS) is often used. 
There is a validation challenge associated with ensuring that 
leachables are within safe limits, however, this is not a problem 
specific to viral therapies and hence, well developed best 
practices and guidelines are available. 
8.2 Process development  
 
From the offset of process development, probably amongst the most important 
challenges to be addressed for process validation of infectious virus processes generally 
(not specific to vaccinia) is the scalability and productivity of the presently used 
purification unit operations, arguably the most common being density gradient 
ultracentrifugation. It has been suggested that chromatography using monoliths could 
present an attractive alternative to ultracentrifugation namely owing to their high 
binding capacity, high flow rate independent binding and resolution, and scalability 
stated by the manufacturers of commercially available monoliths. 
From a validation perspective it is likely that variation in the upstream process will 
affect both the purity and yield of chromatographic unit operations (Wolff & Reichl 
2011). Therefore it is difficult to determine robust operation parameters even when 
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using response service factorial designs such as DoE. Such tools are becoming more 
and more common when approaching the submission of QbD filings, being stipulated in 
the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) guidelines as good practice for 
developing both process knowledge and process understanding. 
One of the other major considerations when using chromatography is sanitization 
validation, whether fixed or packed bed. Columns are not sold as sterile units, and the 
vast majority of chromatography matrices cannot be autoclaved or steam sterilised. It is 
for this reason that the regulators recommend a 0.2 µm sterile filter to be used up and 
down stream of each chromatographic step for all buffers and product fractions. While 
this is not a new hurdle in the world of chromatography, this will become more 
challenging for large viruses that cannot be sterile filtered such as vaccinia. The reason 
for this is that vaccinia virus is larger than 0.2 µm. To mitigate risk of batch failure, 
appropriate control strategies will need to be covered in a risk assessment. This will 
likely detail an enhanced in-process testing for endotoxin after each unit operation, as 
well as reduced cycling of monoliths between batches in order to ensure the process 
remains as closed as possible. Such risk assessment will increase costs upfront but will 
reduce the risk of batch failures.   
The reason why this has not been an issue up to now is that large viruses such as 
vaccinia for use in the vaccine industry have been purified using ultracentrifugation, 
which can be sterilised in place. 
Facilities are currently being designed for processing of viral therapies that utilise single 
use technologies with a 100% disposable flow paths in closed processes. 
The primary recovery steps associated with viral bioprocesses can be a challenge to 
close as cells often require lysis to release the virus. Chemical lysis does have some 
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operational advantages compared to high shear based unit operations such as 
homogenisation from the point of view of single use, closed processing. The addition of 
lysis buffers containing reagents such as Triton X-100 into viral harvest material can be 
performed relatively easily in a closed system, while other cell disruption techniques 
generally require stainless steel due to the high pressure drops required. Material contact 
with stainless steel requires cleaning validation, and is more difficult to close. Other unit 
operations such as sonication have also been used in the past, but have the same 
limitations as homogenisation in terms single use functionality and ability to close. 
Sonication is also difficult to scale up. 
It is possible to close chromatographic unit operations, and especially with the 
advancement of disposable flow path based systems such as the AKTA Ready (GE 
Healthcare Uppsala, Sweden), as well as single use columns packed and shipped by 
companies such as (RepliGen, Waltham MA, USA) single use chromatography is 
becoming common place for clinical manufacturing.  
Smaller viruses such as AAV can be sterile filtered using membranes typically used in 
the mAb sector such as the Express SHC (0.5/0.2 µm filter) (Merck & Co. Kenilworth, 
New Jersey, USA). AAV has an approximate diameter of 25 nm. 
Larger viruses such as vaccinia (300 nm) cannot be sterile filtered; therefore it is likely 
that columns will not be cycled across multiple batches, processes will need to be 
closed, and release testing for endotoxin and bioburden as well as other adventitious 
agents will be performed on selected in process samples as well as on each final bulk 
product prior to vialing.   
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8.3 Product release 
 
Another challenge includes viral degradation and inactivation in standard processing 
conditions (such as pH and salt) likely to be encountered during chromatography, 
filtration or ultracentrifugation operations. The effect of long term storage on 
biopharmaceuticals is an issue that has been discussed for many years. As well as 
putting samples on long term stability studies, it has become increasingly common to 
partake in accelerated stability studies in an attempt to identify drug candidates that are 
particularly prone to degradation or oxidation causing the formation of product related 
impurities such as aggregates and fragments leading to loss of potency. Arguably, 
however, this is unlikely to effectively predict infectious viral stability as harsh 
conditions often encountered during accelerated stability may give variable and 
unrepresentative results, especially owing to the high levels of variability in infectivity 
assays. While accelerated stability studies cannot be a substitution for long term 
stability studies, it is useful when comparing a single product or process intermediate at 
different conditions for likely effects of an environmental stimulant. 
 
8.4 Consumables  
 
As a column supplier, BIA Separations produces a number of chromatography columns 
which need to be cGMP compliant.  In order for this to be achieved, an array of batch 
testing prior to release is required. This includes batch testing of column performance 
by methods such as pulse response to measure HETP as well as integrity tests using 
pressure drop and visual inspection as indicators of any damage. BIA Separations also 
validates the nominal pore diameter of each batch of monolith prior to release to ensure 
the specifications meet their in house quality standards. The appropriate paper work, 
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preferably electronic versions, is also expected to be produced on request. Batch records 
from the production process will make up a large part of the data. 
The aim of process validation is to demonstrate that the product is what the 
manufacturer says it is, and, if undamaged during transport, the product behaves in the 
way the process predicts when it arrives at the manufacturing site. 
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  Chapter 9
 
Conclusions and Future Work 
 
9.1 Conclusions  
 
Two capture steps have been developed and analysed using a range of orthogonal 
analytical methods. 
In order to achieve robust clearance of the required levels of dsDNA it is likely that a 
second purification step will be required before direct injection of vaccinia virus into 
patients. It is also likely that Benzonase endonuclease will need to be added to mitigate 
the risk of higher than acceptable dsDNA levels being recovered in the final product 
resulting in batch failure. As the likely specification of dsDNA is 10 ng/dose, the 
requirement of a second step will ultimately depend on the dosing requirements, which 
will depend on the therapeutic indication being targeted. 
In summary, the developed process using CIM OH does present a reasonably robust and 
saleable option for Vaccinia virus capture from crude cell lysate post clarification. CIM 
OH was shown to be able to remove all quantifiable protein loaded to LLOQ levels. Up 
to 99% of the total dsDNA loaded can be removed without nuclease treatment and 
Vaccinia virus recovery, although variable due to cell based assay precision, was as 
high as 90%. 
Vaccinia virus holds great potential as an oncolytic and immunotherapeutic vaccine 
against a broad spectrum of cancers. Purification of vaccinia virus, however, remains a 
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challenge. This is due to its large size, complex physicochemical properties, and highly 
variable starting material that often contains cell debris, DNA, proteins and aggregate. 
The overall aim of this EngD project was to evaluate, understand, and work to reduce 
the current challenges faced by process scientists and engineers when developing 
vaccinia virus for vaccines and oncolytic therapies. 
The scalability and productivity of presently used purification unit operations were 
identified early on as challenges.  
The stability of vaccinia virus in commonly used processing buffers was evaluated, 
subsequent to which, a monolith process was developed and analysed using a variety of 
orthogonal analytical techniques. These included TCID50 to measure infectivity, NTA 
and qPCR to measure the total number of particles and total number of viral genomes in 
solution, TEM and SEM to analyse viral integrity and levels of aggregation, TRPS to 
measure zeta potential, and BCA and PicoGreen to quantify total protein and DNA. 
Vaccinia virus was shown to be able to adsorb to both CIEX and AIEX monoliths. 
When loading CIM SO3 with crude vaccinia harvest, and after eluting in 50 mM 
sodium phosphate 300 mM NaCl pH 7, DNA and total protein purification factors of up 
to 4.3 and 4 respectively were demonstrated, as shown in Chapter 5. Large viral 
aggregates were also shown to be removed after analysing load and elution fractions 
using TEM. The trade-off when using CIM SO3 is that the recovery of infectious virus 
drops from 84% to 35% when the NaCl concentration in the elution is reduced from 500 
mM to 300 mM pH 7. The DNA purification factor is slightly lower when eluted at 500 
mM NaCl, dropping from 4.3, to between 2.8 and 3.5. A reduction in step recovery 
from 84% to 35% is shown in Section 7.5 to increase the CoG/dose by approximately 
three fold.   
252 
 
DNA and total protein purification factors achievable when using CIM OH monoliths 
were higher than those achieved using CIM SO3. A 90% recovery of infectious virus is 
achieved when vaccinia harvest is loading in 50 mM sodium phosphate 1 M ammonium 
sulfate 2 M NaCl pH 8. All quantifiable protein is removed, and a DNA purification 
factor of up to 88 is achievable. Levels of polydispersity are reduced, when analysed 
using NTA, and large aggregates, imaged using SEM, are removed. The trade-off when 
using CIM OH, is the recovery of infectious virus across the pre-filter. Ammonium 
sulfate appears to cause vaccinia to aggregate significantly in the load, which results in 
a recovery of approximately 35% across the filter. This reduces the overall recovery to 
32%.  
Throughout this work, multiple in-process samples were taken and kept at room 
temperature for the duration of each experiment. All samples collected, were then 
frozen together at the end of each chromatography run to insure that no systematic 
errors would arise as a result of sample handling. It cannot be concluded with certainty 
that changes in either sodium chloride concentration or pH have a significant effect on 
vaccinia virus stability in sodium phosphate buffer due to the RSD in TCID50 
measurements. Mean averaged values, shown in Figure 4.5, suggest that initial increases 
in salt concentration reduced infectivity.  The data also suggests that over time, at room 
temperature, vaccinia virus appears to lose infectivity in DMEM, although once again, 
robust conclusions are difficult to make with confidence due to the low precision of the 
TCID50 assay. 
Vaccinia titre, concentration of DNA and total protein, and levels of polydispersity 
varied significantly from batch to batch and with increasing concentration of 
ammonium sulfate. This had an impact on both the HIC and CIEX monolith 
performance.  
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It is clear that the upstream, primary recovery and pre-filtration steps still need work. In 
particular the primary recovery step used would be very difficult to scale up. Detergents 
were not used in this study as there was concern that vaccinia would lose infectivity 
post lysis therefore reducing viral yield. In the interest of time, a freeze thaw method, 
which involved freezing and then thawing pelleted cells over 3 consecutive cycles, as 
described in Section 3.2.2, was used. Some background on options available for cell 
disruption is given in Chapter 2. Mechanical lysis may be an option for future work; 
however, due to the risk category of the virus (Cat II) it was not possible to explore this 
option. 
 
Previously published work on vaccinia virus purification (Jordan et al. 2012;Wolff, 
Siewert, Hansen, Faber, & Reichl 2010a;Wolff, Siewert, Lehmann, Hansen, Djurup, 
Faber, & REICHL 2010b), suggests that CIM monoliths may perform slightly better 
than membrane adsorbers, however, as previous studies were performed on a different 
strain of vaccinia produced in a different cell line and measured predominantly with an 
ELISA rather than TCID50, this conclusion should be taken with caution.  
In comparison to ultracentrifugation, it is difficult to know how monoliths compare in 
terms of impurity removal. Previous literature shows that large scale continuous 
ultracentrifuges can recovery around 60% of infectious vaccinia virus from a crude 
harvest. The industry is moving away from ultracentrifugation, although there remain 
some advantages to the technology. Ultracentrifugation is a well-established technique 
which makes process development relatively straightforward in comparison to 
adsorption-based methods such as IEX or HIC. Using gradient media such as caesium 
chloride, Iodixanol or sucrose, efficient separation of a number of viral vectors has been 
documented (Dormond et al. 2010;Gias, Nielsen, Morgan, & Toms 2008;Otto-Wilhelm 
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Merten 2014). There are also significant disadvantages to using ultracentrifugation 
technologies. Initial capital is high, and if volumetric throughput is low, or banding time 
is high, then manufacturing costs, as shown in Section 7.4.2, increase exponentially.     
CIM monoliths appear to offer some unique selectivity when purifying vaccinia virus. 
Both CIM OH and CIM SO3 show potential as being valuable stationary phases in the 
purification of oncolytic vaccinia viral constructs, and should be evaluated when 
developing clinical and commercial processes. Variations in analytical measurements 
make overall conclusions on process performance challenging, however, the use of 
multiple orthogonal analytics allows for a qualitative and semi-quantitative picture of a 
complex system to be built. This is critically important early on in process development 
in order to build up levels of process knowledge and understanding. 
In conclusion, the monolith-based purification process proposed in this thesis has the 
enormous potential to produce oncolytic viral products in a more economically viable, 
scalable and robust manner than previously possible. This will impact both academia 
and industry by adding to the toolbox of unit operations that are able to purify vaccinia 
virus. For academic groups it will lead to the production of more commercially 
representative virus material for pre-clinical and proof of concepts studies. It will also 
add value by enhancing our understanding of vaccinia stability, aggregation profiles and 
binding kinetics. In an industrial setting it will facilitate the progression of a new and 
potentially life changing class of viral products to treat cancer.  
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In this work, the recorded dynamic binding capacity of infectious vaccinia virus was 1-
3x10
9
 particles/mL of monolith. 
However, Based on NTA data shown in Figure 5.6 the number of particles between 250 
nm and 350 nm able to adsorb to CIM SO3 from the clarified viral harvest material post 
0.8 µm filtration was 1.1x10
11
/mL. The total number of particles between 0.5 and 1000 
nm able to adsorb to the monolith was 2.3x10
11
 particles/mL. 
It is unlikely that the theoretical capacity of 1.15x10
13 
is achievable. 
A binding capacity of ~1x10
11
 capsids per mL may be a better estimate of maximum 
achievable adsorption capacity; however both numbers should be used with caution. 
It is known from this study that vaccinia virus aggregates and forms large complexes 
especially in the presence of salt (Figure 4.12). The assumption, therefore, that particles 
are able to adsorb in ordered monolayers is likely to be incorrect. 
Monoliths have an open channel structure, however, as the channels are cross linking it 
is possible that some of the monolith surface is  unavailable for vaccinia adsorption, in 
other words not in contact with the convective flow of the mobile phase. Mass transfer 
into these regions would be limited by diffusion, which, due to the relatively large size 
of vaccinia, would be very slow.  It is also likely that charge repulsion and steric effects 
would reduce the binding capacity of vaccinia particles onto the monolith surface. 
The pressure drop measured across the load step was measure to 0.02 MPa on average. 
Based on work by (Andrejcic and Podgornik 2017), and assuming a porosity of 60% for 
1 mL 6 µm channel monoliths (Mao, Cernigoj, Zalokar, Strancar, & Kulozik 2017), the 
deposited layer was calculated to be approximately 80 nm. 
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Based on the NTA data the majority of the adsorbed particles are not made up of 
infectious virus, therefore a deposited layer of 80 nm seems reasonable based on the 
average size of particles in the load. 
 
9.2 Future work 
 
9.2.1 Pre-filtration Yield Optimisation  
 
Pre-filtration performance is one of the key areas of further work that is required to tech 
transfer a cost effective vaccinia process into the clinic. In order to solve this problem, 
there are a number of additional experiments that could be performed.  
As shown in Figure 3.3, virus is diluted 1:5 in process buffer and then filtered through a 
0.8µm cellulose acetate syringe filter prior to loading onto CIM monoliths. The 
recovery of infectious virus across the filter without the presence of ammonium sulfate 
in the diluent is approximately 60%. Switching the order of the dilution and filtration 
steps around, as shown in Figure 9.1A, may solve the problem as ammonium sulfate 
would be added to the feed stream after filtration. Whether this will work or not will 
depend on the nature of the fouling material, and the impact of its removal on CIM OH 
performance. It is possible that this approach could lead to high back pressures across 
the monolith due to the presence of large viral aggregates in the feed steam; however, as 
aggregates are still present in the harvest post filtration prior to column loading, fouling 
as a result of viral aggregation seems unlikely.  
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Figure 9.1 A) Proposed future study involving switching the order of the dilution and pre-
filtration steps B) Proposed order of monolith steps assuming CIM OH pre-filtration 
continues to generate a low yield of infectious virus. 
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If back pressures are too high, or column performance is significantly reduced, an 
alternative approach would be to trial a number of different pre-filters. Due to the size 
of vaccinia virus (approximately 300 nm) a limited number of filters are available as 
many have a nominal pore size below 0.3 µm. A non-exhaustive list of commercially 
available filters is shown in Table 9.1. 
 
Maximum throughput studies on normal flow membrane and depth filters would need to 
be performed in triplicate. A typical pressure cut-off used is 20 psig. The filtrate would 
need to be fractionated at regular intervals to analyse virus and impurity breakthrough. 
Samples may also be measured for turbidity as this can signal breakthrough of 
contaminants leading to fouling. Pmax studies can be used to predict the maximum 
volume throughput achievable from large scale filters (van Reis and Zydney 2007) by 
using models that assume either pore restriction or resistance build up from cake layer 
formation. These can be useful when harvest volumes are limited, and time resources 
are stretched, however, infectious virus recovery would be the main aim of these initial 
studies.  
Flux vs TMP studies can be performed on TFF membranes, to ensure TMP set points 
operate within pressure dependant regions. The cross-flow can also be optimised to 
ensure that sheer stress doesn’t cause viral capsid degradation resulting in membrane 
fouling.  
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Table 9.1 Commercially available pre-column filters potentially applicable for vaccinia 
virus prior to CIM  
Types of 
filter 
Filter Name Chemistry Attributes Manufacturer 
Depth filters 
 Polygard CR  
 
Polypropylene 0.1 - 100 µm pore 
size  
Designed for low 
fouling applications 
EMD 
Millipore 
 Millistak+Pod 
 
Cellulose fibres and 
Diatomaceous 
Earth 
Slight positive 
charged 
Designed for 
primary recovery 
and aggregate 
removal 
EMD 
Millipore 
Membrane filters (normal flow) 
 PolySep II Polypropylene Multi-layer 
membrane 
First layer 1-2 µm 
Second layer 0.1-
1.2 µm 
Designed for 
fouling lipid feed 
streams  
EMD 
Millipore 
 Polygard CN  
 
Polypropylene 0.3 - 30 µm pore 
size  
Slightly 
hydrophobic 
EMD 
Millipore 
Membrane filter (cross flow) 
 KrosFlow hollow 
fibre range  
Modified 
Polyethersulfone 
(mPES), 
Polysulfone (PS), 
Mixed Ester (ME)  
1KD to 0.65um 
UF/DF/MF 
Spectrum Labs 
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If none of these strategies work, then CIM OH may need to be used as a second step. 
The recovery of infectious virus from CIM SO3 is 60 – 70% when eluted in 500 mM 
NaCl. Ammonium sulfate would need to be added to the CIM SO3 elution prior to 
loading onto CIM OH, however, as the majority of the impurities would have been 
removed by CIEX there may be no need for a pre-filtration step. This modified process 
flow is shown in Figure 9.1B. In all experiments described, CIM OH pressure drop, 
column lifetime and process performance will need to be monitored.  
 
9.2.2 Development of an additional purification step to remove dsDNA 
 
It would also be interesting to trial alternative chromatography columns such as SC-
MA, discussed in the literature (Wolff, Siewert, Hansen, Faber, & Reichl 2010a). CIM 
monoliths are able to remove the majority of the DNA, however, depending on the dose 
and the variability in DNA concentration in the harvest, an additional step may be 
required. Depending on the percentage recovery achievable when SC-MA is challenged 
with infectious vaccinia virus Lister strain; this may be a good option as a capture step. 
CIM OH could then be trialled as a polishing step to remove DNA and protein, but 
without the need for a pre-filtration step. When developed using MVA, SC-MA has a 
DBC of approximately 6.42x10
9
 pfu/capsule. If this is the same as for Lister strain, SC-
MA may provide better productivity than a monolith capture step as long as the 
percentage recovery was comparable.  
The challenge to developing a second step will be material availability. Vaccinia will 
need to be produced, purified and then analysed before being available for polishing 
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step optimisation studies. Analytical throughput will also be a bottleneck as the number 
of samples requiring analysis will double. 
 
9.2.3 Qualification of assays to measure residual impurities   
 
PicoGreen is routinely cited in the literature as a rapid, precise and accurate measure of 
total dsDNA. However, some concerns have been recently raised as there is a possibility 
that the PicoGreen reagent is able to pass through the viral envelope and protein capsid 
and access the viral DNA. If this occurs then the assay may give misleading results as it 
would overestimate the concentration of dsDNA in a sample. The magnitude of this 
error would be dependent on viral concentration.  
 
Due to resource limitations the assay was not fully qualified prior to use. A number of 
attributes would therefore need to be assessed before PicoGreen could be used to 
measure dsDNA contamination in either in-process samples or final drug substance 
during a GMP manufacturing campaign.  
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ICH guidelines suggest the following are assessed. 
 Precision 
 Accuracy 
 Sensitivity 
 Specificity 
 Range  
 Linearity 
 Robustness 
PicoGreen reagent transport through the viral envelope would affect both specificity and 
accuracy of the assay. 
In order to assess specificity and accuracy, DNA spiking studies would need to be 
performed. This would require the use of a fully characterised primary reference 
standard. This standard would need to have a known concentration of intact viral 
particles as well as an accurate concentration of dsDNA contamination, ideally 
estimated using an orthogonal assay to PicoGreen such as qPCR. 
Accuracy and specificity could then be determined by spiking lambda DNA into the 
reference standard and measuring spike recovery using PicoGreen. This would assess 
the ability of the assay to quantify the spike, as well as determine whether the virus was 
interfering with the known concentration of dsDNA in the sample. 
9.2.4 Further development of assays to quantify vaccinia virus  
 
Analytical equipment known to be able to resolve vaccinia virus is limited.  
The following list of analytical solutions were each evaluated during the project, 
showed some promise but could not be extensively tested or included in the battery of 
assays due to capital budget restrictions. Each has been covered in detail in Section 2.5. 
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 AIEX-HPLC, analytical monoliths (BIA Separations) 
 HIC-HPLC, analytical monoliths (BIA Separations) 
 TRPS, Tunable Resistive Pulse Sensing, measurements are based on 
individual particle impedance as virus is passed through a stretchable 
nanopore  (IZON) 
 VirusCounter 3100 based on multi-channel flow cytometry detecting 
presence of protein and DNA (ViroCyt, Sartorius) 
 
Future work should include a thorough evaluation of these analytical techniques.  
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   Chapter 10
Appendix A 
 
10.1 Residual Assay standard curves  
 
As detailed in the materials and methods section of this thesis BCA and Quant-iT 
PicoGreen assays were used to analyse total protein and dsDNA in vaccinia in process 
samples. 
The following graphs are copies of typical standard curves generated for each assay  
BCA standard curves were generated using Bovine Serum Albumin (BSA)  
Quant-iT PicoGreen standard curves were generated using λ DNA (isolated from is E. 
coli bacteriophage) 
 
Figure 10.1 Typical λ DNA standard curve. 
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Figure 10.2 Typical BSA standard curve.  
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10.2 CoGs Model Parameters 
 
WFI System   
Effective Utilisation   60% 
Percent Still Blowdown 10% 
Storage Tank Fill Time Sizing (hr) 10 
Bought-in WFI   Yes 
 
PW System   
Effective Utilisation   60% 
Storage Tank Fill Time Sizing (hr) 10 
 
Cost of Works Breakdown  
Installation   38% 
Minor items  0% 
Pipework   20% 
HVAC   34% 
Control   15% 
Electrical Power 25% 
Plant Utilities  3% 
Building   65% 
Fit out   14% 
 
 Exchange Rates   
 EU€ GB£ US$ CHF 
EU€ 1.00 0.86 1.32 1.52 
GB£ 1.16 1.00 1.50 1.76 
US$ 0.76 0.67 1.00 1.08 
CHF 0.66 0.57 0.93 1.00 
 
Other Capital Breakdown  
Validation   15% 
Design Fee  16% 
Construction Management 4% 
 
 
      
 
Internal Capitalisation Costs 
Validation engineering support 0% 
Engineering indirects 0% 
Other support   0% 
User definable add-on 0% 
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Cleaning & Solution Prep  
 Flow rate (L/min/m)  50 
 L:D ratio for vessels  2 
   
   CIP Cycle Timings 
 
 PW rinse (min)  5 
 WFI rinse (min)  5 
 Caustic rinse (min)  5 
 Acid rinse(min)  5 
    Cleaning   
  
 CIP time (full)    1 
 CIP time (rinse)  0.2 
 CIP/SIP Personnel (#)  2 
    CIP Cycles per Day  
 
 Upstream      3 
 Media prep and hold  5 
 Downstream  
 
5 
 Buffer prep and hold  10 
   
  
Aqueous Waste Per m
3
 
Adj 
Cost 
Non-Contaminated US$ 0.20 
Contaminated US$ 0.86 
   
Water Treatment Costs Per L 
Adj 
Cost 
PW Treatment US$ 0.05 
Bought WFI Cost US$ 1.00 
   
 Contaminated Plastics 
Disposal    Per T 
Adj 
Cost 
Incineration US$ 800.00 
Landfill US$ 150.00 
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10.3 Publications by the Author 
 
Vincent, D., Kramberger, P., Hudej, R., Štrancar, A., Wang, Y., Zhou, Y., & 
Velayudhan, A. 2017. The development of a monolith-based purification process for 
Orthopoxvirus vaccinia virus Lister strain. Journal of Chromatography A, 1524, 
(Supplement C) 87-100 available from: 
http://www.sciencedirect.com/science/article/pii/S0021967317313067  
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